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Abstract 
Colorectal cancer (CRC) has a relatively poor prognosis when detected at a later 
stage, therefore understanding its development to allow prevention or early 
detection is key to improving outcomes. Bowel cancer screening allows for the 
detection of tumours and precursor lesions. Even earlier changes could potentially 
be detected; genetic aberrations within the normal bowel before phenotypic 
changes occur. Early lesions may develop independently throughout the bowel or 
through a cancer field effect. FAP adenomas are a useful model due to adenomas 
developing within the same environment and all incurring the same first “hit” within 
APC. Using next generation sequencing the genetic profiles of FAP adenomas can 
be compared to better understand the development of these lesions. 
 
Firstly the sensitivity of pyrosequencing and NGS was determined as was the value 
of PCR-based mutant enrichment techniques. Samples of carcinoma, adenoma and 
their associated normals alongside normal mucosa from patients with normal 
colonoscopies were tested for mutations in commonly mutated genes in CRC using 
NGS. Multiple FAP adenomas from four patients were also tested with this mutation 
panel. Alongside this, copy number analysis was performed. The mutational and 
copy number data was used to ascertain the pattern of adenoma development 
throughout the bowel. 
 
Mutations were detected in carcinoma associated normal in APC, KRAS, CTNNB1 
and SMAD4. The KRAS mutations in carcinoma associated normal differed to the 
KRAS mutation in the matched tumour. No mutations were detected in oncogenes 
in adenoma associated normal or normal mucosa from patients with normal 
colonoscopies. Studying mutations and copy number aberrations in FAP adenomas 
revealed that some adenomas shared specific lesions, indicating that they were 
clonally related.  
 
These results have confirmed previously findings of KRAS mutations in carcinoma 
associated normal mucosa as well as describing mutations in APC, CTNNB1 and 
SMAD4. This combined with the large amount of similarity in terms of mutations and 
copy number seen in adenomas from the same patient provides evidence for the 
cancer field theory. 
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1 Introduction 
Pathology, genetics and early lesions of colorectal cancer 
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1.1 Epidemiology of colorectal cancer 
1.1.1 Incidence 
There are over 1.2 million new cases of colorectal cancer (CRC) diagnosed each 
year worldwide which makes it the third most common cancer in men and second 
most frequent in women (GLOBOCAN, 2008). The incidence of CRC varies 
geographically, with more cases seen in economically developed countries. This is 
due to associations with diet, obesity, sedentary lifestyle and inadequate fibre intake 
alongside other risk factors (Cunningham et al., 2010). Furthermore, the incidence 
has increased in countries that have started to adopt a more westernised diet such 
as Japan and other Asian countries (Cancer Research UK, 2011). In the UK, CRC 
is the third most common cancer type in both men and women with around 110 new 
cases diagnosed every day. It is a disease that affects the older population with 
86% of cases being diagnosed in those patients aged 60 or over as illustrated in 
Figure 1 (Cancer Research UK, 2010). 
 
Figure 1. Colorectal cancer incidence. Number of new cases per year and age-specific 
incidence rates per 100,000 population, UK (Cancer Research UK, 2011). 
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1.1.2 Mortality rate and 5-year survival 
Worldwide, CRC is the fourth most common cause of cancer death. In the UK, it is 
the second highest cause of cancer-death and the five-year survival rates for CRC 
are 54.2% and 55.6% for men and women respectively (2005-2009) (Cancer 
Research UK, 2012b). Patient prognosis for CRC is heavily reliant upon the stage at 
which it is diagnosed (Figure 2). Approximately one-third of CRCs are diagnosed as 
Dukes’ stage A and B (early stage disease) and one-third are categorised as Dukes’ 
stage C and D (later stage, more extensive disease) with the remaining third being 
unknown (Figure 3). Dukes’ A stage has a 5-year relative survival of 93.2% 
compared to 6.6% for stage D (Figure 2) (Cancer Research UK, 2012b) and 
therefore diagnosing cancer at an earlier stage is a key part of improving patient 
outcomes. 
 
 
 
Figure 2. Five-year relative survival rates by Dukes’ stage at diagnosis. England, 1996-2002  
(Cancer Research UK, 2012b).  
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Figure 3. Percentage of cases by Dukes’ stage at diagnosis, England 1996-2002 (Cancer 
Research UK, 2012b) 
 
1.2 Screening 
Population screening for CRC is an effective method to reduce mortality rates due 
to disease being detected at an earlier stage (Mandel et al., 1993). The Bowel 
Cancer Screening Programme (BCSP) in England was initiated in 2006 and was 
fully rolled out by 2009. This consists of faecal occult blood testing (FOBT) for the 
population aged 60 every 2 years and in 2011 the BCSP introduced  flexible 
sigmoidoscopy from age 55 (Atkin et al., 2010). The FOBT is used to detect tiny 
amounts of blood in the stool. Those with positive tests are then subject to further 
investigation which normally involves colonoscopy to visualise the large bowel. By 
this method, mortality can be reduced by up to 25% (Logan et al., 2012).  
 
An alternative method for the detection of lesions from stool is faecal 
immunohistochemical testing (FIT) which tests specifically for the globin protein. 
This differs from FOBT which detects the haem component (Park et al., 2010).  
Typically, stool tests such as FOBT and FIT tend to detect cancer as well as 
incidental adenomas. Visual examinations (flexisigmoidoscopy, colonoscopy etc.) 
allow for the direct detection of both cancer and also premalignant lesions (Quintero 
et al., 2012). There is also the potential to develop mutation testing. If genetic 
mutations were to be detected by a sensitive technique they might either be used as 
the definitive test or as a marker to identify those who are more “at risk” of 
developing colorectal cancer.  
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1.3 Anatomy and histology of the colorectum 
1.3.1 Anatomy of the large bowel 
The large bowel is the region of alimentary canal between the terminal ileum and 
the anus. The colon begins at the caecum which is situated below the ileo-caecal 
valve. The ascending colon stretches up to the hepatic flexure, at which point it 
becomes the transverse colon. This runs to the splenic flexure where it becomes the 
descending colon. This joins to the loop of colon known as the sigmoid which then 
meets the straight rectum before finally ending at the anal canal. The majority of 
CRCs occur in the sigmoid and rectum (Cancer Research UK, 2012a). 
 
A clinical division is often made at a point two-thirds along the transverse colon to 
form the right and left colon. This is due to the different embryological origins; the 
right colon is derived from the embryological midgut and the left colon is derived 
from the hindgut. Reflecting this division, the left and right colon have different 
vasculature.  
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1.3.2 Normal histology of the large bowel 
The gastrointestinal tract is subdivided into five distinct functional layers: mucosa, 
submucosa, muscularis propria, sub serosa and serosa. The mucosa from the 
caecum to rectum consists of epithelial cells that lie on a basement membrane with 
supporting lamina propria beneath. Underneath lies the muscularis mucosae which 
then forms the boundary with the submuscosa. The epithelial cells are folded into 
crypts which provide the large surface area required for the large bowel’s absorptive 
functions. The basic architecture of the colon is illustrated in Figure 4. 
 
 
Figure 4. The internal structure of the colon. Adapted from (Encyclopædia Britannica Online, 
2003). 
 
The slide in Figure 5 shows the histological features of normal colorectal mucosa. 
The epithelium-lined crypts and surrounding lamina propria clearly define the colon 
mucosa with the thin muscle layer of the muscularis mucosae separating it from the 
submucosa. 
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Figure 5. Frozen section of normal mucosa stained with haematoxylin and eosin. 
 
1.4 Staging of colorectal cancer 
1.4.1 Dukes’ Staging 
Staging CRC has a number of advantages. It allows for better prediction of survival, 
enables international comparisons of outcome, helps to determine treatment and 
streamlines clinical trials. The Dukes’ classification system indicates the stage, or 
extent of spread of disease. There are 4 categories: A,B,C1 and C2 described by 
Dukes and category D added by (Turnbull Jr et al., 1967) . Table 1 outlines the 
criteria for each particular stage.  
 
Stage Criteria 
A No invasion beyond muscularis 
propria. 
B Invasion beyond muscularis propria, 
but no lymph node involvement. 
C1 Regional lymph node involvement, 
but not the highest node 
C2 Lymph node involvement at high 
surgical tie 
D Distant metastases. 
Table 1. Dukes’ classification system for colorectal cancer (Turnbull Jr et al., 1967) 
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1.4.2 Tumour, Node, Metastases staging 
TNM staging is a more preferred method of classification due to the higher amount 
of information it provides. Cancers are categorised according to the size of the 
primary tumour (T), the number of lymph nodes involved (N) and the presence of 
any metastases (M) (Table 2). There are various versions of TNM staging and 
version 5 is preferred in the UK rather than version 7 (Quirke et al., 2011).  
 
Category Criteria 
T1 No invasion beyond muscularis propria. 
T2 Invasion into muscularis propria. 
T3 Invasion into subserosa or neighbouring 
tissues. 
T4 Invasion into other organs and peritoneal 
invasion. 
N0 No regional lymph node involvement. 
N1 Metastasis in 1 to 3 regional lymph 
nodes. 
N2 Metastasis in 4 or more regional lymph 
nodes. 
M0 No distant metastasis. 
M1 Distant metastasis. 
Table 2. TNM classification of colorectal cancer (Sobin and Fleming, 1997) 
 
 
1.5 Lesions of colorectal cancer 
The initial model of carcinoma development proposed a step-wise progression from 
normal mucosa to adenoma to adenocarcinoma (Vogelstein et al., 1988). This 
sequence is characterised by activation of oncogenes and loss of tumour 
suppressor genes (TSGs) at different points, contributing to the stages of 
tumourigenesis. However, subsequent classification of early colorectal lesions and 
alternative pathways of tumour development have led to substantial modification of 
this model (Bozic et al., 2010). 
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1.5.1 Aberrant crypt foci  
Aberrant crypt foci (ACF) are defined as an area of colorectal mucosa with two or 
more adjacent enlarged crypts with structural changes (Orlando et al., 2008, 
Anderson et al., 2012). ACF progress to small adenoma via the accumulation of 
molecular damage and are considered the intermediate between normal epithelium 
and early adenoma. They have been shown to have increased proliferative activity 
and often carry a KRAS mutation (section 1.7.2) (Takayama et al., 1998). ACFs can 
be further classified by the degree of dysplasia they show (Sancho et al., 2004).  
Figure 6 shows an example of a dysplastic ACF. 
 
 
Figure 6. Dysplastic aberrant crypt foci. Reproduced with permission from (Redston, 2001). 
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1.5.2 Serrated lesions  
This serrated category refers to a distinct histological appearance that is observed 
and encompasses both neoplastic and non-neoplastic lesions. The surface 
epithelium of the crypts displays a saw-tooth appearance, with increased levels of 
mucin in the cytoplasm (Rex et al., 2012). Serrated lesions are associated with 
microsatellite instability (section 1.6.2) and BRAF mutations (section 1.7.2) and are 
thought to develop to carcinoma through this pathway (Mesteri et al., 2013). There 
are four main types of lesion that are included within the serrated category: 
hyperplastic polyps (HPs), sessile serrated lesions (SSL), traditional serrated 
adenomas (TSA) and mixed polyps (Cunningham and Riddell, 2006, Noffsinger, 
2009, Rex et al., 2012) 
 
HPs are benign polyps with negligible malignant potential (Figure 7A). They are 
most often found in the left colon and are typically less than 5mm in size. Crypts 
within HP are elongated with serrated epithelium in the upper half of the crypt and 
increased proliferation in the basal portion of the crypt (Rex et al., 2012). SSLs are 
characterized by the presence of abnormal proliferation but without the presence of 
mucosal neoplasia (Figure 7B). Serration is seen down to the crypt base. TSAs are 
dysplastic with a villiform/filliform appearance with foci of microcrypt formation and 
display mucosal neoplasia, with associated serration (Figure 7C). They are often 
found on the left-side of the colon (Lash et al., 2010). Mixed polyps are lesions that 
contain a combination of histological types (Figure 7D) and they may include 
neoplastic changes (Rex et al., 2012). 
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Figure 7. Serrated Lesions. A = Hyperplastic polyp. B = Sessile serrated lesion. C = Traditional 
serrated adenoma. D = Mixed polyp. 
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1.5.3 Adenoma and carcinoma 
Colorectal adenomas are defined by the presence of epithelial neoplasia (Quirke et 
al., 2011). They are divided according to their morphological appearance into 
tubular, villous and tubulo-villous. A tubulo-villous adenoma must contain between 
20% and 80% villous component to be classed as such. They are also categorised 
according to the Vienna grading system according to the degree of structural and 
cytological abnormality (Lanza et al., 2011). Colorectal adenocarcinomas are 
defined by the invasion of neoplastic cells through the muscularis mucosae and into 
the submucosa (Bosman et al., 2010). The cells of both adenomas and carcinomas 
display nuclear pleomorphism, increased mitotic activity and disruption of normal 
mucosal architecture, however only carcinomas invade. 
 
 
Category Criteria 
1 No neoplasia 
2 Indefinite from neoplasia 
3 Mucosal low-grade neoplasia 
 Low grade adenoma 
 Low grade dysplasia 
4 Mucosal high-grade neoplasia 
4.1 High grade adenoma/dysplasia 
4.2 Non-invasive carcinoma (carcinoma in-situ) 
4.3 Suspicious for invasive carcinoma 
4.4 Intramucosal carcinoma 
5 Submucosa invasion by carcinoma 
Table 3. Revised Vienna Classification of neoplasia grading (Dixon, 2002). 
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1.6 Genetic instability 
Colorectal cancer is increasingly classified according to molecular pathogenesis. 
The underlying genetic alterations are caused by various mechanisms of genetic 
instability. There are three main forms of genetic instability which are described; 
chromosomal instability (CIN), microsatellite instability (MSI) and CpG Islands 
Methylator Phenotype (CIMP). These pathways cause the subsequent inactivation 
of tumour suppressor genes (TSGs) and activation of oncogenes, thereby resulting 
in tumour formation.   
 
1.6.1 Chromosomal instability 
The most common form of genetic instability seen in colorectal cancer is 
chromosomal instability (CIN) and is observed in up to 85% of tumours (Grady and 
Carethers, 2008). It is defined by an accelerated rate of loss and gain of whole 
sections of genetic material. This leads to aneuploidy, genetic amplification, 
translocations and loss of heterozygosity. (Watanabe et al., 2012) 
 
The most common feature of CIN is the gain or loss of large genetic sequences that 
code for oncogenes and TSGs respectively.  Chromosomal gains are most often 
found at 8q, 20, 7 and 13. Loss of genetic segments most often occurs at 5q, 8p, 
17p and 18q which may result in loss of heterozygosity (Pino and Chung, 2010, 
Ashktorab et al., 2010).  
 
There are multiple causes of CIN, many of which are still not fully understood. 
Mutations in the adenomatous polyposis coli gene (APC) (section 1.7.1), as well as 
its tumourigenic effects, are a suggested initiator of CIN (Pino and Chung, 2010). 
Similarly there appears to be a causative link between Kirsten rat sarcoma (KRAS) 
mutation and aneuploidy (Gordon et al., 2012) (section 1.7.2). Amplification of 
chromosome 7 has been noted in some colon adenomas and also appears to play a 
role in colorectal cancer progression. The epidermal growth factor receptor gene is 
located on chromosome 7 and therefore its expression may be affected (Sartore-
Bianchi et al., 2012).  However, it is unknown whether changes in TSGs and 
oncogenes are due to CIN or the driving force behind it.  
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1.6.2 Microsatellite instability 
Microsatellite instability (MSI) is observed in approximately 15-20% of sporadic 
colorectal cancers and over 95% of tumours from patients with hereditary non 
polyposis coli (HNPCC) (section 1.8.2) (Boland and Goel, 2010).   It is a form of 
genetic instability characterized by the accumulation of abnormally sized short 
nucleotide repeats (microsatellites) throughout the tumour genetic sequence. MSI 
has been shown to be due to errors in DNA mismatch repair (MMR) genes such as 
MSH2, MLH1, PMS2 and MSH6 (Tian et al., 2012). There are two main 
mechanisms by which MMR genes can lose their function; somatic inactivation of 
both alleles of MMR genes or through germline MMR gene mutations followed by 
inactivation of the other copy as seen in HNPCC.  
 
MMR proteins are enzymes that normally function to recognize nucleotide 
mismatches and facilitate their repair. Loss of this function prevents errors that 
occur during cell replication from being corrected. Throughout the genome 
microsatellites of a fixed length are present that are prone to error during replication 
with deficient MMR. Therefore repeat units of DNA of incorrect lengths are 
accumulated throughout the genome resulting in MSI (Markowitz and Bertagnolli, 
2009). Microsatellites in TSGs disrupt the reading frame, thereby rendering the 
protein truncated and inactive. This causes the loss of TSG function and 
subsequent adenoma development. Key TSGs thought to be affected by 
microsatellites include TGFβ receptor type II and components of the Wnt signalling 
pathway (section 1.7.1) (Soreide et al., 2009, Alhopuro et al., 2012). 
 
Tumours can be further classified according to the degree of MSI observed. The 
majority of tumours display either large amounts of MSI or none at all (microsatellite 
stable, MSS) (Ogino and Goel, 2008, de la Chapelle and Hampel, 2010). This gives 
rise to the terms MSI-high (MSI-H) and MSI-low (MSI-L) to further classify MSI 
tumours. More recently the term “hypermutated” has been used to refer to tumours 
with a high mutation rate (over 12 mutations per 10,000,000 bases) and 77% of 
these are reported as MSI-H (The Cancer Genome Atlas Network, 2012). 
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1.6.3 Aberrant DNA methylation 
TSGs become inactivated not only by genetic mutations and partial or whole gene 
loss but also through epigenetic changes; the most common mechanism being 
aberrant DNA methylation. In sporadic CRC, the MLH1 gene is epigenetically 
silenced resulting in MSI (Markowitz and Bertagnolli, 2009). Within the promoter 
region of a gene can be found an area referred to as a CpG island. CpG islands are 
defined as segments of DNA which have a high frequency of the CpG dinucleotide 
that are often found upstream to the gene’s transcription start site (Soreide et al., 
2009). CpG repeats located elsewhere within the genome are normally silenced by 
methylation, however promoter CpG islands remain unmethylated (Issa, 2004). In 
CRC promoter CpG islands in TSGs undergo methylation thereby preventing 
transcription of the gene. Approximately 15% of CRCs display the CpG island 
methylator phenotype, (CIMP) (Markowitz and Bertagnolli, 2009). As well as 
tumours, abberant DNA methylation has been observed in normal mucosa that lies 
adjacent to colorectal tumours (Kim et al., 2010).  
 
Tumours that are classified as CIMP-high have been shown to display distinct 
pathological and molecular features. There are associations with female sex, 
proximal tumour location and high BRAF mutation rates. CIMP-low as an 
independent category is not as strongly defined as CIMP-high, however these 
tumours have been shown to hold a stronger association with KRAS mutations 
(Kawasaki et al., 2008)   
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1.7 Molecular pathogenesis and genetics of colorectal cancer 
 
1.7.1 Wnt Signalling (APC, CTNNB1, TCF7L2) 
The wingless related integration (wnt) signalling pathway regulates cell fate 
determination, cell migration and cell polarity. Wnt target genes are involved in 
tumour formation and invasion and therefore activation of wnt signalling promotes 
tumour growth. (Anastas and Moon, 2012). As illustrated by Figure 8, when the wnt 
pathway is in the “off” state there is an absence of a wnt signal and the frizzled (Frz) 
receptor is free of ligand. This leads to β-catenin binding to a destruction complex 
consisting of adenomatous polylposis coli (APC), axin, casein kinase 1 (CK1) and 
glycogen synthase kinase 3β (GSK3β) protein. This results in the cytoplasmic 
degradation of β-catenin via proteosomes. In the nucleus, target wnt genes remain 
silenced due to the interaction between the repressor groucho and DNA-bound T 
cell factor 4 (TCF4). To change this pathway to the “on” state, firstly the wnt signal 
has to bind to the frizzled receptor (Frz) and co-receptor low-density lipoprotein 
receptor-related protein (LRP). This causes the LRP tail to become phosphorylated 
by CK1, GSK3β and the dishevelled (DSH)-dependent recruitment of axin. This 
results in β-catenin no longer becoming phosphorylated and levels accumulate. β-
catenin then translocates to the nucleus where it stimulates the transcription of wnt 
target genes by displacing groucho and recruiting B cell lymphoma 9 (Bcl-9) and 
Pygopus through TCF4. 
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Figure 8. Wnt Signalling. LRP = lipoprotein receptor-related protein. Frz = frizzled receptor. APC 
= adenomatous polyposis coli. P = Phosphate. CK1 = Casein kinase 1. GSK3B = Glycogen 
synthase kinase 3.TCF4 = T cell factor 4. Bcl9 = B-cell CLL/lymphoma 9. 
 
 
The APC tumour suppressor gene (APC) is found inactivated in 80-95% of sporadic 
colorectal cancers (Markowitz and Bertagnolli, 2009). The APC protein normally 
functions to bind to β-catenin and degrade it thereby inactivating the wnt signalling 
pathway. Mutated APC protein contains structural deformities in its β-catenin 
binding site, leading to unopposed activation of the wnt signalling pathway. β-
catenin accumulates in the cytoplasm and is translocated to the nucleus. Here it 
stimulates the transcription of multiple genes that are involved in tumour formation 
and invasion. Inactivation of both APC genes is found in most sporadic CRCs and 
this loss of APC function is a major step in the initiation of tumourigenesis. 
  
42 
 
The β-catenin protein is encoded by the CTNNB1 gene and CTNNB1 mutations are 
found in around 5% of sporadic CRCs and in up to 50% of tumours with intact APC 
(Pino and Chung, 2010, The Cancer Genome Atlas Network, 2012).  Activating 
mutations in the CTNNB1 gene allow for the β-catenin protein to be stabilized, 
switching on wnt signalling. TCF7L2 mutations are found in around 9% of sporadic 
CRCs (The Cancer Genome Atlas Network, 2012). The TCF7L2 gene codes for 
TCF4 protein and mutation can affect its binding properties allowing for wnt target 
gene transcription (Bass et al., 2011).  
 
1.7.2 RAS-RAF-MEK-ERK pathway 
This pathway controls cell proliferation through the activation of epidermal growth 
factor receptors (Figure 9). Growth factors bind to cell surface receptors which then 
trigger activation of sons of sevenless (SOS). This causes the exchange of GDP for 
GTP on the RAS protein, thereby converting it to the active state. This, in turn, 
stimulates the RAF-MEK-ERK pathway which results in the transcription of genes 
responsible for cell proliferation.  
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Figure 9. RAS-RAF-MEK-ERK signalling pathway. EGFR = Epidermal growth factor receptor. P = 
Phosphate. GRB2 = Growth factor receptor-bound protein 2. SOS = Sons of sevenless. RAS = 
Rat sarcoma. GTP = Guanosine  triphosphate. GDP = Guanosine diphosphate. RAF = Rapidly 
accelerated fibrosarcoma. MEK = Mitogen-activated protein kinase kinase. ERK = Extracellular 
signal-regulated kinase. 
 
The RAS protein family include Kirsten-RAS (KRAS) and neuroblastoma-RAS 
(NRAS) in which mutations are commonly implicated in CRC. Activating mutations 
in hotspots of these oncogenes result in a protein that is permanently in the active 
state with GTP bound. Alternatively, this pathway may be permanently activated 
due to mutations in the RAF gene and most commonly the BRAF gene. 
Approximately 50% of CRCs contain a KRAS mutation, 9% contain a BRAF 
mutation and 5% contain an NRAS mutation (Bamford et al., 2004, Pino and Chung, 
2010). Table 4 shows a breakdown in the prevalence of RAS and RAF mutations in 
CRC. 
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Mutation Prevalence (%) 
KRAS codon 12 33.0 
KRAS codon 13 9.5 
KRAS codon 61 2.1 
KRAS codon 146 1.9 
NRAS codon 12 1.0 
NRAS codon 13 0.1 
NRAS codon 61 1.8 
BRAF codon 600 8.8 
Table 4. Frequency of KRAS, NRAS and BRAF mutations found in colorectal cancer (Bamford 
et al., 2004, Pino and Chung, 2010, The Cancer Genome Atlas Network, 2012). 
 
1.7.3 Phosphoinositide 3-kinase pathway 
The Phosphatidylinositide 3-kinase (PI3K)/ Ak-thymoma (AKT) pathway plays an 
important role in apoptosis and cell survival (Liao et al., 2012). Activated EGFR 
receptors and consequently SOS protein causes activation of the PI3K, AKT and 
mammalian target of rapamycin (mTOR) signalling cascade. This results in 
transcription of target genes (Figure 10). Phosphatase and tensin (PTEN) protein 
acts on AKT to inhibit its signalling and therefore inhibits the pathway at this point.  
 
The PI3K protein is coded for by the PIK3CA gene which is found mutated in 
approximately 15-20% of CRCs (Liao et al., 2012). Mutations in the PIK3CA 
oncogene are found in hotspots; at codons 542, 545-547 and 1047 which result in 
gain of function (Bamford et al., 2004) and permanent activation of the pathway. 
PTEN acts as a tumour suppressor and mutations in this gene result in a loss of 
inhibition of the pathway. PTEN mutations are found in 4% of CRCs.  
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Figure 10. PIK-AKT-mTOR pathway. . EGFR = Epidermal growth factor receptor. P = Phosphate. 
GRB2 = Growth factor receptor-bound protein 2. SOS = Sons of sevenless. PI3K = 
Phosphatidylinositide 3-kinase. AKT = Ak-thymoma. PTEN = Phosphatase and tensin. mTOR = 
mammalian target of rapamycin. 
 
 
1.7.4 TP53  
The tumour protein 53 (TP53) is responsible for Gap 1 (G1) phase cell-cycle arrest; 
allowing for DNA repair to occur during replication, or alternatively induce apoptosis. 
Therefore TP53 acts as a tumour suppressor gene and loss of this protein results in 
increased DNA damage, resistance to apoptosis and loss of other tumour 
suppressor effects (Moran, 2010). The TP53 gene is located on the short arm (p) of 
chromosome 17. It is found mutated in up to 60% of sporadic CRCs (The Cancer 
Genome Atlas Network, 2012). It has been identified as playing an important role in 
the transition from adenoma to carcinoma. TP53 mutation frequency increases with 
the progression of the adenoma-carcinoma sequence (Moran, 2010). Alternatively 
TP53 can be lost through deletion of 17p which occurs frequently in CRC (Pino and 
Chung, 2010).  
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1.7.5 SMAD4 
Mothers against decapentaplegic 4 (SMAD4) is a protein involved in transforming 
growth factor β (TGFβ) signalling. This pathway is responsible for neoplastic cell 
proliferation, especially at the later stages of the malignant process (Labelle et al., 
2011). TGFβ binds to receptors on the cell surface which results in activation of 
SMAD2/3 proteins. These translocate to the nucleus where they interact with 
SMAD4 and cofactor to initiate gene transcription of target genes associated with 
tumour progression. 
 
 
Figure 11. TGFβ signalling. TGFβ = Transforming growth factor β. SMAD = Mothers against 
decapentaplegic.  
 
SMAD4 is located on the long arm of chromosome 18 (18q) and is found mutated in 
10% of CRCs (The Cancer Genome Atlas Network, 2012). Its function is also lost 
through deletion of 18q which is observed in approximately 70% of tumours (Pino 
and Chung, 2010). 
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1.7.6 FBXW7 
F-box/WD repeat-containing protein 7 (FBXW7) plays a role in the major regulatory 
pathways of protein degradation and is involved in cellular division (Akhoondi et al., 
2007). Mutated FBXW7 is thought to interact with c-Myc which is a transcription 
factor. Therefore it is thought that FBXW7 mutation leads to the unregulated 
expression of many genes implicated in cancer growth (King et al., 2013). Mutations 
in the FBXW7 TSG have been found in approximately 11% of CRCs (The Cancer 
Genome Atlas Network, 2012). 
 
1.8 Hereditary colorectal cancer 
Inherited colorectal cancer syndromes account for around 5% of all CRCs. The two 
most common are familial adenomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC). 
 
1.8.1 Familial adenomatous polyposis 
FAP is an autosomal dominant colorectal cancer syndrome and is caused by a 
germline APC mutation. Hundreds to thousands of adenomas form throughout the 
colon and rectum and progression to carcinoma is 100% by the age of 35-40 if left 
untreated (Half et al., 2009). The most common type of APC mutation involves the 
premature introduction of a stop codon resulting in the formation of a truncated APC 
protein. The majority of germline mutations are found in exon 15, known as the 
mutation cluster region (MCR) (Galiatsatos and Foulkes, 2006).   
 
1.8.2 Hereditary non-polyposis colorectal cancer 
HNPCC, also referred to as Lynch syndrome is characterised by an inherited 
germline mutation of the MMR genes (MSH2, MLH1, MSH6, PMS2)  followed by 
subsequent somatic inactivation of the unaffected allele. It is an autosomal 
dominant cancer predisposition syndrome, resulting often in the early development 
of colorectal cancer.  Patients with Lynch syndrome carry an 80% lifetime risk of 
developing colorectal cancer by on average, 45 years of age (Markowitz). 
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1.9 The development of early lesions from normal mucosa 
By studying the pathways involved in colorectal cancer development we have begun 
to understand the events that occur in order for a cancer to develop. A very 
important part of this process is to understand how molecular events effect the 
transition from normal bowel mucosa into adenoma. It has been hypothesised that 
the somatic mutations found in tumours occur before the tumour has developed and 
this has led to the development of the clonal evolution model. 
 
1.9.1 Clonal evolution and mutations in normal mucosa 
Cancer is thought of as an evolutionary process; a cell acquires a mutation which 
gives it a selective growth advantage, allowing it to clonally expand (Greaves and 
Maley, 2012). This clone can then acquire genetic aberrations which allow it to 
develop as an adenoma and further changes to become carcinoma. Alternatively 
some of these clones may not survive and therefore not contribute to the tumour. 
Multiple clones can occur simultaneously and these may evolve separately or 
interact with each other.  If a clone is present in the bowel for a long enough time to 
become “fixed” before the next clone starts to evolve, then clones will develop 
periodically. However, if the time for a new clone to emerge is shorter than the 
amount of time it takes for the first clone to become “fixed”, the clones will interfere 
with each other (Baker et al., 2013).  Figure 12 is a schematic of clone development 
within the bowel. 
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Figure 12. Clonal expansion of the colorectum. The pink on the left of the diagram represents 
normal bowel mucosa. The expanding triangles represent different clones expanding and either 
dying or surviving. Adapted from (Baker et al., 2013) and (Tomasetti et al., 2013). 
 
 
1.9.2 Mutations in normal colorectal mucosa 
Mathematical models have shown that a large proportion of the somatic mutations 
present in tumours occurred before phenotypic changes have occurred (Tomasetti 
et al., 2013). It has also been observed that low level mutations are present in 
histologically normal mucosa in KRAS (Parsons et al., 2010). Therefore mutations 
from abnormal clones in normal mucosa may be detectable with a highly sensitive 
technique. 
 
1.9.3 Cancer field change 
The term field cancerisation was originally used in 1953 to describe histologically 
abnormal tissue that surrounded oral squamous-cell carcinoma (Slaughter et al., 
1953). It has since been used as a theory for multiple cancer types to refer to clonal 
patches of abnormal epithelium (Ha and Califano, 2003, Heaphy et al., 2009).  The 
cells within these patches may share histological or genetic features, indicating that 
they are of clonal origin. This theory has also been applied to the colorectum to 
describe a field of abnormal bowel mucosa from which cancer may arise (Graham 
et al., 2011b, Galandiuk et al., 2012). 
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1.9.4 Clonality in the colon and rectum 
The bowel epithelium is organised into functional units described as crypts whereby 
the epithelium forms invaginations into the underlying lamina propria. Stem cells 
that reside at the base of the crypt divide to maintain the stem cell niche and form 
progenitors. If a stem cell acquires a genetic “hit” such as a mutation or larger 
structural genetic change that confers a growth advantage, it will become dominant 
and take over the stem cell niche. This process is known as niche succession 
(Figure 13A) (Zeki et al., 2011). The progenitors of the stem cell replace terminally 
differentiated cells that are shed from the top of the crypt (Humphries and Wright, 
2008, Gutierrez-Gonzalez et al., 2009). This process whereby stem cells divide and 
differentiate to dominate the crypt is known as monoclonal conversion (Figure 13B) 
(Zeki et al., 2011). Whole crypts can then further divide through bifurcation of the 
crypt into two new crypts in a mechanism known as crypt fission (Figure 13C) 
(Baker et al., 2013). As a result, the bowel is a dynamic structure, constantly 
undergoing micro-structural changes as well as reacting to the surrounding 
environment.  
 
 
Figure 13. Crypt dynamics with normal cells (blue) and mutant (green). Darker colouring 
denotes stem cells. A: niche succession. B: monoclonal conversion. C: crypt fission. Adapted 
from (Graham et al., 2011a). 
 
It is therefore thought that in order for a mutation to have an effect, it must occur 
within the stem cell niche in order to be maintained within the crypt. After a mutation 
in the stem cell has occurred, it will eventually be present within all cells in the crypt 
forming a clone. These clones can then spread throughout the bowel via crypt 
fission. Eventually, there is a variable replacement of the normal epithelial cells 
throughout the bowel with mutant clone cells and this can be widespread. These 
cells still appear histologically normal, but their genetic aberrations predispose them 
to tumour development. This process is referred to as field cancerisation (Galandiuk 
et al., 2012, Graham et al., 2011b). By this theory, a carcinogen can induce a 
mutation at a single site that has the potential to spread throughout the bowel.   
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1.10 Concluding remarks 
Colorectal cancer is a significant cause of cancer death both world-wide and in the 
UK. It has a particularly bad prognosis when detected at a later stage; less than 
50% 5-year survival for Dukes’ C and Dukes’ D. Therefore key to improving 
outcomes is the ability to detect cancer and precancerous changes as early as 
possible. This has already been seen with the introduction of bowel cancer 
screening (Mandel et al., 1993). In the bowel cancer screening programme in the 
UK, the introduction of flexisigmoidoscopy as well as FOBT has allowed for 
cancerous and pre-cancerous lesions to be detected at an even earlier stage in their 
development (Atkin et al., 2010). It could further be explored how to detect changes 
at an even earlier stage in the pathway of tumour progression; genetic changes, 
before phenotypic changes have occurred. This could have the potential to be used 
as a definitive test or as a marker to identify those who are more “at risk” of 
developing colorectal cancer. 
 
1.11 Aims 
For this thesis, the overall aims were as follows: 
 Establish the sensitivity of mutation detection with pyrosequencing and next 
generation sequencing 
 Investigate the presence of KRAS mutations in normal mucosa as well as 
other commonly mutated genes in colorectal cancer. 
 Investigate how FAP adenomas develop and relate to each other according 
to their mutational profiles and copy number changes to better understand 
the development of early adenomas. 
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2 Assessing sensitivity of mutation detection  
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2.1 Introduction 
2.1.1 KRAS mutations in normal colon epithelium 
It has been observed in numerous studies that KRAS mutations may occur in 
histologically normal mucosa (Ronai, 1994, Minamoto et al., 1995, Ronai and 
Minamoto, 1997, Zhu et al., 1997, Zhang et al., 1998, Dieterle et al., 2004, Yamada 
et al., 2005, Kraus et al., 2006, Parsons et al., 2010).  All of these studies reported 
mutations in cancer-associated normal mucosa and Ronai et al.  also reported 
mutations in non-neoplastic associated normal mucosa (Ronai, 1994). These 
studies employed polymerase chain reaction (PCR) based methods to detect KRAS 
mutations in codons 12 and 13. The reported sensitivities of these methods are 
0.01% to 1% mutant DNA within a wild-type background. Table 5 summarises the 
studies detecting KRAS mutations in normal mucosa and the reported sensitivities 
of the methods used. 
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Study Method 
Reported 
Sensitivity 
Sample type Results 
(Ronai, 
1994) 
RFLP 0.01% 
Normal mucosa 
(normal patients) 
9% (1/11) 
Normal mucosa 
(CRC patients) 
15% (2/13) 
Tumour 33% (14/42) 
(Minamoto 
et al., 1995) 
RFLP 0.01% 
Normal mucosa 
(CRC patients) 
20% (14/70) 
Tumour 51% (36/70) 
(Zhu et al., 
1997) 
RFLP & 
DGGE 
0.01% - 
0.001% 
Normal mucosa 
(CRC patients) 
0% 
(0/4) 
 
Normal mucosa 
adjacent – tumour 
54% (7/13) 
Tumour 100% (22/22) 
(Zhang et 
al., 1998) 
ARMS 1% 
Normal mucosa 
(CRC patients) 
0% (0/106) 
Normal mucosa 
adjacent – tumour 
6% 
 
(4/69) 
 
Tumour 28% (41/149) 
(Dieterle et 
al., 2004) 
RFLP 0.01% 
Normal mucosa 
(CRC patients) 
20% (3/15) 
Tumour 8% (74/199) 
(Yamada et 
al., 2005) 
ARMS 1% 
Normal mucosa 
(normal patients) 
0% (0/15) 
Normal mucosa 
(CRC patients) 
31% (20/65) 
Tumour 57% (37/65) 
(Kraus et 
al., 2006) 
RFLP 0.01% 
Normal mucosa 
(CRC patients) 
15% (21/144) 
Tumour 40% (34/84) 
(Parsons et 
al., 2010) 
 
ACB-
PCR 
0.001% 
Normal mucosa 
(normal patients) 
17% (1/6) 
Normal mucosa 
(CRC patients) 
19% (6/31) 
Normal mucosa 
adjacent – tumour 
57% (8/14) 
Tumour 36% (8/22) 
Table 5. Summary of studies detecting KRAS mutations in normal mucosa 
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2.1.2 Isolation of colonic crypts 
If mutations are present in normal colon epithelial cells, they may be at low 
frequency. DNA from whole mucosa would include wild-type (WT) DNA from the 
surrounding lamina propria which could dilute the mutant signal from the epithelium. 
In order for relatively pure collections of colon epithelial cells to be subject to 
genomic analysis, it is preferable for them to be isolated from the surrounding tissue 
architecture. There are two main methods for colonic crypt isolation: laser-capture 
microdissection (LCM) (Espina et al., 2006, Humphries et al., 2011, Galandiuk et al., 
2012) and mechanical dissociation (MD) in the presence of a chelating agent 
(Whitehead et al., 1987).  
 
For LCM, sections of tissue are mounted onto polyethylene napthalate coated slides 
(PEN). A high intensity laser beam obliterates the tissue and membrane 
surrounding the crypt and then catapults the entire intact crypt into a collecting tube 
for downstream processing (Espina et al., 2006). Alternatively, fresh mucosa can be 
first incubated with a calcium chelating agent such as ethylenediaminetetraacetic 
acid (ETDA). This removes calcium from the cell-adhesion molecules and thereby 
releases epithelial cells from the surrounding lamina propria. Whole crypts can then 
be dislodged through mechanical dissociation (Cheng et al., 1984, Goodlad et al., 
1991, Liu et al., 2012). 
 
2.1.3 PCR-based mutation detection techniques 
The PCR-based techniques used for detecting these mutations in normal mucosa 
were restriction fragment length polymorphism (RFLP) and amplification refractory 
mutation system (ARMS). RFLP-PCR is a 2 step PCR. The first round of PCR uses 
primers that introduce a base change just before the mutation site of interest, 
thereby creating an artificial restriction site. This is followed by incubation with a 
restriction enzyme, allowing for enzymatic digestion of wild-type. If a mutation is 
present, the restriction site will not be recognised by the enzyme and the PCR 
produce will evade digestion. Finally a subsequent round of PCR results in the 
enrichment of mutant DNA which can be visualised via gel electrophoresis 
(Haliassos et al., 1989). This process is schematically represented in Figure 14. 
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Figure 14. Restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR). 
The yellow star denotes the base change in mutant DNA. The red star denotes the base change 
incorporated by the long primers used in the first round of PCR to create a restriction site. 
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The ARMS method consists of two complementary PCR reactions to test the DNA 
of interest for a specific mutation (Newton et al., 1989). Each PCR reaction uses a 
common reverse primer; however the forward primer is designed to specifically bind 
to either mutant or WT. One reaction contains a forward primer that is WT to the 
mutation site of interest, whilst the other uses a primer that differs at its 3’ residues 
so that it will be complementary to mutant DNA. After amplification the PCR 
products are visualised with gel electrophoresis. If the sample is WT then only the 
WT primer reaction will show a band on the gel. If the sample is homozygous 
mutant, then only the mutant reaction will show a band. Finally if the sample is 
heterozygous mutant then both reactions will produce a band on the electrophoresis 
gel. A schematic of ARMS is outlined in Figure 15. 
 
 
 
 
Figure 15. Amplification refraction mutation system (ARMS). 
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Mutations can be detected through direct sequencing of PCR products to confirm 
the presence of any mutation at a defined site. Sanger sequencing, the original 
technology for DNA sequencing has a reported detection limit of around 20% and is 
poorly quantitative (Tsiatis et al., 2010, Davidson et al., 2012). Pyrosequencing 
however, is reported to be more sensitive and allows for more accurate 
quantification of mutant allele frequencies (Tsiatis et al., 2010). In order to better 
detect minority mutant alleles, a PCR mutant enrichment technique such as Co-
amplification at lower denaturation temperature (COLD-PCR) and Improved and 
complete enrichment co-amplification at lower denaturation temperature (Ice-COLD 
PCR) have been developed. These methods can have a reported limit of detection 
of 0.2% and 0.1% respectively (Milbury et al., 2012, Milbury et al., 2011). 
 
2.1.4 Co-amplification at lower denaturation temperature – PCR  
Co-amplification at lower denaturation temperature (COLD-PCR) is a method used 
to preferentially amplify the mutated sequence over WT (Li et al., 2008b). It exploits 
the difference in temperature that a single nucleotide mismatch causes in a 
heteroduplex of mutant strand and WT compared to a homoduplex. An extra step is 
added in the PCR whereby all the strands of DNA are heated to denature and then 
cooled to 70°C to encourage cross-hybridisation and the formation of 
heteroduplexes between the mutant strands and WT. The reaction is then heated to 
a critical temperature, Tc, which is higher than the melting temperature of the 
mutant heteroduplex but below that of the WT. This results in only the mutant 
heteroduplexes separating and being available for primers to anneal and thus there 
is preferential amplification of mutant strands over the WT which remains bound. 
This process is schematically represented in Figure 16. 
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Figure 16. COLD-PCR. The yellow star represents the mutation, creating a mismatch when 
heteroduplexes are formed. This results in the availability of mutant template when the reaction 
reaches a critical temperature (Tc). 
 
 
2.1.5 Improved and complete enrichment co-amplification at lower 
denaturation temperature (Ice-COLD) - PCR  
Improved and complete enrichment co-amplification at lower denaturation 
temperature (Ice-COLD PCR) is a technique that has similarities with COLD-PCR, 
except it exploits the difference in melting temperature between heteroduplexes of 
the mutant and a non-extendable reference sequence (RS) oligonucleotide (Milbury 
et al., 2011). The RS, which is identical to the wild-type anti-sense strand, is added 
to the PCR reaction in excess. After heating to denature, the reaction is cooled to 
70°C to encourage the formation of heteroduplexes between both the mutant strand 
and RS and also WT strand and RS. The heteroduplexes with the mutant DNA 
strand contained a mismatch and therefore have a lower melting temperature than 
the WT heteroduplexes. The reaction is then heated to a critical temperature Tc; 
higher than the melting temperature of the mutant heteroduplex, but below that of 
the wild-type. Mutant template was then more widely available for primers to anneal 
and be preferentially amplified over the WT as shown in Figure 17. 
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Figure 17. Ice-COLD-PCR. The yellow star represents the mutation, creating a mismatch when 
heteroduplexes are formed with the reference sequence (RS). 
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2.1.6 Pyrosequencing  
Pyrosequencing is a sequencing-by-synthesis technology that works on the 
detection of light emitted as the result of nucleotides being incorporated into the 
DNA sequence. As each base is added through the actions of the polymerase, 
pyrophosphate (Ppi) is released in equimolar amounts. This generates adenosine 
triphosphate (ATP) from adenosine 5´-phosphosulfate (APS), which then in turn 
converts luciferin to oxyluciferin via the actions of the luciferase enzyme. This final 
reaction causes a measurable burst of light which is directly proportional to the 
amount of nucleotide incorporated into the DNA sequence. Unincorporated 
nucleotides and excess ATP is broken down by the apyrase enzyme which allows 
the process to repeat for the next nucleotide in the sequence. The light generated 
by the enzyme reactions from the sequencing is detected by a camera, interpreted 
by the computer and displayed visually as a pyrogram which can then be used to 
read the DNA sequence and detect changes (Ronaghi, 2001). This overall 
sequence is illustrated in Figure 18. 
 
 
Figure 18. The reactions involved in pyrosequencing adapted from (Ronaghi, 2001). 
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2.2 Chapter aims  
The aims of this chapter are as follows: 
 The development of methods for the isolation of DNA from normal colonic 
mucosa. 
 To investigate the value of PCR based mutant enrichment techniques 
 To determine the sensitivity of pyrosequencing 
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2.3 Chapter Methods 
2.3.1 Preparation of fresh-frozen tissue 
Specimens were collected from anonymous surgical resections for colorectal cancer 
and samples of the tumour and normal tissue from the resection margin were taken.   
These samples were then flash frozen in liquid nitrogen, mounted on optimal cutting 
temperature embedding medium (OCT) (Leica, Milton Keynes, UK) and stored at -
80°C. Between 6 and 10 cryosections of 7μm thickness were taken for DNA 
extraction from both tumour and normal samples from each case. Two methods of 
colonic crypt isolation were investigated: LCM and MD in comparison to DNA 
extraction from whole macrodissected mucosa. 
 
2.3.2 Ethical approval 
Ethical approval for the collection, storage and use of patient material for these 
samples was obtained from the South Yorkshire Research Ethics Committee REC 
reference: 10/H1310/61. 
 
2.3.3 Spot counting 
In order to determine the proportion of mucosa consisting of epithelial cells Spot 
counting analysis (West et al., 2010) was undertaken as outlined in section 2.3.3. 
For each sample to undergo spot counting, 3 cryosections were taken and mounted 
onto glass sides, stained with H&E and then were digitally scanned at 20x 
magnification. Using ImageScope v10 software (Aperio Technologies Inc., Vista, 
CA) the mucosa was identified and a 300-point grid was applied to this area (Figure 
19). A code was applied to each point that was counted as seen in Table 6. The 
epithelial component percentage was calculated from the percentage of points 
coded as “1” amongst the total number of informative points counted. A final 
average was taken from all 3 sections from each sample. 
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Figure 19. Spot-counting analysis on normal mucosa. A: The area of mucosa is selected by 
freehand. B: Random spots applied to selected area for counting. 
 
 
 
 
Component 
Numerical 
code 
Non-informative  0  
Epithelium  1  
Lamina propria  2  
Necrosis  3  
Vessels  4  
Inflammation  5  
Crypt lumen  6  
Mucin  7  
Muscle  8  
Table 6. Coding of tissue components for spot-counting analysis 
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2.3.4 Laser-capture microdissection (LCM) 
Cryosections of 7μm were taken onto glass slides that were not superfrost in order 
to reduce adhesion onto the slide and improve capture of material. Sections were 
also taken onto membrane-coated polyethylene naphthalate (PEN) slides for 
comparison of laser-capture methods. For downstream analysis a minimum yield of 
20ng/μl gDNA required in a volume of 10-20μl (a minimum of 200ng of gDNA in 
total). Using the assumption that each diploid cell contains approximately 6pg of 
DNA:  
 
(200x10-9) / (6x10-12) ≈ 30,000 cells 
 
It was visually estimated that a cross sectional crypt contains around 50 cells 
therefore at least 600 crypts are required to obtain 200ng of gDNA. It is expected 
that material will be lost at every stage in the extraction process and therefore 1000 
crypts per sample were captured to ensure that a sufficient amount of DNA could be 
obtained. 
 
Cryosections were stained before LCM with the following protocol: 
 2 min Mayer’s haematoxylin 
 Rinse in distilled H2O 
 2 min Scott’s tap water 
 Rinse in distilled H2O 
 1 min eosin 
 Rinse in distilled H2O 
 1 min 70% ethanol 
 
2.3.5 Laser settings 
Two laser-capture functions were tested on the sections.  The first used a 
defocused UV laser to fire multiple pulses over a pre-defined area on a glass-
mounted slide.  This catapults the tissue at discrete points into the collecting tube 
and destroys the tissue architecture as shown in Figure 20. However maintaining 
tissue integrity is not a priority for the purposes of DNA extraction.  
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Figure 20. Laser pressure catapulting  
 
 
The second method tested was used with PEN slides and utilises a high intensity 
beam that obliterates the tissue and membrane around the crypt and then catapults 
the intact crypt adhered to the membrane, into the collecting tube.  This allows for 
the crypts to be visualised in the cap of the collecting tube to confirm it has been 
captured and the tissue architecture is maintained (Figure 21). 
 
 
 
Figure 21. A: Laser-dissected crypt from PEN slide. B: Collecting tube cap showing captured 
crypts. 
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2.3.6 Mechanical dissociation of crypts 
Colon epithelial cells may also be isolated from the surrounding tissue through 
incubation with a calcium chelating agent followed by dislodging crypts through 
mechanical dissociation (Cheng et al., 1984, Goodlad et al., 1991). The following 
protocol was adapted from the method as described by Cheng et al. (Cheng et al., 
1984) 
 
Frozen samples were thawed and washed in Hank’s buffered salt solution (HBSS) 
(Invitrogen, UK) to remove OCT.  The samples were subsequently transferred to 
cold (4°C) HBSS calcium and magnesium-free (CMF) (Invitrogen, UK) and washed 
twice.  After the washing steps they were transferred to fresh HBSS CMF with 
EDTA and incubated for 45 mins at 37°C (see appendix for recipe).  Next the 
samples were washed again in HBSS-CMF before being transferred to fresh HBSS-
CMF and underwent mechanical disruption by use of a magnetic stirrer for 2 hours 
at 4°C.  Finally the solution was spun at 750g for 5 mins at 4°C and the pellet 
removed.  A sample was taken for visual confirmation that crypts had been isolated 
(Figure 22) and the remaining pellet was used for DNA extraction with Qiagen 
QIAamp DNA Mini Kit (QIAGEN, UK).  The remaining tissue was fixed in 
formaldehyde and embedded in paraffin wax, before sections were taken and 
stained with H&E (section 2.3.7) to visualise the crypt dissociation (Figure 23).  
 
 
Figure 22. Cytokeratin immunohistochemistry stain to confirm epithelial cells. A: Cytospin of 
pellet from mechanical dissociation. B: Isolated colonic crypt 
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Figure 23. H&E section of mucosa after mechanical dissociation of crypts 
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2.3.7 Preparation of formalin fixed paraffin embedded tissue  
10-20 5μm sections were taken from formalin fixed paraffin embedded (FFPE) 
tissue blocks for DNA extraction. The sections were de-waxed for 12 mins in xylene, 
followed by 12 mins in ethanol and finally 9 mins in graded ethanols before being 
transferred into distilled water for extraction. A further section from each sample was 
cut and stained to guide macro-dissection for DNA extraction. The staining protocol 
used was as follows:  
 2 mins Mayer’s haematoxylin 
 1 min rinse in water 
 2 mins Scott’s tap water 
 1 min rinse in water 
 2 mins eosin 
 1 min rinse in water 
 12 mins ethanol 
 9 mins xylene 
Finally cover slips were mounted onto the slides with Di-N-butyl phthalate in xylene 
(DPX) (CellPath, Powys, UK). 
 
2.3.8 Macrodissection of normal mucosa 
H&E sections for each case to undergo DNA extraction were assessed using light 
microscopy to identify an area of histologically normal mucosa. These areas were 
then annotated on the H&E slide. De-waxed sections were then macrodissected 
using the annotated H&E slide as guidance for the area of tissue to be used for 
extraction. Macrodissection was performed using a needle and/or scalpel blade for 
each section using a dissecting microscope for visual guidance. Figure 24 shows an 
example of a section before and after macrodissection. 
 
Figure 24. Macrodissection of H&E section. A Before macrodissection with area to be removed 
for extract highlighted in green. B section after macrodissection. 
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2.3.9 DNA extraction 
For samples where FFPE sections had been taken, they were macro-dissected 
before undergoing DNA extraction with the Qiagen QIAamp Micro Kit (QIAGEN, 
Crawley, UK). This was done in accordance with the standard protocol with the 
modification of an over-night digestion step and a final elution volume of 25μl H2O.  
 
DNA from crypts isolated from fresh-frozen tissue by MD was extracted with the 
Qiagen QIAamp DNA Mini Kit (QIAGEN, Crawley, UK) in accordance with the 
standard manufacturer’s protocols with an elution volume of 50μl. This was due to 
the higher expected yield of DNA from this method.  
 
All extracted DNA was tested on the nanodrop spectrophometer (Thermo Scientific, 
Washington, USA). This provided an estimate of the DNA concentration as well as 
the quality by providing absorbance ratios. The 260:280 ratio which measures the 
amount of absorbance of light at wavelengths of 260nm and 280nm was used as a 
measure of DNA purity. A value in the range of 1.8-2.0 was taken as optimal.  
 
2.3.10 Cell line DNA 
DNA from cell line SW48 of known concentration was provided by Horizon 
Discovery (Horizon Discovery, Cambridge, UK) containing an engineered 
heterozygous KRAS mutation. Both wild-type (WT) DNA and mutant DNA with one 
of 6 KRAS 12 and 13 mutations were provided as shown below in Table 7. 
 
Mutation cdna notation Amino acid change 
G12A c.35G>C glycine – alanine 
G12C c.34G>T glycine – cysteine  
G12D c.35G>A glycine – aspartic acid 
G12R c.34G>C glycine – arginine 
G12V c.35G>T glycine – valine 
G13D c.38G>A glycine – aspartic acid  
 
Table 7. KRAS codon 12 and 13 mutant DNA provided by Horizon Discovery (Horizon 
Discovery, Cambridge, UK) for testing sensitivities of mutation detection technologies.  
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2.3.11 Polymerase chain reaction amplification of KRAS 
Primers were designed using pyrosequencing assay design software (Biotage AB, 
Uppsala, Sweden) as outlined by Dr. Phil Chambers et al. (Chambers et al., 2013). 
Primers were designed for KRAS codons 12 and 13 to create an 80bp amplicon: 
 
Fwd: 5’GGCCTGCTGAAAATGACTGA3’ 
Reverse: 5’AGCTGTATCGTCAAGGCACTCT3’ 
KRAS Pyrosequencing primer: 5’Biotin-AAACTTGTGGTAGTTGGA 3’ 
 
For standard PCR reactions, HotStarTaq Master Mix from Qiagen (QIAGEN, 
Crawley, UK) was used to create a reaction volume of 25μl or 50μl for downstream 
sequencing (Table 8).  
 
Component 
Volume per 
reaction 
Final concentration 
25μl 
reaction 
50μl 
reaction 
HotStarTaq Master Mix 12.5μl 25μl 
I unit HotStarTaq DNA 
polymerase 
1xPCR buffer* 
200μM of each dNTP 
Forward Primer (25μM) 0.2μl 0.4μl 0.2μM  
Reverse Primer (25μM) 0.2μl 0.4μl 0.2μM 
MgCl2
  (25mM) 0.5μl 1μl 2mM 
H2O 9.6 μl 19.2μl  
gDNA (10ng/ul) 2μl 4μl  
Table 8. PCR reaction composition with the use of Taq polymerase enzyme. * buffer contains 
1.5mM MgCl2. 
 
The thermocycling conditions for KRAS primers with the use of HotStarTaq were as 
follows: 
 95°C for 12 mins 
 40 cycles of: 
 94°C for 10 secs 
 55°C for 20 secs 
 72°C for 20 secs 
 
 Hold at 4°C 
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All PCR products amplified were visualised by gel electrophoresis. A 2% agarose 
gel was made by dissolving agarose in Tris-EDTA buffer (TE) (Promega, Madison, 
USA) by heating and allowing it to set. 4μl of PCR product with 1μl of Orange G 
loading buffer were loaded and the gelrun for 30 mins at 120mV before 
visualisation.  The remaining PCR product was cleaned up using the Qiagen 
MinElute kit (QIAGEN, Crawley, UK), eluting in 20μl. Finally quantification of the 
PCR products was performed by use of a Quant-iT PicoGreen assay (Invitrogen, 
Paisley, UK) following the standard protocol.  
 
Pyrosequencing was performed by Dr. Phil Chambers and Miss Morag Taylor on a 
PyroMark Q96 ID (QIAGEN, Crawley, UK). All sequencing was conducted 
according to the manufacturer’s protocols. 
 
 
2.3.12 Restriction fragment length polymorphism PCR 
An adapted protocol was developed in order to enrich mutations in KRAS codon 12 
to be visualised with gel electrophoresis as well as subsequent pyrosequencing to 
confirm the mutation (Ronai and Minamoto, 1997). The primers used were the same 
as those in the original protocol (Ronai and Minamoto, 1997) and outlined in Table 
9. 
. 
PCR 
stage 
Primer Sequences 
Round 1 
Fwd: 
5’GCGGTTGGGGCTTAATTGCATATAAACTGAATATAAACTTGTGGTA
GTTGGACCT 3´ 
Rev:  
5’GCTGTTGTCATAGTAATGATTCAAAGAATGGTCCTGCACCAG  
Round 2 
Fwd: 5’ GCGGTTGGGGCTTAATTGCA  
Rev: 5’ GCTGTTGTCATAGTAATGAT 
 
Table 9. Primers used in wild-type restriction digest PCR. The underlined sequence of the first 
round primers binds to the gDNA target. The shorter primers used in the second round bind to 
the long tail of the first round PCR primers, indicated by sequences in bold font.  
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A 25μl PCR reaction with Qiagen HotStarTaq (section 2.3.11) underwent a first 
round of PCR with the following thermocycling protocol: 
 95°C for 12 mins 
20 cycles of: 
 94°C for 1min 
 55°C for 1min 
 72°C for 1min 
 
 Hold at 4°C 
 
Following the initial round of PCR, PCR products were incubated with one unit of 
ScrFI enzyme (New England Biolabs, UK) at 37°C with 10xNEB buffer 3 and Dnase 
free H2O. The restriction sites for ScrFI are shown in Figure 25. 
 
 
Figure 25. Restriction site for ScrFI enzyme. N= G,T,A or C. 
 
 
After the initial digestion step samples were then subject to purification using 
QIAquick PCR Purification Kit (QIAGEN, UK) to remove previous PCR and 
digestion buffers. A 12μl aliquot was used as the template for the second round of 
PCR. The same reagents and reaction conditions were used for the second round 
of PCR. After this stage a second digestion step was performed to ensure that all 
wild-type KRAS 12 had undergone digestion. The digestion products were then run 
on a 2% agarose gel and were gel purified to isolate the 196bp product for 
sequencing. 
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2.3.13 COLD-PCR method 
The reaction mix for COLD-PCR was identical to that used for standard PCR (Table 
5) with taq polymerase (section 2.3.11) underwent the following thermocycling 
protocol: 
 95°C for 12 mins 
 
10 cycles of: 
 95°C for 10sec 
 55°C for 10sec 
 72°C for 10sec 
 
30 cycles of: 
 95°C for 10sec 
 70°C for 8 mins 
 Tc for 10sec 
 55°C for 10sec 
 72°C for 10sec 
 
 Hold at 4°C 
The critical temperature, Tc varies for each primer paired used and was determined 
by producing melting curves of mutant:wild-type heteroduplexes (see section 2.4.5). 
 
2.3.14 Ice-COLD-PCR method 
Again, the same reaction mix as before (Table 8 section 2.3.11) for Taq polymerase 
was used for Ice-COLD-PCR. The RS was used as described by Milbury et al. 
(Milbury et al., 2011):  
 
5’CTCTTGCCTACGCCACCAGCTCCAACTACCACAAGTTTATATTCAG-
phosphate3’ 
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The phosphate group at the 3’ end prevents extension by the polymerase during the 
PCR. The thermocycling protocol for Ice-COLD-PCR was as follows: 
 
 98°C for 30 sec 
 
5 cycles of: 
 98°C for 10 sec 
 59°C for 20 sec 
 72°C for 10 sec 
 
 35 cycles of: 
 95°C for 10 sec 
 70°C for 30 secs 
 Tc for 10 sec 
 59°C for 10 sec 
 72°C for 10 sec 
 
 Hold at 4°C 
 
The critical temperature, Tc, was determined by the melting curves of mutant:wild-
type heteroduplexes  (see section 2.4.6). 
 
2.3.15 Analysis of pyrograms 
Pyrosequencing produces the peak heights for each nucleotide that is added to the 
sequence and can therefore produce quantitative results. By comparing the intensity 
of the mutant peak heights to the other peak intensities in the pyrogram the 
percentage of mutant in the sample can be calculated. However, the calculated 
mutant percentage has to be interpreted in the context of the background peaks 
seen in the wild-type, particularly at low mutant allele frequencies. Each of the 
possible 6 KRAS codon 12&13 mutations has to be interpreted individually and the 
formulae were as follows: 
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G12A c.35G>C mutation 
              [           ]   
              [           ]                [           ]
 
 
 
G12C c.34G>T mutation 
              [                   ]                                      )  )
               [                   ]  
                 [                   ]                                  )
 
 
 
G12D c.34G>T mutation 
              [          ]     )   )
              [           ]                [           ]
 
 
 
G12R c.34G>C mutation 
              [           ]   
              [           ]                [           ]
 
 
 
G12V c.35G>T mutation 
               [                                                    )   )
              [                   ]  
               [                   ]                                    
 
 
 
G13D c.38G>A mutation 
               [           ]     )   
              [                  ]                [           ]
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2.3.16 Statistical methods 
To compare yields of DNA obtained through different methods of crypt isolation, the 
median and interquartile ranges were calculated as the data was not assumed to fit 
a normal distribution. P values were calculated by the Mann-Whitney U test to 
compare yields from different colonic crypt isolation methods. All statistics were 
carried out using the Statistical Package for the Social Sciences (SPSS version 20, 
Chicago, USA). 
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2.4 Results 
2.4.1 Spot counting analysis 
Spot-counting analysis was performed on 3 samples of sections of normal mucosa 
in order to determine the percentage of the mucosa that consists of epithelium. A 
median percentage of 51.7% was determined as epithelial cells (Table 10) (for full 
data see appendix section 6.2). 
 
Sample 
Number 
of 
sections 
Number 
of spots 
counted 
Number of 
spots on 
epithelium 
Median % 
epithelium 
Interquartile 
range (%) 
1 5 1437 712 49.8 47.3 – 51.5 
2 5 1377 745 51.8 40.5 – 54.0 
3 4 1086 523 46.2 40.1 – 52.9 
Overall median percentage epithelium 51.7 47.9 – 54.1 
Table 10. Summary of spot counting analysis 
 
2.4.2 Crypt isolation techniques 
A comparison of DNA yield was made between DNA extraction by microdissection 
of whole mucosa and two colonic crypt isolation techniques: laser-capture 
microscopy (LCM) and mechanical dissociation (MD).  
 
For whole mucosa DNA extraction was performed on 5 different frozen samples of 
normal colorectal mucosa. Each sample had six 7μm sections taken for extraction. 
Extraction buffer without any tissue was used as a negative control. Scraping off 
approximately 5mm2 of mucosa per section with the aid of a dissection microscope 
from H&E stained frozen sections produced a consistently high yield of DNA from 
extraction. The median yield obtained was 149ng/μl (interquartile range 131.66ng/μl 
– 158.97ng/μl) compared to the negative control 3.56ng/μl (interquartile range 
3.02ng/μl – 7.43ng/μl). This difference was statistically significant (Mann-Whitney p 
value=0.008). The yield of DNA obtained from this method is shown in Table 11. 
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Sample 
Quantity of DNA extracted (ng/μl) 
Normal mucosa Negative control 
1 149.00 7.43 
2 131.66 9.95 
3 188.97 3.02 
4 158.97 2.74 
5 130.53 3.56 
Median 149.00 3.56 
Interquartile range 131.66 – 158.97 3.02 – 7.43 
Table 11. DNA yield from extraction of whole mucosa 
 
 
LCM was performed on 5 samples of normal mucosa. 3-4 sections of each sample 
were dissected until approximately 1000 crypts had been captured. The median 
DNA yield after extraction was 8.58ng/μl compared to a negative control of 2.81 
(Mann-Whitney p value=0.095) (Table 12). 
 
 
Sample 
Quantity of DNA extracted (ng/μl) 
Normal mucosa Negative control 
1 3.06 1.84 
2 22.9 2.81 
3 3.56 1.66 
4 8.58 4.16 
5 33.11 4.65 
Median 8.58 2.81 
Interquartile range 3.56 – 22.90 1.84-4.16 
  Table 12. DNA yield from extraction of crypts isolated by laser-capture microscopy 
 
 
Finally 5 samples of normal colon mucosa of dimensions ~10mm x 5mm x 0.45mm 
underwent MD to isolate the colonic crypts. A median yield of 522.48ng/μl was 
obtained via this method which was statistically significant from the negative control 
of 3.02ng/μl (Mann-Whitney p value<0.0001) (Table 13). 
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Sample 
Quantity of DNA extracted (ng/μl) 
Normal mucosa Negative control 
1 151.95 3.02 
2 133.52 2.18 
3 1194.46 9.61 
4 1046.15 1.53 
5 522.48 7.78 
Median 522.48 3.02 
Interquartile range 151.95 – 1064.15 2.18 – 7.78 
Table 13. DNA yield from extraction of crypts isolated by mechanical dissociation 
 
Table 14 gives a summary of the DNA yields that were obtained from the two crypt 
isolation techniques in comparison to extraction from whole mucosa. This data is 
also displayed in Figure 26 to show the range and IQR for the different techniques. 
MD produced a significantly higher yield of DNA than LCM: a median yield of 
149.00ng/μl compared to 8.58ng/μl for LCM, p<0.05. 
  
Method 
Median DNA 
yield (ng/μl) 
Negative 
control 
(ng/μl) 
IQR Range 
Whole 
mucosa 
149.00 3.56 131.66 – 158.97 130.53 – 188.97 
p = 0.008 
LCM 8.58 2.81 3.56 – 22.9 3.06 – 33.11 
p = 0.095 
MD 522.48 3.02 151.95 – 
1064.15 
131.52 – 
1194.46 p <0.0001 
Table 14. Comparison of median DNA yield and interquartile range (IQR) from crypt isolation 
techniques laser-capture microscopy (LCM) and mechanical dissociation (MD) compared to 
whole mucosa extraction. P values from Mann-Whitney statistical analysis. 
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Figure 26. Box and whisker plot comparing medians and interquartile ranges of DNA yield from 
crypt isolation techniques laser-capture microscopy (LCM) and mechanical dissociation (MD) 
and whole mucosa extraction. 
 
At low DNA concentrations, nanodrop readings can be subject to interference from 
the extraction buffers.  However, the amount of DNA obtained through MD was 
significantly higher than the negative control, indicated by p<0.0001.  This was 
confirmed by visualising the DNA on an agarose gel (Figure 27). 
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Figure 27. 1.5% agarose gel confirming extraction of DNA through MD from three samples of 
fresh normal mucosa. The recovery of high molecular weight DNA is indicated by arrows. The 
first lane shows a more fragmented sample for comparison. 
 
For the three samples shown in Figure 27 the proportion of DNA recovered at high 
molecular weight (10,000kb and above) was 38%, 28% and 31% respectively. 
 
 
2.4.3 Pyrosequencing of serial dilutions of mutant KRAS 
Pyrosequencing serial dilutions of 6 different KRAS 12 and 13 mutations found the 
limit of detection of the pyrosequencer to lie between 5 and 25% (Table 15) as there 
was variation in sensitivity with each run. Two runs were performed on all 6 
mutations and an extra run was performed on just 2 of the mutations (12A c.35G>C 
and 12C c.34G>T) due to limited amounts of control mutant DNA available. Figure 
28 shows the pyrograms from one run and repeat runs produced comparable 
programs (see appendix). 
 
 Limit of Detection 
Mutation Run1 Run 2 Run3 
G12A c.35G>C 5% 25% 5% 
G12C c.34G>T 25% 25% 25% 
G12D c.35G>A 5% 25% - 
G12R c.35G>C 5% 5% - 
G12V c.35G>T 5% 25% - 
G13D c.38G>A 25% 5% - 
Table 15. Limit of detection of Pyrosequencing for 6 different KRAS codon 12 and 13 mutations 
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Figure 28. A-F: Pyrograms of serial dilutions of 6 KRAS codon 12 and 13 mutations. The 
percentage shown is calculated from the peak height intensities. Solid circled peaks denotes 
detected mutation and dotted-line circles denote peaks on the borderline of detection. 
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2.4.4 RFLP 
After the initial round of PCR, the modified primers successfully amplified the 196bp 
KRAS amplicon in both mutant and WT samples (Figure 29). 
 
 
Figure 29. Amplifciation of 196 base pair KRAS amplicon in mutant and wild-type 
 
After incubation with BstNI enzyme, WT samples were digested and then used as 
template for the second round of PCR, which successfully amplified the 196bp 
mutant whilst no amplification was seen in WT samples (Figure 30). 
 
 
Figure 30. Second-round amplification of restriction digest products.  Only the mutant sample 
is amplified. The 196 base pair KRAS amplicon is indicated by the arrow. 
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In order to determine the limit of detection of this technique, WT-restriction digest 
was performed on serial dilutions of mutant KRAS DNA and were subsequently 
sequenced by pyrosequencing. Through visual inspection of agarose gel 
electrophoresis, mutant DNA could be detected down to 5% (Figure 31). 
Pyrosequencing was performed in order to confirm that the correct mutation was 
present and that the band was not a non-specific product. Through pyrosequencing, 
mutations could be detected down to a level of 2.5% (Figure 32). 
 
 
Figure 31. Serial dilutions of mutant KRAS after WT restriction digest.  
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Figure 32. Pyrograms of serial dilutions of G12C c.34G>T after WT restriction digest showing a 
detection of mutant allele down to 2.5%. 
 
 
2.4.5 COLD-PCR 
In order to determine the critical temperature (Tc) for COLD-PCR, firstly melting 
curve analysis was performed on the mutant-wildtype heteroduplexes (Figure 33). 
The melting temperature of the WT:WT heteroduplexes was found to fall just below 
86°C whereas the mutant-WT melted at around 85°C. Therefore a range from 
84.1°C – 85.5°C was tested as the critical temperature.  
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Figure 33. Melting curves of Wildtype:Wildtype duplexes (blue line) and Wildtype:mutant 
heteroduplexes 
 
A 2.5% dilution of the KRAS G12D c.35G>A mutation was amplified by COLD-PCR 
(section 2.1.4) as well as standard PCR amplification (section 2.3.11) and then 
pyrosequenced. Enrichment was determined by subtracting the WT background 
peaks from both the COLD-PCR sample and a standard PCR sample, then 
comparing the calculated mutant allele frequencies (section 2.3.15). A maximum 
enrichment of 2.1-fold was found at 85.5°C and so this was taken as the critical 
temperature (Table 16, Table 17 and Figure 34). 
 
Tc (°C) Calculated % from 
mutant peak heights 
Enrichment  
(fold) 
84.1 5.64 1.38 
85.1 6.97 1.83 
85.3 7.26 1.93 
85.5 7.76 2.10 
Table 16. Enrichment after COLD-PCR for critical temperatures 84.1°C – 85.5°C on the 2.5% 
dilution of 12Dc.35G>A mutant. 
 
 
Tc (°C) Calculated % from 
mutant peak heights 
Enrichment  
(fold) 
85.5 6.15 1.62 
85.7 5.16 1.06 
85.9 6.17 1.45 
86.1 4.87 1.03 
Table 17 Enrichment after COLD-PCR for critical temperatures 85.5°C – 86.1°C on the 2.5% 
dilution of 12Dc.35G>A mutant. 
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Figure 34 A&B. Enrichment after COLD-PCR for critical temperatures 84.9°C – 86.1°C on the 
2.5% dilution of 12Dc.35G>A mutant. 
 
 
2.4.6 Ice-COLD-PCR 
As with the COLD-PCR technique, melting curve analysis was first performed but 
with the RS:mutant and RS:WT heteroduplexes as shown in Figure 35. From this 
analysis, a temperature range of 83.5°C – 84.5°C was tested as the critical 
temperature. 50% and 25% dilutions of KRAS G12Dc.35G>A were tested and 
enrichment was only seen at 84°C in the order of 1.15-fold (Table 18 and Table 19). 
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Figure 35.  Melting curves of RS:wildtype (RS:WT) heteroduplexes and RS:mutant (RS:M) 
heteroduplexes. 
  
RS:WT 
RS:M 
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Tc (°C) Calculated % from 
mutant peak heights 
Enrichment  
(fold) 
83.5 53.06 1.08 
84.0 56.63 1.16 
84.5 51.64 1.06 
Table 18. Critical temperatures tested on 50% 12Dc.35G>A mutant template 
 
 
Tc (°C) Calculated % from 
mutant peak heights 
Enrichment  
(fold) 
83.5 24.32 0.84 
84.0 32.82 1.14 
84.5 28.26 0.98 
Table 19.  Critical temperatures tested on 25% 12Dc.35G>A mutant template 
 
In order to improve the amount of enrichment seen, the concentration of RS was 
optimised. A range of concentrations (0nM – 50nM) was tested with 25% dilutions of 
two KRAS mutants, G12Dc.35G>A and G13Dc.38G>A. Enrichment was seen at the 
25nM RS concentration for the 12Dc.35G>A (Table 20) and at both 20M and 50nM 
for 13Dc.38G>A (Table 21). Therefore an optimal concentration of 25nM was 
chosen for further experiments. 
 
RS Concentration  
(nM) 
Enrichment (fold) 
0 - 
1 0.95 
5 0.98 
20 0.94 
25 1.46 
50 0.37 
Table 20. Enrichment from a range of RS concentrations for KRAS 12D c.35G>A mutant at 25% 
dilution 
 
 
 
Table 21.  Enrichment from a range of RS concentrations for KRAS 13D c.38G>A mutant at25% 
dilution 
RS Concentration 
 (nM) 
Enrichment (fold) 
0 - 
1 0.96 
5 0.98 
10 0.95 
20 1.23 
50 1.21 
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Finally Ice-COLD-PCR with a Tc of 84°C and RS concentration of 25nM was 
performed on serial dilutions of 3 different KRAS mutants; 12D c.35G>A, 12R 
c.34G>C and 12V c.35G>T. Enrichment was seen at the lower concentrations 
(2.5% - 0.05%) for 12D c.35G>A (Table 22). Enrichment was seen at the 0.5% 
dilution for both 12R c.34G>C and 12V c.35G>T (Table 23 and Table 24), but only 
at 5% and 25% for the 12V c.35G>T mutation (Table 24). The maximum enrichment 
achieved was 2.24-fold.  
 
Dilution 
(%) 
Enrichment 
(fold) 
50 1.15 
25 0.40 
5 0.84 
2.5 1.14 
0.5 2.44 
0.05 1.81 
Table 22. Enrichment from Ice-COLD-PCR on serial dilutions of KRAS 12D c.35 G>A mutation 
 
 
Dilution 
(%) 
Enrichment 
(fold) 
25 1.07 
5 1.00 
0.5 2.24 
Table 23. Enrichment from Ice-COLD-PCR on serial dilutions of KRAS 12R c.34 G>C mutation 
 
 
Dilution 
(%) 
Enrichment 
(fold) 
25 1.23 
5 1.30 
0.5 1.36 
Table 24.  Enrichment from Ice-COLD-PCR on serial dilutions of KRAS 12V c.35 G>T mutation 
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2.4.7 Pyrosequencing of clinical samples 
The extracted DNA from crypts isolated by mechanical dissociation (section 2.3.6) 
in normal mucosa samples from 20 patients with colorectal cancer were 
pyrosequenced.  DNA from the matched tumour was also pyrosequenced (Table 
25). No mutations were detected in any of the histologically normal mucosa. There 
were 6 different KRAS codon12 and13 mutations were detected in 8 (40%) of the 
tumour samples (Table 25). No KRAS 61 or 146 mutations or BRAF mutations were 
detected in any of the tumour or normal mucosa samples. 
 
Sample 
Number 
Mutation  Sample 
Number 
Mutation 
1 WT  11 WT 
2 13D c.38G>A  12 WT 
3 12V c.35G>T  13 WT 
4 12D c.35G>A  14 WT 
5 WT  15 WT 
6 WT  16 12V c.35G>T 
7 12R c.34G>C  17 12V c.35G>T 
8 WT  18 WT 
9 12A c.35G>C  19 WT 
10 12S c.34G>A  20 WT 
Table 25. Pyrosequencing of 20 tumour samples.  
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2.5 Discussion 
2.5.1 Spot-counting analysis 
The spot-counting analysis found 51.7% of the mucosa to consist of epithelial cells 
(section 2.4.1 Table 10). These are the cells that become mutated in CRC and 
therefore are the cells of interest to extract DNA from for mutational analysis 
(Markowitz and Bertagnolli, 2009). The mucosa contains other cell types such as 
fibroblasts, macrophages, lymphocytes etc. that are found predominately in the 
supporting lamina propria (Hunyady et al., 2000). These cells would contaminate 
the DNA extraction and would effectively dilute the mutant epithelial DNA. If 
mutations are to be detected in normal colorectal mucosa they are likely to be at a 
very low level, therefore enriching the epithelial cell population within the DNA 
extraction may increase the chance of detecting mutations within the epithelial cells 
if they are present. If the epithelium were to be separated, then the relative 
proportion of WT:mutant alleles would change, increasing the ratio of WT alleles : 
mutant alleles from 3:1 to 1:1. It is therefore optimal to isolate the colonic crypts in 
order to obtain the purest sample of epithelial DNA possible. 
 
2.5.2 Comparison of crypt isolation techniques 
Despite micro-dissecting approximately 1000 crypts that was estimated to produce 
a sufficient yield of DNA (section 2.4.2) LCM failed to produce enough material for 
DNA extraction to produce a nanodrop reading that was high enough compared to 
the negative control (p=0.095) (Table 12) and could not be visualised on an agarose 
gel. LCM produced the lowest amount of DNA from any of the extraction methods 
(Table 14). It was also the most time-intensive method (approximately 1- 2 days per 
sample) in contrast to MD where multiple samples can be extracted simultaneously 
in a few hours.  
MD produced the highest median yield of DNA but also the largest range and IQR 
(Table 13 and Table 14). The median yield obtained was significantly higher than 
the median yield from the LCM method (p<0.05). However, this large difference is 
most likely caused by the difference in starting material. For whole mucosa, six 7μm 
sections of ~5mm2 were taken for extraction, giving a total volume of starting 
material of ~0.035mm3. In comparison, whole samples of mucosa that underwent 
MD measured ~22mm3 in volume. However, due to the length of time it requires to 
isolate crypts via LCM it would be impractical to perform LCM on a comparably 
sized sample.  The large range of DNA yield for MD may be due to variance in the 
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size of the starting material. Therefore to directly compare methods, starting 
samples of mucosa with set dimensions could be collected. However the advantage 
of a large sample would be the increased ability to identify the presence of a 
mutated clone. All samples extracted by MD produced a high enough amount of 
DNA for downstream sequencing. 
 
The negative control for each extraction produced a reading on the nanodrop; 
however these always fell below 10ng/μl. This could be due to contaminating DNA. 
However it is worth noting that the 260:280 ratios for these readings strongly 
indicated that it was not DNA causing these readings. It was likely due to 
components of the extraction buffers that had washed through with the elution 
buffer. It would be useful to perform PCR on the negative control extractions to 
confirm if the reading was from contamination DNA. 
 
MD is a suitable method for isolating crypts from fresh tissue, however, for FFPE 
tissue this method is not possible and therefore macrodissection with the aid of a 
dissecting microscope is the most practical method available for DNA extraction 
from normal mucosa. Table 11 shows that a sufficient yield of DNA was obtained 
from this method (section 2.3.7). 
 
2.5.3 Limit of detection of pyrosequencing 
The sensitivity of pyrosequencing was found to be between 5%-25% (Table 15) and 
this reflects the findings of previous studies that report a sensitivity of 5% (Ogino et 
al., 2005, Tsiatis et al., 2010). The pyrograms in Figure 28 also show that the 
sensitivity of the pyrosequencer varies according to which mutation is being 
detected (see appendix for full dataset). As seen in Figure 28C the G12Dc.35G>A 
mutation is detected at 5% and is on the limits of detection at 2.5% whereas for the 
12C c.34G>T mutation (Figure 28B), the mutant could not be detected at a dilution 
below 25%. All the pyrograms show that there is very low background at c.34 for the 
A-peak and the single A peaks produce higher intensity peaks than the other 
nucleotides and this may contribute to the increased sensitivity observed for the 
12D c35G>A mutation. Whereas for a G>T mutation, the single “T” peak becomes a 
double and this increase in intensity of the T peak is harder to distinguish (Figure 
28B) than a new peak over background such as a G>A mutation, which is why 
pyrosequencing is less sensitive for the G>T mutation. 
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Diagnostic mutation testing in clinical samples utilises a different method to detect if 
a mutation is present. If a mutant peak height is three standard deviations away 
from the mean then it is classed as a mutation and samples that lie 2-3 standard 
deviations from the mean are repeated. The peaks observed on the pyrograms are 
also used in conjunction with the peak heights. This method is sufficient for clinical 
samples as tumour cell DNA concentration is usually around 20-25% of the mutant 
allele since half the cells are tumour cells and they only carry one mutated allele. 
However, for determining the sensitivity of the pyrosequencer with cell-line DNA 
with a known mutated DNA concentration, dilutions below 25% of the mutant allele 
do not fall over 3 standard deviations and peaks can be difficult to distinguish from 
the background on the pyrogram. Therefore the calculated percentage method can 
be used to determine if the pyrosequencer can detect the presence of a mutation 
when the starting dilution of the mutant cell-line DNA was known. 
 
2.5.4 RFLP 
The WT restriction digestion method allowed for the c.34G>C mutation to be 
detected at 5% when using visual detection with agarose gel electrophoresis (Figure 
31).  The brightness of the bands (and therefore the sensitivity) could be enhanced 
by blotting and probing with fluorescence or radioactivity.  By using WT-restriction 
digest combined with pyrosequencing the c.34G>C mutation could be detected at 
the 2.5% dilution as shown in Figure 32.  Below this dilution the template sequence 
could not be detected as the noise-to-peak ratio was too high as seen in the 0.5% 
and WT sample. From previous pyrosequencing of the 12C c.34G>C mutation the 
lowest dilution to be detected for this mutation was 25% (Figure 28B).  Therefore 
this improved the sensitivity of pyrosequencing and allowed for a lower mutant 
concentration to be detected. 
 
2.5.5 COLD-PCR 
This method enriched the 12Dc.35G>A 2.5% mutant by up to 2-fold at the critical 
temperature of 85.5°C (Table 16 and Figure 34A).  At the lower temperatures, less 
enrichment was seen due to the temperature not being high enough to melt the 
WT:mutant heteroduplex.  If it remains bound, then primers cannot anneal to amplify 
the mutant sequence.  As the temperature was increased and more of the 
WT:mutant heteroduplexes melted, there was an increased amount of template 
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available for the primers. This is seen by the graph in Figure 33. Once too high a 
critical temperature is reached, then the WT:WT duplex will melt and more WT 
template will be available to be amplified.  This will then reduce the amount of 
enrichment seen by the COLD-PCR method as shown in Table 17 and Figure 34B. 
Although a small amount of enrichment was observed, it was not substantial enough 
to greatly improve the limit of detection of pyrosequencing.  
 
2.5.6 Ice-COLD-PCR 
The enrichment from Ice-COLD-PCR and pyrosequencing is reported in the 
literature as  5.5 - 75 fold for mutant DNA dilutions of 0.1%– 10% (Milbury et al., 
2011).  However, the enrichment found in comparison to the literature was much 
lower. 
 
For the optimisation of critical temperature two different dilutions of the KRAS 12D 
c.35 G>A mutation were tested and slight enrichment of 1.14-fold and 1.16-fold was 
detected at the critical temperature of 84°C for both dilutions (Table 18 and Table 
19).  Enrichment was not detected at the 83.5°C or 84.5°C temperature for the 50% 
dilution  which indicates that this method is reliant on an accurate temperature to 
ensure that the RS:M heteroduplex melts but that the RS:WT remains bound. 
 
For RS concentration titration, the original protocol specified an optimal 
concentration of 25nM (Milbury et al., 2011).  Maximum enrichment of 1.46-fold was 
seen at this concentration for the 12D c.35G>A mutation whereas enrichment was 
not seen at other RS concentrations (Table 20).  For the RS titration with the 13D 
c.38G>A mutation, enrichment was seen at both 20nM (1.23-fold) and 50nM (1.21-
fold) (Table 21).  Enrichment was not seen at 50nM for the 12D c.35G>A mutation 
and therefore an optimal concentration of 25nM was chosen.  The RS sequence 
has to be added in excess in order to encourage the formation of heteroduplexes.  
However there is the chance that too high a concentration may result in primers 
binding to the RS sequence, although this is unlikely due to the RS sequence 
design in that it overlaps primers by only 4bp.  Conversely, if too low a concentration 
is added then heteroduplexes will not form and the mutant cannot be enriched. 
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Serial dilutions of 3 different mutations were sequenced after Ice-COLD-PCR (Table 
22, Table 23 and Table 24).  Enrichment was seen only at the lower dilutions (2.5%, 
0.5% and 0.05%) for the 12D c.35G>A mutation (Table 22) with a maximum 
enrichment of 2.44-fold.  For the 12R c.34G>C mutation enrichment was only found 
at the 0.5% dilution (Table 23) and finally for the 12V c.35G>T mutation a slight 
enrichment was seen for all three dilutions tested (25%, 5% and 0.5%) with 
maximum enrichment at 0.5% of 1.36-fold (Table 24).  Enrichment was not seen at 
the 5% dilution for the three mutations tested, although it would be expected.  
Results show that the enrichment seen is moderate and varies with each run and 
results reported in the literature from this technique could not be duplicated. 
 
2.5.7 Tumour Samples 
No mutations were detected in any of the 20 samples of normal mucosa, but KRAS 
codon 12 and 13 mutations were detected in 8 of the tumour samples (Table 25) 
which is a prevalence of 40%.  As the sensitivity of the pyrosequencer lies between 
5-25% if there are mutations in the normal mucosa, then these will not be detected 
by pyrosequencing.  Therefore it was decided to explore a next generation 
sequencing approach for mutation detection. 
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2.6 Chapter Summary 
 Epithelial cells make up 51.7% of the bowel mucosa 
 Mechanical dissociation is a practical and effective method of isolating 
colonic crypts from fresh material, which yields on average 522ng/μl of DNA. 
 Pyrosequencing has a limit of detection between 5% and 25% depending on 
the mutation being detected 
 Restriction fragment length polymorphism improved limit of detection by 10-
fold (25% to 2.5%) 
 COLD-PCR based mutation enrichment techniques failed to produce 
significant enrichment 
 
  
102 
 
 
 
 
 
3 Next generation sequencing detection of KRAS in normal 
mucosa 
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3.1 Introduction  
3.1.1 Next generation sequencing 
Next generation sequencing (NGS) is a broad term that encompasses sequencing 
technologies that allow for multiple DNA templates to be read simultaneously. This 
high output of multiple reads gives NGS its advantages of high throughput, high 
sensitivity and low cost per read (Mardis, 2008). There are various NGS platforms 
with differing biochemistries; however they all have three broad components in 
common; library generation, sequencing and bioinformatic analysis (Shendure and 
Ji, 2008, Metzker, 2010). Commonly used platforms are the Illumina sequencers 
including the Genome Analyzer IIe (GAIIe), Miseq and Hiseq sequencers (Illumina, 
San Diego, USA). Other common NGS sequencers include the ion torrent and 
SOLiD sequencing (Life Technologies, San Francisco, USA) and 454 sequencing 
platforms (Roche, Branford, USA).  
 
Ion torrent sequencing works via the detection of Hydrogen ions released during 
DNA polymerisation. As nucleotides are added in a known sequence, a hydrogen 
ion is released if it is incorporated into the sequence from the template molecule. 
This results in a change in pH which can then be detected. This technology offers 
rapid sequencing speeds and low running costs (Quail et al., 2012). The 
disadvantage to this technology is that homopolymer repeats of 5 nucleotides or 
longer reduce accuracy (Loman et al., 2012). 
 
Sequencing by Oligonucleotide Ligation and Detection (SOLiD) sequencing works 
via the ligation of probes rather than sequencing by synthesis. The template is 
immobilised and then four fluorescently labelled probes are added to the template. 
Where the probe matches the template sequence, ligation occurs and the 
fluorescent label is detected. The probe is then denatured from the template and the 
process repeats seven times with the other probes to decode the template 
sequence. This results in each base within the template being detected twice which 
leads to high accuracy and low SNP miscall probabilities. However, due to its 
sequencing chemistry, SOLid sequencing has reported issues with sequencing 
palindromic sequences (Huang et al., 2012). 
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454 sequencing works by pyrosequencing in parallel. Rather than an overall signal 
as is obtained through classic pyrosequencing, each individual template molecule is 
stabilized and sequenced individually through pyrosequencing. Some modified kits 
have enabled read lengths of 1000bp. However, it faces the same issues as 
pyrosequencing with accuracy of calling homopolymer repeats (Quail et al., 2012). 
Table 26 outlines the main advantages and disadvantages of the most commonly 
used NGS sequencing technologies. 
 
 
Sequencer Read length Accuracy 
Output data 
per run 
Time per 
run 
Illumina  HiSeq 
2000 
Paired end 
100bp 
98% 600 Gb 11 days 
Ion torrent 400 bp 99% 1.2-2 Gb 7.3 hours 
SOLiD 4 
Paired end 50bp 
x 25bp 
99.94% 100 Gb 11-13 days 
454 sequencing Up to 1000bp 99.9997% 0.07 Gb 23 hours 
Table 26. Comparison of next generation sequencing platforms. Data obtained from company 
websites. 
 
3.1.2 Illumina next generation sequencing 
Before sequencing can take place, libraries have to be prepared from the sample as 
outlined in Figure 36. These libraries must then be stabilised onto the sequencer 
flow cell. The flow cell contains a “lawn” of oligonucleotides; any DNA template that 
has complementary adaptors on its ends will anneal to oligonucleotides on the 
flowcell and be sequenced. The template DNA can be either gDNA, PCR generated 
targets or hybridization capture targets depending on the application of the 
sequencing, but they all must contain the Illumina adaptors to enable sequencing.  
 
After the DNA library has been prepared, it is applied to an 8-channel flowcell 
followed by a series of heating and cooling steps to allow the DNA molecules to 
hybridize, before the molecules undergo bridge amplification in order to generate 
clusters.  Each cluster contains approximately 1000 copies of the original DNA 
fragment and each flow cell can contain over 100 million clusters (Mardis, 2008). 
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Figure 36. Library preparation and cluster generation for Illumina sequencers.  Adapted from 
Mardis (2008). 
 
Once clusters are generated, the forward and reverse sequencing primers are 
added and anneal to the adaptor sequence.  With the addition of polymerase, 
fluorescently tagged nucleotides are added.  Each base has a unique fluorescent 
tag and as they are incorporated into the DNA sequence, the dye is cleaved and the 
fluorescence is detected.  An imaging step occurs after every addition of fluorescent 
nucleotides in order to determine the sequence from the clusters.  This process 
repeats for varying read lengths. Each cluster can be read in both a forward and 
reverse direction in a process known as paired-end sequencing (Shendure and Ji, 
2008). 
 
3.1.3 Library preparation for targeted sequencing 
Whole genome sequencing is a common application of NGS, however for the 
purposes of mutation detection, it may not be able to detect low allele frequencies 
due to low numbers of template covering the key cancer genes (Meyerson et al., 
2010). It is therefore desirable to employ a target enrichment/capture method so 
that only areas of interest are sequenced and high coverage can be obtained. There 
are a number of approaches for target capture including PCR, molecular inversion 
probes, hybrid capture and in-solution capture (Mamanova et al., 2010).  
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PCR is a robust method for target amplification and can be modified in a number of 
ways for NGS library preparation. PCR amplicons of genetic targets can be created, 
adaptors ligated and directly sequenced as outlined in Figure 37 (Chambers et al., 
2013, Peeters et al., 2013). Due to the adaptors containing a barcode sequence, 
multiple targets can be amplified for one patient and pooled together before 
barcoded adaptors are attached. This method is appropriate where the number of 
targets remain small, however, if larger numbers of targets are to be interrogated a 
parallel PCR method is favourable such as outlined in Chapter 4.  
 
 
Figure 37. Schematic of library generation by ligating Illumina adaptors onto PCR amplicons 
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Adaptor ligation is not idea for preparing PCR amplicons for NGS sequencing for a 
number of reasons: 
 There are many incubation and clean up steps which increase the risk of 
sample contamination. 
 Up to 20% of the DNA is lost in every clean up step and therefore libraries 
require a final enrichment PCR. Also this allows for the final adaptor 
sequences to be added to the libraries. However, this means that PCR 
amplicons that have undergone 40 cycles of PCR originally have an extra 
12-15 cycles that can incorporate error. 
 Multiple reactions and clean up steps incur a high cost and are time 
consuming. 
 
To overcome these issues, a one-step method was developed; targeted amplicon 
library creation (TALC). The Illumina adaptor sequences are incorporated into the 
targeted PCR primers as an additional tag; therefore adaptors are added as the 
target is amplified. Primers containing an index are also added to the PCR, 
therefore allowing the gDNA to be amplified for the gene of choice and indexed 
simultaneously. Targets are then pooled equally for each patient and a final pool of 
patients is purified before it is ready for sequencing. The advantage to this TALC 
approach is a faster method with fewer steps and purifications. There is only one 
single PCR step which reduces the chance of PCR error. An overall schematic is 
outlined in Figure 38. 
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Figure 38. Schematic of targeted amplicon library creation (TALC) showing the primer 
sequences used to create final libraries in a single PCR reaction. 
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3.1.4 Bioinformatic approaches 
The management and analysis of NGS data poses a number of challenges to 
efficiently and accurately analyse multiple samples due to the large amount of data 
obtained in a single NGS run. There are numerous tools to manipulate NGS data for 
variant calling offering different functions, but they all broadly slot into a general 
analysis pipeline outlined in Figure 39. Each base call from the sequencer is given 
an associated quality score. This is computed by analysing parameters relevant to 
the specific sequencing chemistry. These parameters are then compared to a large 
empirical data set of known quality to generate a quality score for each base call. 
These scores are known as Phred scores (Phil’s Read Editor) and quantify the 
quality of the base-call based on the probability of a miscall (Ewing and Green, 
1998, Voelkerding et al., 2009). Scores are encoded symbolically and fall between 0 
and 40. They are calculated on a logarithmic scale where miscall probabilities of 0.1 
(10%), 0.01 (1%) and 0.001 (0.1%) are given scores of 10, 20 and 30. They are 
calculated as Q=-10log10P or P=10
-Q/10
 where Q is the Phred quality score and P is 
the base-calling error probability (Voelkerding et al., 2009).  
 
 
 
Figure 39. General pipeline of NGS data analysis showing the steps required to generate a final 
mutation report from raw output reads from the sequencer. 
  
Raw reads 
Demultiplexing 
Filtering and 
alignment 
SNP filtering and 
variant calling 
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The raw reads directly outputted from the sequencer are bioinformatically 
demultiplexed and split into separate read files per sample. After this step the reads 
from each sample can be aligned to a reference genome, where reads with poor 
quality scores are filtered out. There is a huge range of sequence alignment 
software available and due to the relatively short read lengths compared to Sanger 
sequencing, NGS data favours short-read sequencing alignment programmes 
(Horner et al., 2010). Aligned data can then be interrogated for variant calls. Many 
programmes exist for this purpose with the aim to identify true SNPs and somatic 
mutations from artefactual non-reference alleles which may be incorporated through 
library preparation and sequencing. These variant callers are also affected by the 
depth of sequencing (Stead et al., 2013). 
 
In order for data analysis to be easily automatable through a pipeline, data is 
encoded in a number of file formats that can be inputted into open-access software. 
Table 27 summarises some of the commonly used file formats used in NGS 
analysis pipelines. 
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File 
format 
Description Example Format 
FASTA Simple text-based 
format for representing 
nucleotide sequences  
>1 
GTACGTACGGAATGTACG 
>2 
GTACGGACGGAATGTACG 
The information for each sequence runs over two lines. Firstly 
the header line begins with “>” followed by sequencing 
information. The nucleotide sequence is on the following line. 
FASTQ Text-based format for 
nucleotide sequences 
and quality scores 
@SEQ_ID_1 
GTACGTACGGAATGTACG 
+ 
456#$%((//$$6776%((//$$ 
 
Information is contained over 4 lines. Firstly the“@” line is 
followed by sequence identifier. The second line contains the 
sequence. The “+” line may contain more sequence identifier 
information. The final line contains the characters that encode 
the Phred score for each base. 
SAM Sequence 
Alignment/Map format. 
TAB-delimited text 
format for aligned 
reads.  
@HD 
@SQ SN:chr1 LN249450621 
1   0   chr1   3155567   37   22M   *   0   
0   GGCCTGCTGAAAAT   
BDDBB@BEE@CE@   MD:Z:22 
The “@HD” line contains header information. “@SQ” lines 
contain the alignment reference information and are in 
alignment sorting order. Each subsequent line contains the 
aligned reads with 11 fields separated by tab characters. Each 
field contains alignment information and scores for how well the 
read aligns. 
BAM Binary format of SAM 
files.  
 These files contain compressed information from SAM files and 
are therefore quicker to use with programs, but they are not 
easily human readable. 
MPILEUP Text-based format for 
summarizing the base 
calls of aligned reads to 
a reference  
APC_1  T  1365 ........A   
=AFDFFDDD 
Each line contains 6 tab separated fields: sequence identifier, 
position in sequence, nucleotide at that position, number of 
reads covering that position, bases at that position, mapping 
qualities of those bases. “.” (dot) denotes that the base matches 
the reference. 
VCF Variant Call Format. 
File for storing gene 
sequence variation 
#CHROM POS ID REF
 ALT QUAL   
KRAS1213 8 . T    G .
  
Header line begins with “#” symbol and names the fields of 
interest. Each line shows within a target at what position a 
variant is found and provides information about that variant. 
 
Table 27. Common file formats used in NGS pipelines 
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3.1.5 Sequencing errors 
With the high sequence output of next generation sequencers, it may be possible to 
detect rare allele variants. However, challenges are faced where the sequencing 
error rate may be too high to confidently identify very low level variants. Previously 
reported error rates for Illumina sequencing lie between 0.05% and 1%, however this 
depends on multiple factors such as DNA template quality, read length, base-calling 
algorithms and the type and site of variant detected (Kinde et al., 2011, Chen et al., 
2012). Errors can be introduced at a number of steps: tissue preparation, initial PCR 
amplification, library enrichment, amplification on the flowcell and errors occurring 
during sequencing. However, these can be addressed in a number of ways in order 
to minimise error and maximise the accuracy of rare-variant calling. The use of high 
fidelity polymerase such as Phusion minimises errors introduced during PCR 
amplification. Bioinformatic tools can be used to recalibrate quality scores and 
perform realignments to reduce potential artefacts such as the Genome Analysis 
Toolkit (GATK) (McKenna et al., 2010, Chen et al., 2012).  
 
In order to call low frequency variants, it is important to keep the coverage of the 
target of interest high so that mutant calls can be confidently made. For single-end 
sequencing the error rate is not even throughout all amplicons and the quality scores 
decline after the first 30 bases of the read (Chen et al., 2012, Li et al., 2008a). 
Therefore calling mutations at any position within a gene such as TP53 is challenging 
as any base within the read could be mutated. This is in contrast to detecting 
mutations in an oncogene like KRAS where mutational hotspots are clearly defined 
as demonstrated in Figure 40. For this reason, it may be possible to set a low 
threshold for mutation detection in an oncogene and sensitively identify very low level 
mutations whereas higher levels may have to be set for tumour suppressor genes.  
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Figure 40. Mutational profiles for A. KRAS oncogene and B. TP53 tumour-suppressor gene from 
the COSMIC database 
 
Separate to sequencing errors, there may be errors within the starting template DNA. 
This may particularly affect DNA extracted from FFPE tissue. It is reported that de-
amination of cytosine bases results in C:G>T:A sequence artefacts and this is seen 
in FFPE tissue (Do et al., 2013). These artefacts may therefore affect the overall 
error rate of NGS. 
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3.2 Chapter Aims 
The aims of this chapter are as follows: 
 To investigate the sensitivity of NGS 
 To investigate where mutations can be detected in cancer-associated normal 
mucosa, adenoma-associated normal mucosa alongside non-neoplastic 
normal mucosa by NGS 
 The development and improvement of NGS library preparation and 
automated analysis 
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3.3 Methods 
3.3.1 Generation of PCR amplicons for NGS library preparation 
In order to assess the limit of detection of NGS, mutated cell line DNA dilutions were 
amplified for KRAS codons12 and 13 as outlined previously in Chapter 2. The taq 
polymerase used previously was substituted for Phusion Hot Star Flex Master Mix 
(New England Biolabs, Hitchin, UK) due to its improved amplification error rates and 
PCR accuracy.  The PCR reaction conditions are described in Table 28. 
 
Component 
Volume per reaction 
Final concentration 25μl 
reaction 
50μl 
reaction 
Phusion Hot Start Flex 2X 
Master Mix 
12.5μl 25μl 1X Phusion Hot Start Flex 
Master Mix 
Forward Primer (25μM) 0.5μl 1μl 0.5μM  
Reverse Primer (25μM) 0.5μl 1μl 0.5μM 
Dimethyl sulfoxide (DMSO) 0.75μl 1.5μl 3% 
H2O 8.75μl 17.5μl  
gDNA (10ng/μl) 2μl 4μl  
 
Table 28. PCR reaction composition with the use of Phusion polymerase enzyme. 
 
The thermocycling conditions with the use of Phusion Hot Star Flex were as follows: 
 98°C for 30secs 
 
 40 cycles of: 
 98°C for 5secs 
 60°C for 10secs 
 72°C for 15secs 
 
 Hold at 4°C 
 
After confirmation of successful amplification on a 2% agarose electrophoresis gel, 
PCR products were cleaned up using Qiagen’s MinElute PCR purification kit 
(QIAGEN, Crawley, UK) eluting in 15ul EB buffer. Quantification of PCR products 
was performed by use of a Quant-iT PicoGreen assay (Invitrogen, Paisley, UK) 
following the standard protocol. 
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3.3.2 RFLP and NGS 
Alongside this, in order to determine the enrichment gained from RFLP and NGS, 
RFLP amplicons from mutant serial dilutions were prepared as previously outlined in 
chapter 2. At the very low mutant allele frequencies the mutant PCR product 
amplified by the RFLP method was present at very low quantities and had to undergo 
a further 15 cycles of PCR in order to gain enough to use for NGS library 
preparation. The mutant amplicons were then gel purified using Qiagen’s gel 
purification kit (QIAGEN, Crawley UK) and eluted in 15ul EB buffer before 
undergoing standard NGS library preparation. 
 
3.3.3 NGS amplicon library preparation 
Standard Illumina Protocols were adapted for the use of PCR products as starting 
material.  A full overview of the library prep process is shown in Figure 42. Y-shaped 
adaptors were ligated onto PCR products before being enriched to create the final 
library. The use of Y-shaped adaptors meant that PCR products with adaptors 
correctly ligated could easily be amplified by PCR. If the adaptors were 
complementary and not-Y-shaped, the PCR primers would be complementary and 
form primer-dimers preferentially over amplifying the final library, illustrated in Figure 
41 and Figure 42. Final libraries were loaded onto the sequencer by Dr. Sally 
Harrison in accordance with the manufacturer’s protocols on a Genome Analyser IIe, 
Miseq or Hiseq sequencing machine (Illumina, San Diego, USA).  
  
 1
1
7
 
  
Figure 41. Diagram illustrating the structure of Y-shaped adaptors and how they anneal to A tailed PCR products. 
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1
8
 
 
 
 Figure 42. Schematic of NGS library enrichment from adaptor-ligated PCR products. 
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3.3.4 End-repair 
The End-It DNA End-Repair Kit (Epicentre Biotechnologies, Madison, USA) was 
used to ensure that all PCR products were blunt ended to allow for the downstream 
steps of A-addition and ligation. A starting amount of 100-150ng of DNA was found 
to be optimal. The DNA was added to the reaction mix (Table 29) and left to 
incubate at 25°C for 45 mins. The samples were then cleaned up by a QIAquick 
PCR Purification Kit (QIAGEN, Crawley, UK) and eluted into 34.6μl elution buffer 
(EB). 
 
Component Volume 
DNA (15ng/μl) 10μl 
End-Repair 10X Buffer 5μl 
dNTPs 5μl 
ATP 5μl 
End-Repair Enzyme Mix 1μl 
H2O 24μl 
Total volume: 50μl 
Table 29. Reaction mix for end-repair. 
 
3.3.5 A-addition 
The A-addition step was performed by the addition of ATP in the presence of 
klenow fragment, exonuclease minus (Promega, Madison, USA). This resulted in 
the addition of an adenosine nucleotide onto the 3’ end of the blunt-ended PCR 
product. This A-overhang would then allow for the adaptors to ligate in the next 
step. The reaction mix (Table 30) was incubated at 37°C for 30 mins and then 
cleaned up by Qiagen MinElute PCR Purification Kit (QIAGEN, Crawley, UK), 
eluting in 10.2μl EB. 
 
Component Volume 
DNA  34.45μl 
Klenow 10X Buffer 5μl 
DNA Polymerase I Large 
(Klenow) Fragment, 
Exonuclease Minus: 
0.55μl 
1mM dATP 10μl 
Total volume: 50μl 
Table 30. Reaction mix for adenosine (A)-addition 
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3.3.6 Ligation of adaptors 
Custom adaptors (Morgan et al., 2010) were ligated to the end-repaired A-
overhanged PCR products with the LigaFast Rapid DNA Ligation System (Promega, 
Madison, USA). The reaction mix (Table 31) was incubated at 25°C for 15 mins and 
then 65°C for 20 mins to deactivate the enzyme.  
 
Component Volume 
DNA  10μl 
2X Rapid Ligation Buffer 15μl 
T4 DNA Ligase 3μl 
H2O 1μl 
Adaptor (2μM) 1μl 
Total volume: 30μl 
Table 31. Reaction mix for adaptor ligation 
 
The reaction was cleaned up with Agencourt AMPure XP magnetic beads 
(Beckman Coulter, High Wycombe, UK). The standard clean up protocol was 
followed except the ratio of beads was halved to 0.9X in order to better remove 
unwanted adaptor-dimers of around 100bp. Therefore for a 30μl reaction volume; 
27μl of Agencourt AMPure XP (Beckman Coulter, High Wycombe, UK) was added. 
The final elution step was with 40μl EB. 
 
3.3.7 Enrichment PCR 
The final library prep step was enrichment PCR to extend the adaptors and amplify 
correctly ligated libraries.  
 
Component Volume 
Phusion High Fidelity 
Mastermix 
25 μl 
H2O 13 μl 
PE-PTO primer F (25μM) 1 μl 
PE-PTO primer R (25μM) 1 μl 
DNA 10 μl 
Total 50 μl 
Table 32. Reaction mix for PCR enrichment 
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The PCR reaction (Table 32) underwent the following thermocycling programme:  
 
 98°C for 30 sec 
 
 12 cycles of: 
 98°C for 10 sec 
 65°C for 30 sec 
 72°C for 30 sec 
 
 72°C for 5 mins 
 
The final libraries were cleaned up with Agencourt AMPure XP (Beckman Coulter, 
High Wycombe, UK) following the standard protocol with a concentration of 1.8X 
beads and eluting into a final volume of 30μl EB.  The libraries were tested by 
Agilent Bioanalyser DNA 1000 LabChip (Agilent, Santa Clara, USA) and Quant-iT 
PicoGreen assay kit (Invitrogen, Paisley, UK) to assess for library quality and 
concentration respectively before being pooled together in equal amounts and run 
on the Illumina sequencer. Figure 43 shows the expected trace from the Agilent 
Bioanalyser where there is a clear sharp peak at the expected final size and no 
adaptor-dimer peaks. 
 
 
Figure 43. Bioanalyser trace of final PCR amplicon library. 
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3.3.8 Fixation of cells for DNA to investigate formalin effects  
Cells were grown in culture in order for their DNA to be extracted as control DNA 
and to investigate the effects of fixation on mutation error rate. The cells grown were 
a breast cancer cell line, MCF7 and two colon cancer cell lines: SW48 and SW480. 
All cell lines were grown in Roswell Park Memorial Institute (RPMI) medium with 
glutaMAX and 10% fetal calf serum (FCS) (Invitrogen, Paisley, UK) and cells were 
grown in a T75 flask to subconfluency and counted. 
 
The old medium was aspirated and the cells were washed with 8ml phosphate 
buffered saline (PBS). This was then aspirated and 2ml of trypsin was added before 
incubation for 2 mins at 37°C to trypsinise the cells. After incubation, 8ml of RPMI 
medium was added to deactivate the trypsin before the cells were transferred to a 
centrifuge tube. They were spun at 1000g for 3 mins to form a cell pellet before the 
old medium was aspirated and the cells were resuspended in 8ml PBS. This was 
then split into aliquots so that there were approximately 5x106 cells per aliquot. The 
aliquots were then spun again at 1000g for 5 mins to pellet the cells, the old medium 
was aspirated and the cells were resuspended in 200μl PBS and transferred to a 
microcentrifuge tube for DNA extraction. 
 
In order to investigate the effects of fixation on sequencing error rate, cells were 
fixed in differing percentages of formalin. Aliquots of cells were prepared and 
resupsended in 8ml of 1%, 5% or 10% formalin. They were incubated on a roller at 
room temperature (20°C -25°C) for 30 mins to allow the cells to fix. They were then 
spun at 1000g for 3 mins to pellet the cells and the formalin discarded. The cells 
were washed with PBS, spun as before and the PBS discarded and then 
resuspended in 200μl fresh PBS for DNA extraction. DNA from cells was extracted 
with the Qiagen QIAamp DNA Mini Kit (QIAGEN, Crawley, UK) in accordance with 
the standard manufacturer’s protocols and eluted into a 50μl volume of H2O. 
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The DNA from cells fixed at differing percentage formalin was then amplified for 5 
targets: KRAS codons 12&13, KRAS codon 61, NRAS codons 12&13, NRAS codon 
61 and BRAF codon 600. The primers used are outlined in Table 33 and were 
amplified with Phusion polymerase (section 3.3.1). Primers were designed using 
pyrosequencing assay design software (Biotage AB, Uppsala, Sweden) as outlined 
by Dr. Phil Chambers (Chambers et al., 2013). PCR amplicons were quantified by 
Invitrogen’s Quant-iT PicoGreen dsDNA BR assay kit (Invitrogen, Paisley, UK) 
before all the 5 targets were pooled for each sample and underwent standard library 
preparation (sections 3.3.3-3.3.7). 
 
Gene Target Primer Sequences 
Amplicon 
length (bp) 
KRAS codons 
12 & 13 
Fwd: 5’GGCCTGCTGAAAATGACTGA 
80 
Rev: 5’AGCTGTATCGTCAAGGCACTCT 
KRAS codon 
61 
Fwd: 5’AATTGATGGAGAAACCTGTCTCTT 
86 
Rev: 5’TCCTCATGTACTGGTCCCTCATT 
NRAS codons 
12 & 13 
Fwd: 5’CTTGCTGGTGTGAAATGACTGAG 
79 
Rev: 5’TGGATTGTCAGTGCGCTTTTC 
NRAS codon 
61 
Fwd: 5’GAAACCTGTTTGTTGGACATACTG 
83 
Rev: 5’TCGCCTGTCCTCATGTATTG 
BRAF codon 
600 
Fwd: 5’TGAAGACCTCACAGTAAAAATAGG 
91 
Rev: 5’TCCAGACAACTGTTCAAACTGAT 
Table 33. Gene targets and primers used for PCR 
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3.3.9 Investigating KRAS in cancer-associated normal mucosa  
38 samples of FFPE normal colorectal mucosa from patients with tumours with 
KRAS codon12&13 mutations were processed and underwent DNA extraction and 
NGS sequencing as previously described (sections 2.3.9 and 3.3.3) alongside a WT 
control. The tumour samples had been previously confirmed as KRAS mutant by 
pyrosequencing. The samples of normal mucosa that were sequenced by NGS 
were repeated in a second independent library preparation process and sequencing 
run. These samples were also run alongside the tumour samples for those patients 
to confirm the pyrosequencing mutation calls with NGS.  
 
3.3.10 Ethical approval 
Ethical approval for the collection storage and use of patient material was obtained 
from the national research ethics service (NRES) committee London – Bloomsbury 
REC reference 12/LO/1217. 
 
3.3.11 Targeted amplicon library creation 
TALC is a one-step PCR method for generating targeted libraries developed by me 
to address the issues faced with adaptor ligation of PCR amplicons. There are 4 
primers added to the reaction: the forward and reverse targeted primers, the 
universal forward primer and the indexing reverse primer. There were 8 targeted 
primers created for KRAS, NRAS, BRAF and PIK3CA as shown in Table 34. 
 
  
 1
2
5
 
Gene 
Target 
Primer Sequences 
Amplicon 
length 
(bp) 
Final 
library 
length 
(bp) 
KRAS 
codons 
12/13 
Fwd: 5’ ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAATGGTCCTGCACCAGTAAT 3’ 
168 290 
Rev: 5’ GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAGGCCTGCTGAAAATGACTGAAT 3’ 
KRAS 
codon 
61 
Fwd: 5’ ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACACAAAGAAAGCCCTCCCCAG 3’ 
154 276 
Rev: 5’ GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGACTGTGTTTCTCCCTTCTCAGG 3’ 
KRAS 
codon 
146 
Fwd: 5’ ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTATTTATTTCAGTGTTACTTACCTGTCT 3’ 
161 283 
Rev: 5’ GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTACTCTGAAGATGTACCTATGGTCCT 3’ 
NRAS 
codons 
12/ 13 
Fwd: 5’ ACACTCTTTCCCTACACGACGCTCTTCCGATCTGACAAGTGAGAGACAGGATCAGG 3’ 
158 280 
Rev: 5’ GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTGACTGAGTACAAACTGGTGGTG 3’ 
NRAS 
codon 
61 
Fwd: 5’ ACACTCTTTCCCTACACGACGCTCTTCCGATCTTTGATGGCAAATACACAGAGGAA 3’ 
150 272 
Rev: 5’ GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCCCCAGGATTCTTACAGAAAACA3’ 
BRAF 
codon 
600 
Fwd: 5’ ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCCTCAATTCTTACCATCCACA 3’ 
163 285 
Rev: 5’ GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTACTGTTTTCCTTTACTTACTACACCTCA 3’ 
PIK3CA 
codons 
542/ 545 
Fwd: 5’ ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTCAAAGCAATTTCTACACGAGAT 3’ 
173 295 
Rev: 5’ GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCCAATAGGTATGGTAAAAACATGCTG 3’ 
PIK3CA 
codon 
1047 
Fwd: 5’ ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCCTTAGATAAAACTGAGCAAGAGG 3’ 
170 292 
Rev: 5’ GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTGTGGAATCCAGAGTGAGCTTTC 3’ 
Table 34. Targeted primers used with TALC. 
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The PCR mastermix was made using the FastStart High Fidelity PCR system 
(Roche, Basel, Switzerland) and was made for each target with forward and reverse 
targeted primers and the universal primer. 22µl of mastermix was added to 2µl of 
gDNA at 10ng/µl and 1µl of bar-coding primer at 12.5µM. The reaction mix is shown 
in Table 35 and the thermocyling conditions are shown in Table 36. 
 
Reagent 
Volume 
(µl) 
Final 
Concentration 
FastStart High Fidelity Buffer without MgCl2 (10x) 2.5 1x 
MgCl2 (25mM) 4.5 4.5mM 
DMSO 1.25 5% 
Nucleotides (10mM) 0.5 0.2µM 
FastStart High Fidelity Enzyme (5U/µl) 0.25  
Forward Target Primer (25µM) 0.5 500nM 
Reverse Target Primer (25µM) 0.5 500nM 
Universal Primer (25µM) 0.5 500nM 
H2O 11.5  
Barcode Primer (12.5µM) 1 500nM 
DNA (10ng/µl) 2  
Total 25  
Table 35. Reaction mix for TALC 
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Temperature (°C) Time Number of cycles 
50 2 mins 
1 70 20 mins 
95 10 mins 
95 15 sec 
10 60 30 sec 
72 1 min 
95 15 sec 
2 
80 30 sec 
60 30 sec 
72 1 min 
95 15 sec 
8 60 30 sec 
72 1 min 
95 15 sec 
2 
80 30 sec 
60 30 sec 
72 1 min 
95 15 sec 
8 60 30 sec 
72 1 min 
95 15 sec 
5 
80 30 sec 
60 30 sec 
72 1 min 
Table 36. Thermocycling protocol for TALC 
 
All samples were then run on an Agilent Bioanalyser DNA 1000 LabChip (Agilent, 
Santa Clara, USA) to quantify the amount of library. Firstly, targets for each patient 
were pooled. Finally each barcoded patient pool was combined to form the final 
library. This was then run on a 2.5% agarose gel and the final library band at 300bp 
was excised and purified using Qiagen’s MinElute gel purification kit (QIAGEN, 
Crawley, UK) eluting in 20µl EB. 31 FFPE samples underwent TALC library prep 
that had previously been sequenced with adaptor-ligated libraries. 
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3.4 Bioinformatics 
3.4.1 Demultiplexing and quality filters 
Two methods of demultiplexing samples from within the run data were tested. Firstly 
reads were separated by barcode only using a custom perl script written by Dr. 
Stefano Berri. The input contained all of the reads from the sequencing run and the 
script outputted de-multiplexed reads into individual files with the barcode trimmed 
from the 5’ end of the read. The second method used a programme designed by Dr. 
Ian Carr, AgileQualityFilter: 
(http://dna.leeds.ac.uk/agile/AgileQualityFilter/) which demultiplexed and filtered the 
reads according to user inputted thresholds outlined in Table 37. 
 
 
Option Setting Description 
Maximum number of 
uncalled bases per 
sequence  
0 Due to the high amount of coverage 
obtained, a high threshold was set, 
where any reads containing “N” 
bases within the sequence were 
filtered out 
Minimum score to call a 
base 
20 Reads containing bases with a Phred 
score less than 20 (miscall probability 
higher than 1%) were filtered out 
Minimum median quality 
score for a read 
36 Within each read, the median Phred 
score of all the bases had to be a 
minimum of 36 (miscall probability of 
0.025%) or the read was filtered out 
Table 37. Parameters used with AgileQualityFilter software 
 
Filtering kept on average 89% of the reads for downstream analysis and improved 
the mean Phred scores of the reads by 2.52 points, which is a 1.7-fold improvement 
in base-call error probability from 0.05% to 0.03%. The effects of filtering on 4 
independent runs from the Illumina GAIIe are shown in Figure 44. It was therefore 
decided to include this initial filtering step in the bioinformatics pipeline, to improve 
quality scores and therefore improve confidence of mutant calls downstream. 
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Figure 44. Effect of filtering on percentage of reads maintained and the mean Phred quality 
score of reads. 
 
3.4.2 Look-up method for variant detection 
This approach was used in order to produce a mutation report quickly and easily 
directly from filtered reads. Initially, custom perl scripts written by Dr. Graham Taylor 
were developed to search for a short sequence that was either WT or mutant within 
the reads (Chambers et al., 2013). This was further developed into a programme 
with a user-interface that could be run on the Windows operating system by Dr. Ian 
Carr, AgileVariantFastaFinder: 
(http://dna.leeds.ac.uk/agile/AgileFastaVariantFinder/).  
 
This method does not require reads to be aligned to a reference sequence, making 
it ideal for targeted sequencing with low numbers of targets. The alignment process 
can be difficult to run on a Windows platform, requiring the user to have a basic 
knowledge of Linux and some computer programming skills. Also alignments can be 
time consuming and memory-heavy for the computer. In cases where only a few 
target sequences are to be interrogated, full alignment is not necessary and the 
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coverage at each site may be in the 1000s. This programme works for analysing 
oncogenes where only mutational hotspots are checked for mutations. However in 
the case of TSGs, an alignment approach is needed due to mutations occurring at 
any point within the tested amplicon. 
 
3.4.3 Alignment  
Aligning reads for targeted sequencing allows for data to be passed into a pipeline 
using published software to make variant calls. This is especially useful when there 
are a large number of files with a large number of targets and allows the process to 
be easily automated. Also alignment is required when allele frequencies at each 
position within the read are to be assessed in order to estimate the error rate from 
the percentage of non-reference bases. 
 
Alignments were performed using the Burrows-Wheeler Aligner (BWA) software (Li 
and Durbin, 2009) available at: http://bio-bwa.sourceforge.net. Reads were aligned 
to custom reference sequences containing the amplicons rather than the whole 
genome in order to speed up the alignments. The reference sequence was indexed 
using BWA with default settings. Alignments were performed using the BWA aln 
algorithm with the seed function disabled. A seed is a certain number of bases at 
the start of the read, set by the user, in which no mismatches are allowed. This is 
important for aligning whole genome or whole exome data, however for targeted 
PCR amplicons a seed would interfere with downstream analysis. All other options 
for BWA were in accordance with the default settings. After alignment, SAM files 
were outputted for each sample which could then be subject to further analysis. 
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3.4.4 Assessing allele frequencies and coverage 
In order to determine the error rate of sequencing, the percentage of non-reference 
bases at each position within the read was determined with a custom perl script 
written by myself AllFreqChecker.pl (see appendix for full script). It uses SAM files 
for aligned reads and the fasta file of the reference sequence. The script works by 
checking which target the sequence aligns to and at what position. It then checks 
each base within the read and if it does not match the reference, it will check which 
base it is and keep a tally. Once this has been repeated for all reads of all targets 
within a file it calculates the percentages of each non-reference base within the 
reads for a certain file. Alongside this it produces a total of the number of reads 
aligned to each target for each sample which can be used to produce a coverage 
report. 
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3.5 Results 
3.5.1 Limit of detection of NGS 
By assessing the mutant allele frequency of serial dilutions of KRAS mutant DNA, 
the lowest allele frequency of inputted DNA that could be detected was 0.5% as 
shown in Table 38. This was replicated in two different KRAS mutants: G12A 
c.35G>C and G12C c.34G>T and for two independent library preparations and runs. 
Figure 45 A-H shows the plot of non-reference bases at each position within the 
amplicon for one run of the G12A mutant serial dilution. Other runs produced similar 
looking plots. 
 
 
Mutation tested 
and frequency 
Mutation 
detected 
Run1 allele 
frequency 
Run2 allele 
frequency 
c.35 G>C 
 
50% c.35G>C 49.53% 51.33% 
25% c.35G>C 21.18% 19.50% 
5% c.35G>C 4.56% 1.26% 
2.5% c.35G>C 1.98% 1.92% 
1% c.35G>C 0.64% 0.63% 
0.5% c.35G>C 0.14% 0.21% 
0.05% WT 0% 0% 
0.005% WT 0% 0% 
c.34 G>T 
50% c.34G>T 54.14% 57.73% 
25% c.34G>T 20.04% 23.61% 
5% c.34G>T 3.23% 2.93% 
2.5% c.34G>T 1.50% 1.53% 
1% c.34G>T 0.87% 0.69% 
0.5% c.34G>T 0.31% 0.25% 
0.05% WT 0% 0% 
0.005% WT 0% 0% 
Table 38. Detected mutant allele frequencies for serial dilutions of mutant KRAS DNA 
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Figure 45. A-H. Non-reference allele frequencies for serial dilutions of G12A c.35G>C mutant 
KRAS showing minimum detection level of 0.5% mutant allele frequency. 
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3.5.2 Enrichment with RFLP and NGS 
Table 39 shows the enriched allele frequencies detected for the G12A mutation and 
G12C mutation. The maximum enrichment gained was 200-fold. RFLP enabled the 
G12A mutation to be detected at a level of 0.05% (Figure 46) and the G12C 
mutation at 0.005% (Figure 47). However, there was a high level of contamination 
and error within the PCR product and therefore it was decided that this method was 
not reliable or consistent enough to use with NGS.  
 
 
Mutant dilution 
Mutant allele 
frequency 
detected 
Enrichment 
(fold) 
G12A 
50% 80% 1.6 
25% 88% 3.52 
5% 53% 10.6 
2.5% 28% 11.2 
1% 8% 8 
0.5% 11% 22 
0.05% 2% 40 
0.005% 0% - 
G12C 
50% 39% 0.78 
25% 29% 1.16 
5% 11% 2.2 
2.5% 11% 4.4 
1% 0% - 
0.5% 0% - 
0.05% 9% 180 
0.005% 1% 200 
Table 39. Mutant allele frequencies detected for serial dilutions of G12A and G12C KRAS 
mutant DNA showing the amount of enrichment attained. 
 
138 
 
 
 
Figure 46. Non-reference allele frequencies for 0.05% and 0.005% G12A c.35G>C mutant KRAS 
enriched with RFLP PCR showing a minimum detection level of 0.05% of the mutant allele and a 
high frequency of PCR errors around the site of interest. 
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Figure 47. Non-reference allele frequencies for 0.05% and 0.005% G12C c.34G>T mutant KRAS 
enriched with RFLP PCR showing a minimum detection level of 0.005% of the mutant allele and 
a high frequency of PCR errors around the site of interest. 
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3.5.3 Effect of formalin of cells and error rates 
Fixing cell lines in different percentages of formalin had no effect on the sequencing 
error rate as show in Figure 48 A-B. This was the case for 2 different cell lines that 
had libraries run in duplicate. The sequencing error rate was calculated by taking 
the median of all the non-reference allele frequencies from each position within 
each target. The overall median non-reference allele frequency was calculated as 
0.1%.  
 
 
Figure 48. A &B. Median non-reference allele frequency for 5 amplicons in A. MCF7 cell line 
DNA and B. SW480 cell line DNA that has been fixed with 0%,1%15% and 10% formalin. 
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The percentage of G>A base changes increased with 5% and 10% formalin fixation 
for the MCF7 cell line DNA (Table 40) however this was not found to be statistically 
significant. No significant differences were seen in any of the other base changes. 
For SW480 there were no significant differences in any of the base changes for any 
percentage of formalin fixation (Table 41). 
 
 
MCF7 formalin fixation 
Base change 0% 1% 5% 10% 
A>G 17% 17% 16% 15% 
A>T 3% 6% 5% 5% 
A>C 26% 26% 27% 27% 
G>A 9% 11% 14% 14% 
G>T 7% 5% 6% 5% 
G>C 6% 1% 2% 2% 
T>A 2% 2% 2% 2% 
T>G 8% 9% 8% 8% 
T>C 11% 11% 11% 11% 
C>A 4% 6% 4% 4% 
C>G 4% 1% 2% 3% 
C>T 3% 4% 4% 4% 
Table 40. Percentage of base changes in background noise for MCF7 cell line DNA fixed at 
different percentages of formalin showing an increase in the proportion of G>A changes. 
 
 
 
 
SW480 formalin fixation 
Base change 0% 1% 5% 10% 
A>G 18% 17% 19% 18% 
A>T 3% 3% 5% 3% 
A>C 29% 31% 25% 29% 
G>A 6% 7% 7% 7% 
G>T 11% 7% 7% 9% 
G>C 2% 2% 6% 2% 
T>A 2% 2% 2% 3% 
T>G 8% 9% 10% 9% 
T>C 11% 11% 10% 10% 
C>A 4% 4% 6% 5% 
C>G 2% 4% 2% 2% 
C>T 3% 4% 4% 4% 
Table 41. Percentage of base changes in background noise for SW480 cell line DNA fixed at 
different percentages of formalin showing no significant differences. 
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3.5.4 Detection of KRAS mutations in cancer-associated normal 
mucosa 
Out of the 39 samples of DNA from cancer-associated normal mucosa, 38 were 
successfully sequenced. Mutations were detected by AgileFastaVariantFinder in 11 
(29%) ranging from 1.3% - 8.7% mutant allele frequency (Figure 49). The mutation 
calls from both repeats of these samples are shown in Table 42. Data files were 
visualised by running them through the AllFreqChecker.pl script, and an example is 
seen in Figure 50. These mutations were confirmed on a second independent run 
with an independent library preparation. Out of those 11 samples with KRAS 
mutations in normal, only 3 contained the same KRAS codon12&13 as the tumour 
sample from the same case. Figure 51 shows the frequency distribution for KRAS 
found in CRC according to the COSMIC database compared to the distribution 
found in the 11 mutated normal samples. 
 
 
Figure 49. Mutant allele frequencies in 38 clinical samples of cancer-associated normal mucosa 
showing mutant allele frequency for each of the 38 samples plus a WT control, with detected 
mutations in 11/38. 
 
 
Sample % mutant run 1 % mutant run 2 
1 1.38% 2.02% 
2 1.48% 1.64% 
5 3.10% 1.70% 
8 3.06% 2.31% 
9 1.33% 1.58% 
10 4.37% 5.00% 
17 2.96% 2.49% 
18 1.60% 1.51% 
21 4.55% 4.09% 
32 8.68% 8.21% 
35 2.06% 2.79% 
Table 42. KRAS mutant allele frequencies from duplicate runs of 11 samples with mutations in 
normal mucosa. 
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Figure 50. Example of allele frequencies for KRAS amplicon in normal mucosa sample 
 
 
 
 
 
 
 
Figure 51. Frequency distribution of the different KRAS codon 12&13 mutations found in 
colorectal cancer from the COSMIC data base compared to those detected in normal mucosa 
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3.5.5 Comparison of TALC to adaptor ligation 
TALC produced equivalent results compared to adaptor-ligated PCR libraries in 
terms of mutation calls and percentage allele frequencies. Figure 52 shows results 
for 23 samples prepared for sequencing by adaptor-ligation and TALC. The 
concordance between the two methods produced a Pearson’s r value of 0.9968 
showing very high correlation between the two methods. For the 23 samples 
prepared for sequencing by both methods the mean difference in percentage allele 
frequency was 1.4% (σ = 1.9%). The median error rate of the 23 samples tested for 
KRAS by TALC was 0.4%. There was no trend in the error rate across the amplicon 
as illustrated in Figure 53. 
 
 
Figure 52. Correlation between adaptor-ligated PCR libraries and TALC for calling mutant allele 
frequencies 
 
 
Figure 53. Error rates across the KRAS amplicon 
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3.6 Discussion 
3.6.1 Limit of detection of NGS 
There is a range of reported sensitivities from 0.1% mutant allele frequency 
(Flaherty et al., 2012) to 2% (Milbury et al., 2012) depending on the targets of 
interest, coverage and the bioinformatics approaches used. In the case of the serial 
dilution study of fresh cell line DNA, we were able to detect 0.5% mutant DNA within 
a WT background reproducibly for two different KRAS codon 12&13 mutants. 
However, when testing clinical FFPE samples, the background noise was higher 
compared to the fresh cell line DNA at 0.4% (see Figure 50 and Figure 53). For this 
reason it was decided that the cut-off threshold for FFPE clinical samples should be 
at 1% therefore allowing for greater certainty when making variant calls and 
reducing the chance of false positives. It is also recommended to prepare and 
sequence samples in duplicate to allow for greater certainty when making mutation 
calls (Schmitt et al., 2012). 
 
High accuracy in mutation calling is especially important when testing clinical 
samples where patient’s therapy is directed by mutation results. It is currently 
unknown what the significance of a 1% mutation allele frequency holds for patient 
outcome or response to therapy, but the advance of NGS in recent years has made 
these studies now possible. It is expected that the incidence of mutations in 
common cancer genes such as KRAS, NRAS, BRAF and PIK3CA will rise with the 
increased implementation of high coverage targeted NGS testing due to the higher 
sensitivity (Hadd et al., 2013). Clinical trials are now stratified according to a tumour 
genotype that can be targeted with treatment instead of morphology. The high 
sensitivity of NGS may help to answer questions about response to therapy in future 
clinical trials. Previously, if a patient’s tumour contains low level mutated clones at a 
frequency below that which could be detected, it may be assumed that their tumour 
is wild-type. This would result in therapy being directed towards the EGFR-RAS-
RAF signalling pathway and in certain cases drug-resistance may develop. The 
advance of NGS would allow for the identification of these low-level mutant clones 
which may be selected for by treating with anti EGFR agents and therefore grow, 
become dominant within the tumour and cause treatment resistance (Moch et al., 
2012). This is dependent on the time the clone takes to expand and may be 
addressed by treatment with multiple agents. If tumour evolution is similar to 
bacterial or viral evolution then three agents may be necessary as found in 
mycobacteria tuberculosis or human immunodeficiency virus. 
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3.6.2 Use of RFLP with NGS 
RFLP enabled a 0.05% dilution of mutant G12A c.35 G>C KRAS to be detected and 
a 0.005% dilution of G12C c.34 G>T mutant. However, the amount of PCR error 
seen at the site of interest (c.DNA positions 34 and 35) was very high. At low mutant 
allele frequencies the PCR error was present at an even higher allele frequency. 
The extra steps of PCR involved in this method means that error is far more likely to 
become incorporated into the amplicon and be amplified further. Due to the 
worryingly high level of PCR error seen with this method and the sufficient baseline 
sensitivity of NGS without enrichment, it was decided not to use RFLP with clinical 
samples. 
 
3.6.3 Effect of formalin on error rates 
For targeted sequencing of KRAS codons12 and 13 the median percentage of non-
reference bases across the 80bp amplicon was 0.1% for fresh cell line DNA. After 
fixing cells in formalin there was no effect on the error rate as shown in Figure 48. 
This was the case for two independent cell lines that were fixed in increasing 
percentages of formalin at 1%, 5% and 10% and were tested in duplicate. The error 
rate for the BRAF and KRAS 12/13 and NRAS 61 amplicons was higher in both cell 
lines across all levels of formalin fixation. This could be due to the efficiency of the 
PCR being sequence dependent which may affect PCR error rate. Also the reads 
will be affected by the amplification of pseudogenes contaminating the final genes. 
Although the majority of pseudogene reads can be filtered out, some will remain and 
affect the analysis. The KRAS12/13 and BRAF amplicons contain the most bases 
differences to the pseudogene amplicons. The NRAS12/13 and NRAS61 primers do 
not amplify a pseudogene so the final reads will be free of this contamination. This 
follows the same pattern seen in error rates for the amplicons (Figure 48). Therefore 
pseudogene contamination will ultimately contribute to the error rate and could 
partly explain the differences seen in error rate between the amplicons. 
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There was an increase in the proportion of  G>A base changes in the MCF7 cell line 
DNA that was fixed at 5% and 10% compared to non-fixed DNA (Table 40). 
Although this difference was not found to be statistically significant this may be due 
to the small sample size. It is known that formalin induces G>A changes and an 
increasing trend as the percentage of formalin fixation increases can be seen 
(Williams et al., 1999). There were no changes seen in the proportion of C>T 
changes for either cell line and SW48 showed no significant differences in any of 
the base changes from fixation.  
 
The no change in error rate or the proportion of G>A and G>C base changes 
between fresh and fixed could be due to one of two reasons. Firstly, it may be 
possible that formalin fixation has no effect on error rate; however this is highly 
unlikely due to the median error rates of runs of FFPE 0.4% in contrast to that found 
for fresh samples (0.1%) in both our studies and the literature (Hadd et al., 2013). It 
is likely that the experiment used to model the effects of formalin fixation was not an 
accurate representation of tissue fixation and did not take into account other 
processes that FFPE tissue undergoes such as hot-plating. When tissue is fixed, it 
can be immersed in 10% formalin for a number of hours, often overnight, to allow for 
the formalin to perfuse through the tissue and sometimes a number of days for large 
resections. Therefore cells are slowly exposed over a long time period. In the case 
of the cell-line experiment, cells were left in formalin for only half an hour as the 
cells are free in solution and fixation is instantaneous. As a result, the formalin may 
not have had the same effect on the cell-line DNA as it would with the DNA in a 
tumour sample. The error rates observed for the fixed cell-line DNA were the same 
as those for un-fixed cell line DNA and this suggests that the formalin did not have 
any effect on the cells in this particular case. However, it is reported that FFPE 
tumour samples still produce an error rate that is double for fresh (Hadd et al., 2013, 
Yost et al., 2012) and this was also seen in tumour FFPE samples tested (Figure 
50). 
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3.6.4 KRAS in cancer-associated normal 
Next generation sequencing was able to detect mutations in 11 of 38  (29%) cancer-
associated normal mucosa samples. These mutations were confirmed on a second 
independent NGS run (Table 42). It was found that the majority of these mutations 
did not match those found in the tumour and Figure 51 shows that the mutation 
distribution matches that seen for KRAS in colorectal cancer. This is a strong 
indication that these are true mutations that are being detected and not DNA from 
exfoliated tumour cells co-extracted with the normal mucosa that are being 
sequenced. The range of mutant allele frequencies found in normal was 1.3% - 
8.7% that would usually fall below the detection limit of pyrosequencing.  
 
It is known that KRAS and BRAF mutations are present in hyperplastic polyps and 
serrated lesions, the latter which are thought to be early cancer precursor lesions 
(Chan et al., 2003). Therefore if KRAS mutation is an early event, its presence in 
normal mucosa from cancer patients, whose bowels have been exposed to 
carcinogens, is not unlikely. The detection of these low level clones suggests that 
genetic changes are more frequent than thought previously and support the 
hypothesis that cancer is an evolutionary process where mutations offer a cell a 
growth advantage. Multiple clones may develop with one becoming dominant which 
expands and forms the tumour phenotype (Baker et al., 2013). However, other low-
level background clones may still be present which would explain why the mutations 
detected in normal mucosa differed to those observed in the tumour. It was noted in 
the sample of normal mucosa with the highest rate of KRAS mutant at 8.7% that 
there were an excess number of bifid crypts. It would be expected that patients with 
inflammatory bowel disease (IBD) would have a higher crypt turnover rate and 
therefore have more bifid crypts, however the patient did not have IBD and the 
pathology report described the samples as normal. An example of the bifid crypts 
seen in this case is shown in Figure 54. 
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Figure 54. Sample of normal mucosa with high number of bifid crypts, annotated in green.  
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3.6.5 Usability of TALC 
Targeted amplicon library creation (TALC) allows for the generation of indexed, 
targeted libraries in a one-step PCR. There are several distinct advantages to this 
method over the traditional adaptor-ligation version of library generation. 
 
1. There is a significant time and cost reduction in generating libraries.  
For adaptor-ligation, before library preparation can begin, all samples have to 
undergo PCR amplification, clean-up, quantification and pooling of targets. The 
majority of the workflow for TALC is equivalent to this initial PCR amplification step. 
This also results in a significant reduction in the cost of reagents.  
 
2. The number of preparation steps is dramatically reduced. 
This eliminates opportunities for sample contamination and human-error in library 
preparation.  
 
3. Adaptor-dimers can interfere with the final library during sequencing for adaptor-
ligated libraries. 
The final gel purification of the pooled library allows for a clean library without 
adaptor contamination. Adaptor peaks can be difficult to eliminate with adaptor-
ligated prepared libraries and reduce the number of useful sequencing runs. 
 
4. Reduction in the number of PCR cycles. 
Adaptor ligated libraries undergo a final enrichment step of 15 PCR cycles which 
increases the risk of introducing artefacts. TALC only requires the initial 35 cycles of 
amplification and may therefore reduce this artefact risk, which is an important 
factor in calling variants.  
 
TALC libraries were sequenced with paired-end sequencing and therefore the error 
rate did not change across the amplicon (Figure 53). The quality scores of the 
bases reduce along the read and therefore for single-end sequencing it is expected 
that the error rate will increase as a result. However, paired-end sequencing 
compensates for this by reading the amplicon in both directions, averaging out the 
error rate across the read.  
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3.7 Chapter Summary 
 NGS has a limit of detection of 0.5% for fresh DNA and 1% for FFPE DNA. 
 RFLP with NGS is not reliable for specific mutation enrichment. 
 FFPE DNA samples have a background noise that is higher than fresh DNA. 
 Fixing cell-lines directly has no effect on background sequencing noise. 
 Mutations can be detected in cancer-associated normal mucosa by NGS. 
 Targeted amplicon library creation is an improved methodology for targeted 
library creation due to reduced costs and time preparation, less 
contamination probability, and fewer PCR cycles. 
 One non-inflammatory bowel disease sample with a very high KRAS 
mutation rate showed many bifid crypts correlating a mutational change to a 
phenotype. 
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4 High throughput mutation detection and copy number 
changes in early lesions 
  
153 
 
4.1 Introduction 
4.1.1 FAP adenomas as a model of field cancerisation 
Field cancerisation refers to the theory that there are multiple clonal patches of pre-
cancerous disease that may share genetic aberrations. Familial adenomatous 
polyposis (FAP) provides a useful model of field cancerisation. Patients affected by 
this condition inherit a mutated copy of the APC gene in all cells. They also share 
the same genetic background and modifiers as well as the same micro-biome and 
thus are an excellent model for studying the development of neoplastic lesions. As 
the bowel receives a “second hit” within APC, multiple adenomas develop 
throughout the colon (Will et al., 2010). The second hit is known to be different 
between different adenomas. Also there has been substantial progress in identifying 
and characterising the “second hit” of APC and how it relates to the inherited 
germline mutation (Lamlum et al., 1999, Crabtree et al., 2003, Will et al., 2010). 
Germline mutations between codons 1285 and 1398 are associated with allelic loss 
of APC. A germline mutation before codon 1285 is associated with a somatic 
mutation after codon 1285 whereas a germline mutation after codon 1399 is 
associated with a somatic mutation before 1284  (Lamlum et al., 1999) Crabtree et 
al., 2003) 
 
However, other gene mutations that may occur and how these adenomas evolve 
are less thoroughly investigated.  FAP adenomas have been previously reported as 
polyclonal which has led to the hypothesis of multiple fields of mutant crypts 
interacting (Thirlwell et al., 2010). A study by  Obrador-Hevia et al. revealed that 2 
out of 10 adenomas from an FAP patient contained a KRAS codon 12 mutation, 
however these two mutations were different (Obrador-Hevia et al., 2010). Similarly a 
study by (Jones et al., 2007) of 22 adenomas from 5 FAP patients revealed that 
different copy number changes were observed between FAP adenomas. This 
indicates that although FAP adenomas share a similar genetic background and are 
within the same environment, it appears individual adenomas may evolve in 
different ways. There are however no large studies of this process. 
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4.1.2 High-throughput targeted NGS library creation 
Small numbers of genetic targets can be interrogated by NGS by a simple PCR 
approach such as that outlined in Chapter 2. However, for the purposes of 
investigating a much broader panel, a multiplexed PCR approach is more suitable. 
High-throughput multiplex parallel PCR has been claimed to be performed on a 
microfluidic platform such as the Access Array by Fluidigm (Fluidigm, San 
Francisco, USA). Each Access Array chip contains 48 sample inlets and 48 assay 
inlets. PCR primers can be multiplexed within these inlets to create a maximum of 
480 amplicons for each of the 48 samples. The Access Array chip contains 
integrated fluidic circuits (IFC) whereby each sample is mixed with the primers in 
micro-PCR chambers, which allows for nanolitre reaction volumes. The resulting 
amplicons can then be barcoded in a simple PCR reaction and then pooled together 
on one NGS run (Halbritter et al., 2012). An overall schematic of this process is 
outlined in Figure 55. 
 
Figure 55. Schematic of library generation by Fluidigm Access Array (Fluidigm, San Francisco, 
USA). Adapted from (Halbritter et al., 2012). 
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4.1.3 Copy-number analysis and NGS 
Characterising larger genetic structural lesions is important in understanding the link 
between mutation genotype and overall phenotype. It has long been established 
that aberrant chromosomal copy number is a characteristic of chromosomal instable 
cancers (CIN) (Rajagopalan et al., 2003, Pino and Chung, 2010).  Many studies 
have reported chromosomal gains or losses in CRC and some have linked these to 
clinical outcome. (Poulogiannis et al., 2010, Xie et al., 2012, Janssen and Medema, 
2013, Burrell et al., 2013).  
 
CIN is a common feature of carcinoma as the genomic damage accumulates over 
time. Copy number aberrations are thought to be a late feature of colorectal 
progression. Commonly seen aberrations seen in adenoma include gains of 
chromosome 7, 13, 19 and 21 and losses in 1p, 9q, 17, 19 and 22 (Jones et al., 
2007, Flora et al., 2012, Yamamoto et al., 2012) 
 
Techniques for detecting copy-number variation (CNV) vary from large genome-
wide assays such as array comparative genome hybridization (aCGH) and NGS to 
more targeted approaches such as fluorescent in-situ hybridization (FISH), multiplex 
ligation-dependant probe amplification (MLPA) and other molecular techniques 
(Aradhya et al., 2013). NGS is an advantageous approach for CNV due to its broad 
range across the genome combined with resolution down to single nucleotides. This 
is achievable for small quantities of low quality DNA and resolution can be adjusted 
to allow for greater multiplexing of samples (Hayes et al., 2013). Algorithms for 
determining CNV from NGS data vary depending on their intended application. They 
work in principle by comparing the number of reads that once aligned, map 
throughout the genome in comparison to a normal control. CNAnorm is an ideal 
analysis tool for determining CNV in tumours due to it adjusting for possible 
contamination of normal cells within the tumour (Gusnanto et al., 2012). 
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4.2 Chapter aims 
The aims of this chapter are as follows: 
 To develop a targeted panel of CRC genes to be used with the Fluidigm 
Access Array (Fluidigm, San Francisco, USA). 
 To assess the performance of the Fluidigm Access Array (Fluidigm, San 
Francisco, USA). 
 To investigate mutations in carcinoma, adenoma and their associated 
“normal” mucosa alongside non-neoplastic mucosa using the Fluidigm 
Access Array (Fluidigm, San Francisco, USA). 
 To investigate mutations in a cohort of fresh carcinomas and their matched 
normals as well as a cohort of FFPE carcinomas and their matched normal. 
 To investigate mutations in multiple adenomas from FAP patients. 
 To investigate copy-number variation in multiple adenomas from FAP 
patients. 
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4.3 Methods 
4.3.1 Samples 
For 32 cases of CRC FFPE blocks were selected for the tumour and corresponding 
normal mucosa from the resection margin. Similarly 32 cases of sporadic adenoma 
and their matched normal mucosa were selected. For adenomas, biopsy blocks 
were used and the normal mucosa selected was at least 5cm from the tumour as 
recorded in the pathology report. Also 32 biopsies of non-dysplastic mucosa from 
patients with normal colonoscopies were selected. All blocks were sectioned and 
DNA extracted as previously outlined in Chapter 2. 
 
Blocks from four FAP patients were also selected for DNA extraction. Patient 1 = 22 
adenomas, patient 2 = 40 adenomas, patient 3 = 7 adenomas and patient 4 = 7 
adenomas. For each patient, a sample of muscle was also selected to act as a 
normal control. NGS libraries were generated from these FAP samples alongside 
the carcinoma, adenoma and normal samples using the Fluidigm Access Array 
(Fluidigm, San Francisco, USA). This produced 240 samples in total to be 
sequenced on a single run on the Illumina Hiseq (Illumina, San Diego, USA). 
 
Blocks of 6 carcinomas and their matched normal were repeated for mutational 
detection with Fluidigm alongside 6 samples of fresh frozen carcinoma and normal. 
The libraries were created in duplicate in order to determine the amount of error 
from formalin fixation and PCR to improve confidence in mutation calling.  
 
Alongside mutational analysis, the 80 FAP samples also underwent copy number 
variation analysis using NGS. All 80 samples were sequenced on a single Hiseq 
run. 
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4.3.2 Fluidigm system of high-throughput target enrichment 
A panel of key colorectal gene targets was designed by collating mutation 
frequencies from the literature (The Cancer Genome Atlas Network, 2012) and the 
Sanger database COSMIC v.66 (Bamford et al., 2004). When designing the panel, 
the number of targets had to be balanced with the target size and number of 
samples intended to assess in order to have high enough coverage of each target 
whilst maintaining sensitivity. Table 43 shows the targets chosen to create a design 
of 157 amplicons. Amplicons were designed to be 188bp or less in order for the 
whole target to be covered with a paired end read and a 6bp indexing read. The 
Illumina Hiseq (illumina, San Diego, USA) has a minimum output of 400 million 
reads in a paired-end run and 80% of these are of high quality. Therefore for 157 
amplicons, 240 samples could be multiplexed to produce a coverage of 8,500 for 
each target.  
 
Gene 
Mutation 
Frequency 
Target 
size (bp) 
Number 
of 
amplicons 
APC 81% 8532 106 
TP53 60% 413 6 
KRAS 43% 12 3 
PIK3CA 18% 18 2 
FBXW7 11% 9 3 
SMAD4 10% 1659 28 
NRAS 9% 9 2 
TCF7L2 9% 48 2 
CTNNB1 5% 42 1 
BRAF 8% 3 1 
PTEN 4% 9 3 
 Total 10754 157 
Table 43. Targets chosen for Fluidigm assay 
 
Libraries were prepared in accordance with the standard Fluidigm protocol for the 
use of multiplex amplicon tagging with the access array. The pre-amplification step 
suggested for FFPE tissue was omitted due to high yields of PCR product 
generated without this step.  The purification of libraries protocol was modified to 
normalise the quantities of each library added to the final pool due to uneven 
amplification during PCR from differing template qualities. Mutations present in 
KRAS 12 &13 were validated with pyrosequencing as outlined Chapter 2. 
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4.3.3 Copy-number library preparation 
In order to determine the chromosomal copy-number of the 80 FAP adenoma 
lesions, each sample of gDNA was fragmented, adapters ligated, libraries amplified 
and then pooled together and sequenced on a single lane of the Illumina Hiseq 
(illumina, San Diego, USA). In contrast to the previous library preparation approach 
as outlined in chapter 3 section 3.4.1, the index for each sample was read in a 
separate indexing read rather than incorporating the barcode into the first 6 bases of 
the read. This allowed for the NEBNext adaptor for illumina to be used for every 
sample. This adaptor contains a loop due to a uracil residue. After initial ligation of 
the adaptor, the loop is removed by adding Uracil-Specific Excision Reagent 
(USER) enzyme. The 6bp is then added in the final PCR enrichment step by using a 
different index primer for every sample. 
 
4.3.4 Shearing of gDNA 
gDNA was quantified by Quant-iT PicoGreen assay (Invitrogen, Paisley, UK) and 
200ng of each sample was diluted with TE buffer to a volume of 250μl and 
transferred to glass shearing tubes. Shearing was performed with the Covaris S2 
system (Covaris, Massachusetts, USA) for 25 cycles per sample to produce 
fragmented DNA of an average size of 200bp. Samples were then cleaned up and 
concentrated with the Qiagen MinElute kit (QIAGEN, Crawley, UK) eluting in a final 
volume of 11μl. 1μl of each sample was run on an Agilent Bioanalyser DNA 1000 
LabChip (Agilent, Santa Clara, USA) to ensure that DNA had been successfully 
sheared to the required size fragments. 
 
4.3.5 End-repair 
An End-repair step was performed to produce blunt-ended DNA fragments from the 
uneven-ended fragments produced from the shearing step. This End-repair was 
performed using the NEB End-repair kit (New England Biolabs, Hitchin, UK) as 
outlined in Table 44. 
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Component Volume 
NEBNext End Repair Reaction Buffer (10x) 5μl 
NEBNext End Repair Enzyme Mix 2.5μl 
dH2O 33.5μl 
gDNA 9μl 
Total volume: 50μl 
Table 44. Reaction mix for CNV end-repair 
 
The reaction mix was incubated at room temperature (20-25°C) for 30 mins. The 
reaction was then cleaned up using Qiagen MinElute kit (QIAGEN, Crawley, UK) 
clean-up eluting in 21μl EB. 
 
4.3.6 A-addition 
After the ends of the DNA fragments had been blunted, an adenosine-addition step 
was performed to create an “A” overhang. This would allow for ligation of adapters 
containing a “T” overhang. The reaction mix is outlined in Table 45. 
 
Component Volume 
NEBNext dA-Tailing Reaction Buffer (10x) 2.5μl 
Klenow Fragment (3´→ 5´ exo–) 1.5μl 
End Repaired, Blunt DNA 21μl 
Total volume:  25μl 
Table 45. Reaction mix for CNV A-addition 
 
The reaction mix was incubated at 37°C for 30 mins. The reaction was then cleaned 
up using Qiagen MinElute kit (QIAGEN, Crawley, UK) eluting in 12.5μl EB. 
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4.3.7 Adaptor ligation 
Adaptor ligation was performed using the NEBNext Adaptor (New England Biolabs, 
Hitchin, UK) with a T4 ligase enzyme. The reaction is outlined below in Table 46. 
 
Component Volume 
Quick Ligation Reaction Buffer (5x) 5μl 
NEBNext Adaptor 2.5μl 
Quick T4 ligase 2.5μl 
dH2O 2.5μl 
DNA 12.5μl 
Total volume:  25μl 
Table 46. Reaction mix for CNV adaptor ligation 
 
The reaction was incubated at 20°C for 15 mins. 3μl of USER enzyme was added to 
each sample and then incubated for a further 15 mins at 37°C to remove the uracil 
residue loop from the adaptors. The reaction was then cleaned up using Qiagen 
PCR purification kit (QIAGEN, Crawley, UK) eluting in 50μl EB. 
 
4.3.8 Size-selection 
The resulting DNA fragments have a wide spread in size around the 200bp average. 
Therefore a size-selection step was performed using Agencourt AMPure XP 
magnetic beads (Beckman Coulter, High Wycombe, UK). This works as a two-step 
process, to firstly remove unwanted large fragments and then smaller fragments. 
The polyethylene glycol (PEG) within the bead buffer is the key agent to precipitate 
DNA and bind it to the magnetic beads. It is the ratio of this buffer to the DNA 
volume that affects the size of DNA fragments captured. 
 
Firstly 40μl of beads was added to each 50μl sample, resulting in a 0.8 bead buffer 
to DNA ratio and incubated at room temperature for 5 minutes. This results in the 
capture of larger fragments onto the beads (300bp and higher) and smaller 
fragments remain in the supernatant. The samples were then moved to a magnetic 
rack and the beads were allowed to separate from the supernatant. The supernatant 
containing smaller fragments was transferred to a new tube whilst the larger 
fragments on the beads were discarded. 10μl of beads were then added to each 
sample. This volume, plus the 40μl already added, resulted in a 1:1 bead buffer to 
DNA ratio. This allowed for the capture of fragments 200bp in size and larger onto 
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the magnetic beads whilst small fragments remained in the supernatant. After 
separation on the magnetic rack, the supernatant was removed and this time 
discarded. The fragments left on the beads underwent two washes with 80% 
ethanol before they were finally eluted into 20μl of EB. 
 
4.3.9 Enrichment PCR 
The final enrichment step enabled samples to be barcoded with an individual 6bp 
index. This is done by performing a PCR with a different indexing forward primer for 
each sample. The reaction mix can be seen in Table 47. 
 
Component Volume 
NEB High Fidelity PCR master mix (2x) 12.5μl 
Universal PCR primer 1.25μl 
Indexing PCR primer 1.25μl 
DNA 10μl 
Total volume:  25μl 
Table 47. Reaction mix for CNV Indexing PCR enrichment 
 
The PCR reaction (Table 47) underwent the following thermocycling programme: 
 98°C for 30 sec 
 
 15 cycles of: 
 98°C for 10sec 
 65°C for 30sec 
 72°C for 30sec 
 
 72°C for 5 mins 
 
These final libraries were then cleaned up using Agencourt AMPure XP magnetic 
beads (Beckman Coulter, High Wycombe, UK) following the standard protocol with 
a 1x bead ratio and eluting into 30μl of EB. The libraries were visualised using an 
Agilent Bioanalyser DNA 1000 LabChip (Agilent, Santa Clara, USA). Figure 56 
shows an example trace from the Agilent Bioanalyser where there is a clear peak at 
the expected size range with no adaptor-dimers. 
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Figure 56. Bioanalyser trace of final gDNA CNV library. 
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4.4 Bioinformatic pipelines 
4.4.1 Bioinformatic pipeline for mutation calling 
For analysis of data generated from Fluidigm libraries, an automated pipeline was 
set up using published software. For file formats please refer to Chapter 3, Table 
27. Reads were firstly aligned using BWA alignment software, with default settings 
allowing for a 4% mismatch rate within the read. This generated SAM files which 
were then converted to sorted and indexed BAM files using SAMtools with default 
settings alongside the –q60 option to remove reads with a poor mapping quality (Li 
et al., 2009). Reads then underwent local realignment and base quality recalibration 
with the GATK (Li and Durbin, 2009). Local realignment looks for indels within the 
reads and realigns around them to allow for more accurate variant calls 
downstream. The base quality recalibration step looks for known SNPs within the 
reads and recalibrates the Phred scores to allow for SNPs to be discovered and 
more reliable variant calls. 
 
The output from GATK was then fed back into SAMtools to generate mpileup files. 
When using Samtools mpileup, the –d1000000 option was applied (maximum read 
depth) to allow the programme to work with high coverage. Also the –C50 option 
was used to reduce the effects of reads containing excessive mismatches. The final 
step in the pipeline to call variants was performed using VarScan version2 (Koboldt 
et al., 2012). Where matched tumour and normal samples were available, the 
VarScan –somatic command was used and VarScan –mpileup2snp for other cases. 
The settings were adjusted to call for a minimum allele frequency of 5% and a 
minimum coverage of 100 in Fluidigm libraries.  
 
4.4.2 Clustering analysis of mutation profiles 
In order to call mutations in adenomas from patients with FAP, the base changes in 
each tumour sample was compared to a normal muscle control. This was done 
using VarScan version2 with the “somatic” algorithm. In this way, SNPs and any 
PCR artefacts that were shared between adenomas and the control were filtered out 
from the analysis. This means that the germline APC mutation could not be 
identified. The remaining sites that were mutated in more than one adenoma were 
then compared for each sample to compile a matrix using a custom perl script 
mut_matrix.pl (see appendix). Heatmaps to display all shared mutations across the 
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samples were created with TM4 software (Saeed et al., 2003). Dendrograms were 
drawn to display clustering of adenomas that shared mutations by hierarchal 
clustering. 
 
4.4.3 Bioinformatic pipeline for copy number variation 
Samples sequenced for CNV analysis underwent an indexing read as part of the 
sequencing process and therefore the raw output of the sequencer were 
compressed fastq files for each individual sample. Therefore a demultiplexing step 
was not required. Sequencing was performed with the illumina Hiseq (illumina, San 
Diego, USA) on two lanes in “rapid mode” which resulted in single-end sequencing 
of 50bp read length. This amount of sequence had been previously validated by Dr. 
Henry Wood to be shown as sufficient for determining copy number (unpublished).  
All samples were decompressed and aligned to the genome using BWA “aln” and 
“samse” options with default settings. The output SAM files were then converted to 
BAM files using default settings with samtools. Due to sequencing being performed 
on two lanes of the Hiseq, two files were produced for each sample and therefore 
these BAM files were merged for each sample with the samtools “merge” algorithm.  
 
In order to determine copy number ratios, the CNAnorm pipeline was used. Firstly, 
BAM files were converted to tab delimited files, to provide compatible input for the 
CNAnorm programme. This was done using the bam2windows.pl perl script with 
default settings. These .tab files were then inputted to the CNAnorm programme 
which compared each sample to a normal control and produces plots of copy 
number ratio along the genome every 2Mb. Plots were generated for individual 
chromosomes, for example Figure 57 as well as a general overview of the whole 
genome for each sample  as seen in Figure 58. 
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Figure 57. CNAnorm output CNV plots for chromosome 7 in two adenomas A: sample 21 and B: 
sample 24 from the same patient.  
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Figure 58. Copy number variation profile overview for the entire genome of a single adenoma 
showing increased copy number of chromosomes 7 and 13. 
 
4.4.4 Comparison of copy number profiles 
In order to compare the profiles of lesions from the same patient across the 
genome, a matrix approach was adopted. The raw output from the CNAnorm 
produced text files which showed the position in the genome at around 200Mb 
intervals and the adjusted, normalised copy number ratio (Figure 59). Two custom 
perl scripts, matrix1.pl and matrix2.pl were used to code these profiles (see 
appendix for script). For each 200Mb window, a copy number above 1.2 was coded 
as a “1” whilst a copy number below 0.8 was coded as “2”. A normal copy number 
was coded as “0”. This enabled shared aberrations to have the same entry within 
the matrix for those adenomas that had those shared aberrations, whilst unique 
aberrations were coded differently in the adenoma matrix. In this way, small 
aberrations could be compared between adenomas simultaneously to larger 
chromosomal gains and losses. 
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Figure 59. Text output from CNAnorm programme showing copy number ratio across the 
genome. 
 
Due to nucleotide repeats at the telomeres and centromere, reads that map to these 
regions may not be aligned accurately. Therefore these positions within the genome 
are not as reliable for determining copy number. Ratios from the telomeres and 
centromere were removed from the analysis to improve the accuracy of the data. 
Once matrices had been generated for multiple samples from one patient they were 
inputted into  
 
TM4 software (Saeed et al., 2003) was used to create heatmaps of regions of gains 
and losses as well as cluster the adenomas using hierarchical clustering to produce 
dendrograms. These dendrograms allowed for the adenomas to be examined for 
how related they were to each other according to their chromosomal copy 
aberrations. 
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4.5 Results 
4.5.1 Mutations in carcinoma and carcinoma-associated normal 
duplicates 
12 samples of carcinoma and their associated normal mucosa from the resection 
margin were sequenced in duplicate with the Fluidigm Access Array (Fluidigm, San 
Francisco, USA) library generation system. The P53 gene did not amplify evenly 
and did not obtain enough coverage to be included in the analysis. The percentage 
of samples containing mutations in the tested genes are shown in Figure 60 in 
comparison to the COSMIC database (Bamford et al., 2004). 
 
 
Figure 60. Mutation frequencies for carcinoma and carcinoma-associated normal compared to 
the cosmic reference database for colorectal cancer (Bamford et al., 2004) with a 5% detection 
threshold. A: whole genes tested. B: genes where hotspots were tested. 
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8 of the 12 carcinomas contained mutations in APC with an allele frequency range 
of 11%-35%. There were mutations in KRAS in 5 of the 12 carcinomas; all were 
located in codons 12&13 with an allele frequency range of 32%-48%. One sample 
contained a KRAS codon 12 mutation in the normal mucosa with an allele frequency 
of 9%. Only one carcinoma contained a 30% PIK3CA mutation at codon 545 and 
this carcinoma also had a KRAS mutation.  There were SMAD4 mutations in 3 of 
the 12 carcinomas with a mutant allele frequency range of 35-59%. Two of the 
carcinoma associated normal samples contained a SMAD4 mutation (7.06% and 
19%), and these cases did not contain SMAD4 mutations in their corresponding 
tumour. Two of the carcinomas had CTNNB1 mutations (15% and 26%) and one of 
these had a mutation at a different location in CTNNB1 in the normal mucosa. 
 
The analysis was repeated for a minimum allele frequency of 1%, the distribution of 
frequencies in the tested genes is shown in Figure 61. By lowering the minimum 
cut-off the number of mutations called increased by 1.7-fold. There were more 
mutations seen in the carcinoma-associated normal mucosa, however, there were 
no new genes that were implicated. Figure 62 and Figure 63 display the distribution 
of mutations found in APC for carcinoma and carcinoma normal at a 5% and 1% 
minimum allele frequency. 
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Figure 61. Mutation frequencies for carcinoma and carcinoma-associated normal compared to 
the cosmic reference database for colorectal cancer (Bamford et al., 2004) with a 1% detection 
threshold. A: whole genes tested. B: genes where hotspots were tested. 
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Figure 62. Distribution of mutations found in carcinoma and carcinoma associated normal in APC at a 5% minimum allele frequency threshold compared to the 
mutation distribution from the COSMIC database (Bamford et al., 2004). The red and green points show the locations of APC mutations in individual carcinoma and 
normal samples compared to the frequency of mutations at that position according to COSMIC (blue bars). 
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Figure 63. Distribution of mutations found in carcinoma and carcinoma associated normal in APC at a 1% minimum allele frequency threshold compared to the 
mutation distribution from the COMIC database (Bamford et al., 2004). The red and green points show the locations of APC mutations in individual carcinoma and 
normal samples compared to the frequency of mutations at that position according to COSMIC (blue bars). 
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4.5.2 Validation of KRAS codon 12&13 mutations 
The 5 carcinomas with KRAS 12 &13 mutations alongside a WT carcinoma were 
validated by pyrosequencing. The results are as follows in Table 48. The mutant 
allele frequency of lesions 3, 4 and 5 fell below the sensitivity of pyrosequencing 
and therefore could not be detected. 
 
Sample NGS Pyrosequencing 
1 c.38 G>A  21.36%  c.38G>A  32.7%  
2 c.35 G>T  28%  c.35G>T  29.7%  
3 c.38 G>A  9.2%  WT  - 
4 c.35 G>T  6.8%  WT  - 
5 c.35 G>A  5%  WT  - 
6 WT  0% WT  - 
 
Table 48. Comparison of sequencing of KRAS codon 12 and 13 mutated tumours with NGS and 
pyrosequencing. 
 
 
4.5.3 Agreement between duplicates 
For 6 fresh tumours and their matched normals, when libraries were created and 
sequenced in duplicate using the Fluidigm Access-Array, a total of 195 mutations 
were called in carcinoma associated normal and 273 in carcinoma (Figure 64). 
These mutations were called with a minimum coverage of 300 and 5% minimum 
allele frequency threshold. Of these mutations, 80 were detected in both duplicates 
in carcinoma associated normal and 95 in carcinoma, resulting in an overall 
agreement rate between the duplicates of 81%.  
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Figure 64. Proportion of mutations shared between duplicates 1 and 2 for fresh tumours and 
matched normals. 
 
For 6 FFPE tumours and matched normals a total of 888 mutations were called in 
carcinoma associated normal and 910 in carcinoma. Only 39 of these were detected 
in both library duplicates for carcinoma associated normal and 58 in carcinoma 
(Figure 65), equating to an overall agreement rate between the duplicates of 11%. 
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Figure 65. Proportion of mutations shared between duplicates 1 and 2 for FFPE tumours and 
matched normals. 
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This analysis was repeated for a range of minimum allele frequency thresholds as 
shown in Table 49. When plotted (Figure 66), a clear relationship could be seen for 
fresh tissue however there was no obvious trend for FFPE and the agreement rate 
between duplicates remained from 10% to 21%. 
 
Allele frequency  
threshold 
Agreement between 
duplicates 
Fresh FFPE 
1% 33% 13% 
2% 68% 11% 
5% 85% 10% 
10% 89% 13% 
20% 97% 21% 
Table 49. Percentage of reads that are random PCR error for fresh and FFPE tissue for a range 
of different minimum allele frequency cut-offs. 
 
 
Figure 66. Plot of percentage agreement between library duplicates against minimum allele 
frequency threshold for a series of fresh and FFPE samples 
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For the cohort of fresh samples, the 195 mutations detected in 2 duplicates from 6 
carcinoma associated normal samples equated to an average of 16 mutations 
called in each single duplicate per sample. Similarly, for carcinoma, the 273 
mutations in total averaged out to 23 mutations for a single duplicate. The amount of 
sequence interrogated was 26,767 bases and so this equates to a mutation rate of 
0.06% and 0.09% for carcinoma associated normal and carcinoma respectively in 
fresh tissue. This equates to between 0.1 and 0.2 bases per amplicon of an average 
size of 170bp. 
 
In FFPE there was an average of 74 mutations called in carcinoma associated 
normal and 76 in carcinoma in each single duplicate. This gives a mutation rate of 
0.3%. For an average amplicon of 170bp, this equates to 0.5 mutated bases in each 
amplicon. For the oncogene amplicons: KRAS, NRAS, BRAF and PIK3CA, this 
would equate to 4 mutated bases within the 8 amplicons. However, only 36bp of 
sequence are analysed across these 8 amplicons, as only mutations in the hotspots 
were of interest in this study. This would result in 0.1 mutated bases across the 
oncogenes (0.3% of 36bp). For a threshold of 5%, only 10% of mutations were 
detected in both duplicates (Table 49). Therefore, across the oncogenes, if a 
sample is tested in duplicate, the background error is 0.09 bases per 36bp (0.025%) 
which was considered low enough in order to be able to interrogate FFPE samples 
for the oncogenes where they were not tested in duplicate (section 4.5.4). 
 
There was a significantly greater proportion of G>A and C>T changes in the FFPE 
cohort compared to fresh (Table 50). When mutations were called from duplicate 
libraries, 41% were C>T changes and 35% were G>A for FFPE. For mutations 
called in duplicate in the fresh cohort, 36% were C>T changes and 18% were G>A. 
Comparing the FFPE and fresh cohort mutations called in duplicate, the differences 
in the proportion of C>T and G>A changes was not significant. 
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Base 
change 
Proportion of mutations 
p-value 
Fresh FFPE 
G>A 31% 46% <0.0001 
C>T 11% 36% <0.0001 
A>G 9% 8% 0.4973 
T>C 10% 5% <0.0001 
G>T 6% 1% <0.0001 
T>G 4% 1% <0.0001 
C>A 12% 1% <0.0001 
T>A 6% 1% <0.0001 
A>C 5% 1% <0.0001 
G>C 0% 0%  
C>G 6% 0% <0.0001 
A>T 0% 0%  
Table 50. Proportion of base changes for fresh and FFPE cohorts. p values calculated from z-
test statistic. 
 
 
4.5.4 Mutations in carcinoma, adenoma and carcinoma-associated 
normal 
For carcinoma, adenoma and their associated normals run in single-plex, mutations 
were detected in the hotspots oncogenes in carcinoma, adenoma and carcinoma-
associated normal mucosa as shown in Figure 67 and Figure 68. No mutations 
were detected in adenoma-associated normal mucosa or in normal mucosa from 
patients with normal colonoscopies in the oncogenes. Mutation calls in the tumour 
suppressor genes could not be determined due to poor coverage and high false 
positive background noise from FFPE material as previously discussed. Also for the 
normal mucosa from patients with normal colonoscopies there was no other control 
tissue available such as blood in order to the determine patients’ SNPs and 
therefore these could not be removed from the data making mutations 
undeterminable.  
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Figure 67. Mutations present in hotspots of oncogenes for 32 cases of carcinoma (red) and 
their associated normal mucosa (green). 
 
 
 
Figure 68. Mutations present in hotspots of oncogenes for 32 cases of adenoma. No mutations 
in these oncogenes were detected in the associated normal mucosa. 
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4.5.5 Mutations in FAP adenomas 
Heat maps were generated to display the mutations from each adenoma. Only 
mutations present in more than one adenoma were included in the analysis in order 
to remove mutation calls that may be error incorporated by the PCR cycles. A black 
cell represents that the adenoma is WT at the position of interest and a red cell 
signifies a mutation. Those mutations of an allele frequency of 20% and higher have 
a stronger intensity colour. Hierarchical clustering was performed to analyse 
similarities between adenomas based on their mutational profiles. 
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Figure 69. Heatmap with dendrogram for mutations called in 22 adenomas from patient 1 and 
their location within the bowel. 
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Figure 70. Heatmap with dendrogram for mutations called in 40 adenomas from patient 2 and 
their location within the bowel. 
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Figure 71. Heatmap with dendrogram for mutations called in 7 adenomas from patient 3 and 
their location within the bowel. 
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Figure 72. Heatmap with dendrogram for mutations called in 7 adenomas from patient 4. 
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4.5.6 Copy number profiles of FAP adenomas 
Copy number profiles were generated for 75 out of 76 (99%) of the tested 
adenomas. Patterns of losses and gains in adenomas from the same patient 
showed that chromosomal aberrations were shared, but the amount of similarity 
varied between patients. The most common aberrations seen were gains in 
chromosomes 7,8 and 13. 
 
Figure 77 -  
Figure 82 show examples of lesions from the same patient. The percentage of the 
genome with abnormal copy number was calculated for each patient by dividing the 
number of windows across the genome that had an abnormal copy number (below 
0.8 and above 1.2) by the total number of windows. This was then plotted against 
the maximum diameter of each adenoma to see if there was correlation. For patient 
1 and 2, there was no correlation between the size of the lesion and the percentage 
of abnormal copy number across the genome (Figure 73 and Figure 74), however 
there was slight positive correlation seen for patient 3 and patient 4 (Figure 75 and 
Figure 76).  
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Figure 73. Percentage of abnormal copy number vs size of lesion for patient 1. 
 
 
 
 
Figure 74. Percentage of abnormal copy number vs size of lesion for patient 2. 
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Figure 75. Percentage of abnormal copy number vs size of lesion for patient 3.  
 
 
 
 
Figure 76. Percentage of abnormal copy number vs size of lesion for patient 4.  
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Figure 77. Copy number profiles of two lesions from patient1. Unique copy number changes for each adenoma are circled in blue and shared aberrations in purple. 
This shows a clear relationship between the two in 8 sites with at least 15 differences between them showing divergent evolution. 
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Figure 78. Copy number profiles of two lesions from patient 2. Unique copy number changes for each adenoma are circled in blue and shared aberrations in purple 
showing shared whole gains of chromosomes 7 and 13 as well as unique gains of 8 and 9. 
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Figure 79. Copy number profiles of two lesions from patient 3. Unique copy number changes for each adenoma are circled in blue and shared aberrations in purple. 
These adenomas show whole chromosome gains of 7 and 13 which is frequent in adenomas but also many other changes. 
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Figure 80. Copy number profiles of two lesions from patient 4. Unique copy number changes for each adenoma are circled in blue and shared aberrations in purple 
showing 3 small shared aberrations. 
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For patient 3, all adenomas contained a small aberration in chromosome 11. These 
can be viewed at greater resolution in Figure 81. 
 
 
Figure 81. Plot of chromosome 11 for all adenomas from patient 3 to show different patterns of 
loss. 
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4.5.7 Clustering analysis 
As before for the mutational profiles, heat-maps were drawn from the copy number 
matrices generated from each adenoma to show areas of gain (red) and loss 
(green). Positions where copy number was normal for all samples were omitted 
from the sample to allow for only areas of abnormality to be analysed. Hierarchical 
clustering was performed to assess similarity between adenomas in each patient. 
Adenomas from all patients were numbered in the order proximal-distal. 
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Figure 82. Heatmap for copy number profiles in adenomas from patient1. 
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Figure 83. Heatmap for copy number profiles in adenomas from patient2. 
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Figure 84. Heatmap for copy number profiles in adenomas from patient3. 
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Figure 85. Heatmap for copy number profiles in adenomas from patient4. 
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Comparison between copy number and mutations 
For each adenoma, the percentage of abnormal copy number across the genome 
versus percentage of mutations present in that adenoma of all shared mutations 
from that patient were plotted together (Figure 86). This was to determine whether 
copy number or mutations were having a dominant effect in any of the patients. 
 
 
 
Figure 86. Plot of mutation rate against abnormal copy number rate for all adenomas from 
patients 1-4 showing clustering of patients according to the degree of mutations or abnormal 
copy number present. 
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4.6 Discussion 
4.6.1 Use of Fluidigm for targeted sequencing 
The ability of a technology to accurately detect mutations is highly dependent on the 
false positive rate and the ability to correctly identify and remove these false 
positives. By creating duplicate libraries using the Fluidigm Access Array (Fluidigm, 
San Francisco, USA) with a cut-off of 5%, it was revealed that 81% of mutations 
called in fresh tissue were present in both duplicates and only 11% in FFPE (Figure 
64 and Figure 65). The mutations not detected in both duplicates are due to three 
main sources of error: formalin induced changes for FFPE samples, PCR error and 
sequencing error.  
 
It has previously been described that formalin fixation results in deamination and 
depurination of cytosine and guanine residues (Williams et al., 1999, Kerick et al., 
2011, Do et al., 2013) resulting in C>T and G>A artefacts in the PCR amplicons. 
The effects of formalin fixation have been previously explored in Chapter 2. In the 
cohort of FFPE samples that were sequenced alongside fresh samples, a 
significantly larger proportion of C>T and G>A changes were observed in mutations 
only detected in one of the repeats (Table 50). When the analysis was repeated for 
only mutations that were detected in both duplicates, this significant difference was 
removed, illustrating that by running samples in duplicate the bias in FFPE tissue for 
G>A and C>T changes can be removed. These artefacts have been reported to be 
significantly reduced by pre-treatment of gDNA with uracil-DNA glycosylase (UDG). 
Cytosine is converted to uracil through deamination and this is detected by the DNA 
polymerase as a thymine base which causes the resulting C>T change after PCR. 
UDG breaks uracil residues from their sugar phosphate backbone, causing the DNA 
polymerase to stop during amplification. As a result it has been reported that 60% -
81% of these artefacts can be removed from NGS targeted high coverage amplicon 
sequencing (Do et al., 2013). This information was available only after the 
experiment was run and this should be explored further. 
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For fresh tissue, as the minimum allele frequency cut-off for calling mutations was 
increased, the amount of agreement between each duplicate increased (Figure 66). 
This is likely due to the high number of starting template copies for fresh tissue. If a 
PCR error occurs in one template copy within an early cycle, the high number of 
template copies dilutes the effect of this error resulting in it having a lower allele 
frequency. For errors that occur in the later stages of the PCR, they are amplified 
less which results in them having a lower allele frequency. Therefore these errors 
can be filtered out by either having a higher minimum allele frequency cut-off or by 
running samples in duplicate. It would also be of value to run samples in triplicate 
and even quadruplicate to determine the point at which mutation calls do not 
change between multiple libraries from one sample. 
 
For FFPE samples the amount of agreement between duplicates for mutation 
calling remained low, regardless of the minimum cut-off for mutant allele frequency. 
FFPE DNA is more fragmented than fresh (Hadd et al., 2013) and therefore 
contains fewer copies of starting template for PCR. Formalin can also cause cross-
links to form between histones which may obstruct the polymerase, effectively 
reducing the amount of a starting template available (Teo and Shaunak, 1995). A 
low number of copies will mean that the error rate of the polymerase will have a 
more significant effect. Errors that occur within the early cycles of the PCR will be 
amplified and have a higher allele frequency. Therefore these cannot be filtered out 
by increasing the minimum allele frequency threshold as was seen for FFPE tissue.  
 
Even with fresh tissue and a minimum allele frequency threshold of 10%, there were 
11% of mutations that were not detected in both duplicates. This could partly be due 
to the polymerase used with the Fluidigm system. Although quoted to have a higher 
fidelity than standard taq polymerase, this enzyme is not the highest fidelity 
polymerase available and still induced errors within the PCR. These challenges can 
be overcome by running samples in duplicate and a higher fidelity enzyme should 
be optimised for the access array system. It may also be possible to determine the 
amount of starting template copies from FFPE tissue by use of qPCR, however, 
both of these methods have significant cost and time implications. However all of 
these options need to be tested to determine the optimal conditions for the Fluidigm 
access array in order to determine how reliable the assay can be. 
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4.6.2 Mutations in carcinoma and carcinoma associated normal tested 
in duplicate 
For the cohort of fresh and FFPE carcinomas that were tested in duplicate, the 
distribution of mutations within the matched genes tested was similar to the 
distribution observed in the COSMIC database (Figure 60) (Bamford et al., 2004). 
Mutations were also seen in carcinoma-associated normal mucosa in APC, KRAS 
and SMAD4. There was a slightly higher number of SMAD4 mutations in the 
carcinomas (25%) than the COSMIC database (14%) but this was not significant 
(p=0.059). It has also been reported in other studies that SMAD4 mutation 
frequency in CRC is up to 35% (Miyaki and Kuroki, 2003). KRAS mutations have 
been previously observed in carcinoma associated normal mucosa (Minamoto et al., 
1995, Yamada et al., 2005, Jonsson et al., 2010) as well as the cohort tested in 
Chapter 2 (ref). This experiment has shown KRAS mutations in normal mucosa in 
an independent cohort of samples with a different method of library preparation.  
 
Mutations were also observed in APC in normal mucosa. APC loss is an early event 
within the development of colorectal cancer (Cunningham et al., 2010) and 
mutations in APC have been previously seen in very early lesions of colorectal 
cancer such as aberrant crypt foci (Orlando et al., 2008). When the minimum cut-off 
was set at 5%, the distribution of mutations in APC in carcinoma occurred across 
the gene and at particular sites that had a high frequency previously reported 
(Figure 62) suggesting that the data is reliable. 
 
When the mutation minimum cut-off was lowered to 1% (Figure 63), 2 mutations in 
both carcinoma and carcinoma associated normal were clustered around the 3’ end 
of exon 15. This has not been previously reported and the majority of mutations 
normally lie within the mutation cluster region. Only 2% of mutations reported in 
APC lie within this region of the gene (codon 1689 and above). It could be that 
these APC mutations are only weakly transforming and do not greatly affect the 
phenotype or as these mutations are low level (1% -5%) they could also likely 
represent PCR artefact in the amplicons that cover this region. Different 
polymerases can insert errors within the PCR at non-random points. Therefore it 
would be ideal to repeat the testing of this region of APC for these samples with a 
different polymerase to see if the mutations remained. Alternatively they could have 
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been falsely called by the VarScan variant caller software. It has previously been 
shown that there is poor concordance with different variant callers. A study that 
compared 4 of the most commonly used including VarScan, revealed that only 36 
mutations were detected by all 4 variant callers out of a total of 2920 possible 
mutations (Figure 87) (Roberts et al., 2013). It would perhaps be beneficial to scan 
data with multiple variant callers however this does increase the time and computer 
power required to analyse data. Also without understanding the causes of the 
variation seen, it could be problematic and result in true findings being filtered out.  
 
 
Figure 87. Overlaps between somatic single nucleotide variant sets from exome data. 
Reproduced with permission from (Roberts et al., 2013). 
 
A mutation in CTNNB1 was seen in one of the samples of normal mucosa which 
also contained a mutation in the tumour. The mutation in the normal mucosa was 
different to that in the tumour. CTNNB1 mutations have been previously observed in 
histologically normal rat colon mucosa that has been treated with a carcinogen 
(Yamada et al., 2000).  
 
The finding of SMAD4 mutations in carcinoma-associated normal mucosa is more 
unexpected. This could partly be explained by the presence of copy number 
aberrations. Loss of the 18q chromosome is reported in up to 60% of CRC 
(Woodford-Richens et al., 2001). Although the bioinformatic pipeline for calling 
mutations takes into account commonly reported SNPs there are always SNPs 
unique to that patient. These are normally filtered out by analysing the normal and 
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tumour samples in parallel. However, for cases where the tumour has 18q loss, a 
SNP in SMAD4 may appear to be a mutation in the normal mucosa. Obtaining copy 
number data for these samples alongside the mutational profiles would be useful to 
further investigate these SMAD4 mutations in normal tissue. 
 
Figure 61 shows the mutational distribution when calling mutations at a minimum 
allele frequency of 1%. This resulted in a small increase in the number of tumours 
with mutations compared to 5%, which did not greatly affect the overall distribution 
for carcinomas. However, there was a much greater increase in the number of 
samples with mutations in the normal mucosa. This indicates that mutations in 
normal mucosa are either at a very low level in a small number of cells. This may 
represent the genetically damage background of normal mucosa in patients with 
carcinoma. Low level mutations in normal could either be carcinogen induced or due 
to faulty DNA repair or alternatively they could be artefact. To investigate this 
further, it could be possible to look for SNPs associated with cancer and see if this 
correlates with mutations in normal mucosa (Dunlop et al., 1997). 
 
4.6.3 Carcinoma, adenoma and non-neoplastic normal 
 For the cohort of carcinoma, adenoma and their associated normals as well as non-
neoplastic associated normal samples, libraries were not tested in duplicate since 
the error rate of the Fluidigm Access Array (Fluidigm, San Francisco, USA) was 
higher than anticipated. All samples were FFPE and therefore the mutational data 
obtained was not reliable enough to make mutation calls as the error rate was 
subsequently shown to be around 80%. However for the oncogenes tested, 
mutational calls could still be made with some confidence as only hotspots were 
interrogated. The probability of an error occurring within the one or two base 
positions of the oncogenes investigated compared to the entire 30kb of sequencing 
was low enough at 0.025% to call mutations at these positions with a degree of 
certainty. Furthermore a subset of the KRAS mutated carcinomas was validated by 
pyrosequencing. Where the mutant allele frequency was high enough, the mutations 
could be confirmed with pyrosequencing (Table 48). 
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For the 32 carcinomas tested, mutations were observed in hotspots of KRAS, NRAS 
and PIK3CA genes. Of the KRAS codons 12 and 13 mutated tumours, 
approximately a third of those also contained mutations within the normal mucosa. 
This is very similar to the other cohort of carcinomas tested for KRAS 12 and 13 
mutations in chapter 3. For one sample, a mutation was observed in PIK3CA. It 
would be highly useful to repeat this sample to determine if this mutation is real as 
PIK3CA mutations have not previously been reported in normal mucosa. If this is a 
true mutation, there could be implications with regards to the use of aspirin as a 
chemopreventative agent. Aspirin has been shown to benefit those patients that 
have a PIK3CA-mutated tumour (Liao et al., 2012) and identifying PIK3CA 
mutations in normal mucosa could help identify those patients that might benefit 
from taking aspirin as a CRC preventative agent.  
 
Of the 32 adenomas tested, mutations were seen in KRAS 12 and 13 and PIK3CA 
545 and 546. There were no mutations seen in the adenoma-associated normal 
mucosa for these samples. Similarly, there were no mutations present within KRAS, 
NRAS or PIK3CA for samples of normal mucosa from patients with normal 
colonoscopies. 
 
4.6.4 Mutational profiles of FAP adenomas 
Mutations in FAP adenoma samples were determined by comparing the mutations 
present in each adenoma to a normal muscle control for each patient. This allowed 
for SNPs and PCR artefacts that occur at specific points within the amplicon to be 
filtered out. Thus identifying the germline APC mutation was not possible and due to 
ethical conditions the patients were anonymous therefore this information could not 
be obtained through medical records. For each patient, only sites where a mutation 
was present in one or more adenoma were included in the phylogenetic analysis. 
This allowed for random PCR errors to be removed from the analysis as the chance 
of a random error in 30kb of sequence to occur in same location for two or more 
samples was very low (1x10-7%). Mutational profiles of adenomas from 4 FAP 
patients revealed different degrees of clustering based on their mutation similarities. 
Patients 1, 2 and 4 had adenomas sampled from the entire bowel, whereas patient 
3 had adenomas located in the sigmoid and rectum. 
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For patient 1 the heatmap of mutations showed that the 11 adenomas on the right 
side of the colon contained more mutations (37) than the 11 adenomas on the left 
(20) (Figure 69). This difference was statistically significant (p=0.0105). This could 
be due to the microflora within this region of the bowel producing a higher number of 
carcinogens therefore causing more mutations to occur. The cluster analysis for 
patient 1 revealed that some lesions appeared to develop independently, whilst 
other lesions clustered together. The structure of the dendrogram revealed a cluster 
with adenomas 12, 16, 18 and 19 as these contained few shared mutations in the 
tested genes and were independent. Adenomas 8 and 17 contained the same APC 
mutation; however adenoma 17 also acquired a mutation in KRAS indicating that 
the APC mutation had occurred first. Adenomas 3 and 14 branched together and 
had the same mutations in APC and SMAD4. These lesions were located 10cm 
apart in the ascending colon which indicates that a mechanism allows for mutated 
cells to spread at least this distance. 
 
Patient 2 had no significant difference in the number of mutations located in the left 
and right hand side of the bowel (Figure 70). The dendrogram from patient 2 
showed a pattern of relatively independent adenomas throughout the bowel with a 
limited amount of clustering. A cluster of adenomas that did not branch further 
represented that these contained no shared mutations with any of the adenomas 
from this patient and were independent. On closer inspection of other parts of the 
dendrogram, there was branching of adenomas that were located in the bowel 
nearby. For adenomas 8 and 12, both from the ascending colon, they shared the 
same mutation in APC. It could also be seen where adenomas clustered due to 
them sharing a mutation but then one adenoma containing extra mutations such as 
adenomas 2 and 11. By chance, adenomas located closer together should share 
molecular lesions and adenomas located at a greater distance from each other 
should share less. However relationships are seen at a greater distance and 
therefore a mechanism is enabling clones to spread at greater distances throughout 
the bowel. 
 
For patient 3 (Figure 71) adenomas 5 and 6 from the rectum shared multiple APC 
mutations. Adenomas 1 and 3 shared mutations in CTNNB1 and they were both 
located in the sigmoid. A similar pattern was also seen in patient 4 (Figure 72). 
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Adenomas 3 and 4 shared PIK3CA and multiple APC mutations. They were closely 
located in the colon but were embedded in two separate FFPE blocks. Adenoma 4 
also contained extra low level APC mutations. The other adenomas from this patient 
branched separately, showing that they were relatively independent. Again, this 
shows that mutations spread locally however there may be independent events 
occurring in larger fields within the bowel. 
 
Although some degree of clustering was revealed in adenomas through testing this 
gene panel, it is important to note that mutations in other genes could be occurring 
which may affect the relationships between adenomas. It would be very interesting 
to repeat this with whole exome sequencing however this would currently be very 
costly; both in sample preparation and the amount of sequencing required for 
sufficient coverage for sensitive detection. In order to check the reliability of the 
mutational phylogenetic trees it would be important to validate mutations. Therefore 
as this data stands, the copy number dendrograms are more reliable as the process 
is less prone to error. 
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4.6.5 Size of FAP adenomas and copy number aberrations 
A trend could be seen for 3 out of the 4 patients between the size of the adenoma 
and the amount of abnormal copy number present across the genome. (Figure 73 - 
Figure 77). Aberrant copy number is associated with later stage tumour progression 
and therefore larger adenomas are more likely to have copy number aberrations. 
The most commonly seen chromosomal aberrations were gains in chromosomes 7, 
8 and 13. These are also commonly reported in sporadic adenomas (Meijer et al., 
1998, Jones et al., 2007). 
 
4.6.6 Copy number profiles of FAP adenomas 
Creating matrices from the copy number ratios was an effective way to observe 
clustering of adenomas as they enabled those adenomas that shared marker 
aberrations to cluster together on the phylogenetic tree. Copy number analysis of 
the same 80 adenomas from patients 1-4 revealed substantial clustering of 
adenomas. For patient 1 (Figure 82), many adenomas were fairly independent, 
similar to the mutational analysis dendrogram. However, adenomas 5, 12 and 16 
contained much larger chromosome structural changes than the other adenomas 
tested. Interestingly, 5 and 16 both contained whole gains of chromosome 8, but 
adenoma 5 also had gains in 3, 13 and 14 whilst adenoma 16 had a chromosome 7 
gain. This would indicate that these adenomas contain a common origin, but had 
then evolved independently. Adenomas 6 and 21 clustered according to their CNV 
profiles even though adenoma 6 is located within the ascending colon and adenoma 
21 is from the rectum (Figure 88). Although they are located far apart within the 
colon, copy number analysis revealed these adenomas to share a molecular 
background even though they were not related by their mutational profiles. This 
suggests that multiple mechanisms drive adenoma formation and that molecular 
aberrations can spread over a distance within the bowel. 
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Figure 88. Copy number profiles of adenomas 6 and 21 from patient 1 located in the ascending colon and rectum respectively. 
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Adenomas from patient 2 clustered into two main subtrees with adenoma 24 
clustering independently (Figure 83). This adenoma adenomas had gross 
chromosome structural changes and was independent of all other adenomas tested.  
 
For the 8 adenomas that clustered together they all shared a chromosome 7 gain 
(Figure 89) and some also had a chromosome 13 gain (Figure 90). These lesions 
may have evolved from the same background, or chromosome 7 and 13 gains could 
have occurred independently at the proximal and distal ends of the bowel, creating 
two similar cancer fields. Out of all 40 adenomas tested in patient 2, 9 had a 
chromosome 7 gain (23%) and 11 had a chromosome 13 gain (28%). This is similar 
to the frequencies previously reported in adenoma (Meijer et al., 1998, Pino and 
Chung, 2010). Therefore the probability of an adenoma containing both by chance 
is 6% which equates to 2 out of the 40 adenomas. For patient 2, 6 out of the 40 
adenomas (15%) contained both chromosome 7 and chromosome 13 gains which is 
not statistically significantly higher than the expected 5% of adenomas. Therefore it 
cannot be said that lesions from the caecum can spread through to the rectum and 
these adenomas may have both developed the same copy number aberrations by 
chance. 
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Figure 89. Adenomas with chromosome 7 gains for 8 adenomas clustered in cluster 1. 
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Figure 90. Adenomas with chromosome 13 gains for 6 out of 8 adenomas clustered in cluster 1.  
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For cluster 2 a cluster of 4 adenomas from the descending colon and rectum all 
contained a chromosome 13 gain. For the other adenomas there were very few 
copy number changes present. This cluster consisted of 25 adenomas located 
throughout the bowel. This pattern of grossly abnormal adenomas located nearby to 
adenomas with few copy number changes suggests that there are other factors 
involved in the evolving cancer field and that the dynamics are highly complex. 
 
In contrast, adenomas from patients 3 and 4 contained relatively few large 
chromosome structural changes. For patient 3 (Figure 84), there was little clustering 
of the adenomas due to their copy number profiles being relatively normal. 
Adenomas 6 and 7 from the rectum both had a small gain at 12p, causing them to 
branch together on the nearest-neighbour tree. All of the adenomas shared a loss at 
chromosome 11, but the patterns of loss differed slightly between adenomas (Figure 
81). This is evidence of the evolution of a shared change showing that the 
adenomas are related. 
 
For patient 4 (Figure 85), lesion 7 had a 15q deletion but otherwise had very 
minimal changes. The other adenomas from this patient appeared to be relatively 
normal. The contrast in copy number changes not only throughout the bowel for 
each patient but also comparing different patients illustrates that chromosomal 
changes are only one of many contributing factors to adenoma development in FAP. 
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4.6.7 Comparison of copy number and mutations 
For all four patients, there was very little similarity between the clustering of 
adenomas according to their mutational profiles and copy number aberrations. It is 
worth noting that for many of the adenomas, there is little copy number change and 
so these adenomas with cluster together with very short branching but may branch 
out and cluster differently as they contain more mutations. This difference in the 
dendrogram patterns may be due to mutational events and larger chromosomal 
changes occurring at different points within the development of the adenomas. 
However, it could also be due to the mutational data containing artefacts that could 
be interfering with the true clustering patterns.  
 
By plotting all adenomas together according to how mutated they are and how 
abnormal their copy number is, it can be seen that adenomas cluster together and 
appear to have different trajectories (Figure 86). Patient 1 and patient 2 mainly 
cluster together having low mutation rate (30% and below) and low abnormal copy 
number rate (20% and below). There are a few adenomas from each patient that 
are outliers from this cluster that have a low mutation rate but a high abnormal copy 
number. For patient 1 the median adenoma size was 4.54mm (IQR = 3.61 – 8.55) 
and one of the outliers with an abnormal copy number rate of 30% was 10mm in 
diameter. Therefore the high copy number rate could be driving its growth. Similarly 
for patient 2, the median adenoma size was 4.70mm (IQR = 3.48 – 8.46) and the 2 
adenomas with the largest abnormal copy number rate at 39%, 46% and 55% were 
16mm, 7mm and 8mm in diameter respectively. Patient 4 has two lesions that 
cluster in the low mutation/low CNV region of the scatter plot, but also has 4 that 
have a higher mutation rate but still lower copy number. This could indicate that the 
adenomas from this patient are proliferating through a different mechanism that is 
more mutation-driven. Finally patient 3 has lesions that are all of a high abnormal 
copy number rate (35% and above) with a range of mutation rates. This patient is 
the oldest (27years) in comparison to patient 1 (16years), patient 2 (23 years) and 
patient 4 (18 years). This could be an indication why their adenomas have high 
mutation rates and high abnormal copy number as more aberrations have been 
acquired over a longer period of time. Alternatively for this patient the mutations 
could be having less impact than copy number during growth. Overall this plot 
suggests that there could be different mechanisms driving adenoma growth and one 
mechanism may be dominant or both may occur. 
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4.7 Chapter Summary 
 The Fluidigm Access Array (Fluidigm, San Francisco, USA) as an NGS 
library preparation method allows for multiple mutations to be detected to a 
low allele frequency in highly multiplexed samples when tested in duplicate. 
 FFPE material contains a significant proportion of G>A and C>T artefacts 
compared to fresh tissue. 
 KRAS mutations can be detected in carcinoma-associated normal mucosa 
using the Fluidigm Access Array (Fluidigm, San Francisco, USA) in a 
separate cohort of patients, confirming this does occur. 
 Mutations can also be detected in APC, SMAD4, CTNNB1 and PIK3CA in 
carcinoma-associated normal mucosa. 
 No mutations have been detected in adenoma-associated normal or non-
neoplastic normal mucosa in KRAS, NRAS BRAF or PIK3CA at 5% 
sensitivity. 
 FAP adenomas show a positive correlation between size and degree of 
abnormal copy number across the genome. 
 FAP adenomas cluster locally within the bowel both by their mutational and 
copy number profiles. 
 Abnormalities, both mutational and copy number occur more frequently in 
the same areas of the bowel but can also occur at a great distance. 
 Different mechanisms appear to drive different patient’s adenoma growth 
processes. 
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5 Discussion, conclusions and future directions 
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5.1 Discussion 
Colorectal cancer has a survival much poorer when detected at a late stage; Dukes’ 
C and Dukes’ D tumours have a 5-year survival rate of less than 50% (Cancer 
Research UK, 2012b). Therefore detecting changes early to prevent the 
development of cancer as well as finding it at an early more treatable stage is key to 
improving outcomes. This has already been seen with the implementation of the 
bowel cancer screening programme. Faecal occult blood testing has reduced the 
stage of presentation of carcinoma and the introduction of flexible sigmoidoscopy 
will identify and remove adenomas and as well can detect early cancer. Looking for 
genetic changes within the normal bowel mucosa before phenotypic changes occur 
might allow the identification of individuals who may progress to cancer at an even 
earlier stage. 
 
5.1.1 Crypt isolation 
In order to look for mutations in normal mucosa, it would be beneficial to isolate only 
epithelial cells. This is to allow for more sensitive detection as epithelial cells make 
up 51.7% of the mucosa. By extracting DNA from the whole mucosa, potential 
mutations are diluted and the detection technique has to be more sensitive to 
compensate.  
 
Of the two isolation techniques investigated: mechanical dissociation of colonic 
crypts in the presence of a chelating agent (MD) and laser-capture microdissection 
(LCM), only MD was able to produce a consistently high enough yield of DNA for 
reliable downstream use. Despite a considerable time commitment for trouble-
shooting LCM, attempts were unsuccessful and whole mucosa had to be used for 
FFPE DNA extraction. It is worth noting that previous studies using LCM for colonic 
crypt isolation have looked at a small number of gene targets with Sanger 
sequencing (Humphries et al., 2011) which is non-quantitative and insensitive and 
cannot detect low allele frequencies below 20%. For a targeted NGS approach it is 
important that a high quantity of gDNA is used to ensure a high starting number of 
template copies to reduce error. Therefore LCM may not be a suitable technique to 
use where NGS of whole mucosa is sufficiently sensitive. 
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5.1.2 Sensitivity of mutation detection 
In order to be certain of the presence of mutations in normal mucosa it was 
necessary to obtain the highest sensitivity and specificity. Therefore 3 PCR based 
enrichment techniques were investigated (RFLP, COLD PCR, ICE COLD PCR) as 
well as pyrosequencing and ultimately NGS as it became available.  
 
The COLD-PCR enrichment methods failed to produce any significant mutant allele 
enrichment. This is a relatively new approach that has not yet been replicated by 
other groups and has recently become available as a commercial PCR kit 
(Trangenomic Inc, 2013). It is highly temperature dependant and many 
environmental factors may interfere with the effectiveness of its enrichment. RFLP 
produced a moderate enrichment for pyrosequencing, but due to the increased 
chance of sample contamination and extra PCR cycles amplifying errors it was 
decided that the benefit of this technique could not justify its use when NGS was 
sufficiently sensitive. 
 
The sensitivity of pyrosequencing was found to be relatively insensitive and lie 
between 5% to 25%, depending on the type of base substitution detected. This is 
comparable to other similar pyrosequencing studies which reported a 5% sensitivity, 
however they only tested a G>A base change which pyrosequencing is best at 
detecting (Tsiatis et al., 2010). NGS was found to have a sensitivity of 1%. 
Therefore in order to consistently be able to detect mutations at 5% an NGS 
approach was chosen. 
 
5.1.3 Development of TALC 
The original method of adaptor ligation was not an ideal method for preparing PCR 
amplicons for sequencing. This was due to the multiple steps the process involved 
which led to high risk of contamination as well as being time intensive and high in 
cost. Also this method required extra cycles of PCR, totalling the number of PCR 
cycles to 55 which is not ideal and introduces artefacts. Therefore a new method 
was developed to incorporate the NGS adaptors into the original PCR; targeted 
amplicon library creation (TALC). TALC was shown to produce equal results to the 
adaptor ligation method and reduced the preparation time and costs significantly.
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5.1.4 Mutations in histologically normal mucosa 
KRAS mutations in normal mucosa have been reported in both carcinoma-
associated and also non-carcinoma associated normal mucosa in multiple studies 
(Ronai, 1994, Yamada et al., 2005, Parsons et al., 2010). Therefore the approach 
taken was firstly to investigate if this could be replicated. Through NGS sequencing 
of KRAS codon 12 & 13 amplicons run in duplicate, mutations could be detected in 
11 out of 38 (29%) samples of carcinoma associated normal mucosa from patients 
with KRAS mutated tumours. The mutations detected in the normal mucosa had 
allele frequencies of between 1% and 9%, confirming that a highly sensitive 
technique is required to detect these low level mutations.  
 
In a separate cohort, KRAS mutations were detected in 41% of carcinomas and 8% 
of the associated normal samples. There were no mutations found from normal 
mucosa where the tumour did not also contain a KRAS 12 & 13 mutation. No KRAS 
mutations were detected in the adenoma associated normal mucosa or the normal 
mucosa from patients with normal colonoscopies. The finding of RAS mutations in 
normal mucosa being restricted to cases with RAS mutations in the cancer might 
suggest that extreme carcinogens are inducing such mutations or that these 
patients have an inherent risk of suffering these mutations for an unknown reason. 
 
The bioinformatic approach to analysing data for KRAS and other oncogene 
hotspots is relatively straightforward in comparison to interrogating large tumour 
suppressor genes where a mutation could occur at any point. For a cohort of 
carcinoma, adenoma and their associated normals as well as normal mucosa from 
patients with normal colonoscopies, mutations in the oncogenes were only detected 
in carcinoma associated normal mucosa and not mucosa from adenoma patients or 
normal mucosa unassociated with neoplasia. It may be that techniques are still not 
sufficiently sensitive or that they do not exist. At present searching for these 
mutations does not seem to be valuable. 
 
There were KRAS mutations in 11% of the carcinoma associated normal mucosa 
and 31% contained a mutation in the tumour. This equates to 35% of mutated 
tumours also containing a KRAS mutation in their normal mucosa. These three 
separate experiments have confirmed the previously studies’ findings that KRAS 
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codon 12 and 13 mutations are present in cancer associated normal mucosa and 
that these mutations occur at a low level. The finding of KRAS mutations in normal 
that in most cases differ to the tumour supports the cancer field theory. If the whole 
bowel is exposed to a carcinogen that induces a base change in KRAS, different 
bases may be substituted within different areas of the bowel. If an affected area 
then develops further mutations to give it a growth advantage, a tumour may 
develop. However the differing mutations in KRAS at other parts of the bowel 
unaffected by neoplasia show that the background mucosa is genetically abnormal. 
It would be valuable to widen the search for mutations in normal mucosa by looking 
at other genes. 
 
It was seen that DNA that had been fixed in formalin had an increased number of 
G>A and C>T changes once amplified by PCR compared to fresh DNA. This is a 
known phenomenon and these artefacts could be removed by treating gDNA with 
UDG to remove the formalin effects of amination and depurination of guanine and 
cytosine residues. 
 
The interpretation of tumour suppressor gene data from the samples of normal 
mucosa from patients with normal colonoscopies was not reliable due to the 
unavailability of blood samples to remove SNPs from the analysis. For the cohort of 
carcinomas and adenomas and their associated normals, SNPs could be filtered 
out, but the error rate from PCR amplification of formalin was too high to allow for 
reliable interpretation of tumour suppressor gene data as these samples were not 
tested in duplicate. It would therefore be useful to repeat this experiment with UDG 
pre-treatment of DNA to remove formalin induced errors and in duplicate or triplicate 
to remove PCR errors. This could be done by duplicate processing of samples to 
produce libraries and multiplexing them on a single NGS run. 
 
From the cohort of carcinoma and carcinoma associated normal that were run in 
duplicate, as well as providing useful insights into the amount of PCR error 
generated it revealed mutations in normal mucosa in genes other than KRAS. 
Mutations were also seen in APC, SMAD4 and CTNNB1. This further shows that 
mutations occur in normal colonic mucosa as well as the cancer. This could be due 
to the bowel having a longer exposure to carcinogens and the patients with 
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carcinoma being on average 4.5 years older than the adenoma cohort (the median 
age of carcinoma cohort was 71years and 65.5 for the adenoma cohort). 
 
This is not a longitudinal study and is only able to provide a snap shot of the 
mutational landscape of carcinoma associated normal mucosa. To address this 
question of how mutational damage occurs over time it would be useful to monitor 
the mutations present and see if they change over time as this would give a picture 
of population of mutant clones present at different times. This could possibly be 
enabled by taking samples of normal mucosa during flexisigmoidoscopy as part of 
the bowel cancer screening programme, as patients are monitored periodically and 
follow-up data would be available (Logan et al., 2012).  
 
It is hypothesised that mutations within the normal mucosa are induced by the 
carcinogenic metabolic products of the bacteria that breakdown faecal material 
(Guarner and Malagelada, 2003). It has already been observed that fusobacterium 
is associated not only with carcinoma but also adenoma (McCoy et al., 2013). 
Therefore it would be interesting to classify the gut flora present within patients with 
mutations in normal mucosa compared to those without mutations to try and identify 
the most mutation-inducing bacteria. In this way patients could then be screened for 
their gut flora composition and those at higher risk of developing cancer could be 
identified and have their gut flora altered as a preventative measure for colorectal 
cancer. 
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5.1.5 FAP adenomas  
In order to gain insight of how adenomas develop in the bowel, FAP patients were 
used as a model to study the molecular profiles of adenomas. The mutational and 
copy number profiles of the adenomas showed that clustering can occur locally 
within the bowel and sometimes at greater distances i.e. some adenomas within the 
ascending colon and transverse colon share molecular lesions. Conversely, in many 
cases, adenomas also appeared to develop independently.  However, this is only 
according to their mutations in the genes tested and their copy number aberrations 
and it is highly likely that other mechanisms are driving adenoma development. It 
would therefore be useful to repeat this not only for more FAP patients but also 
looking at other molecular aberrations. This could include methylation, long non-
coding RNA and micro RNA expression as well as using exome sequencing instead 
of targeted. By comparing all patients, it appeared that different mechanisms were 
driving the development of adenomas in different patients. By repeating with larger 
number of patients, this pattern may become clearer.  
 
The copy number data from these adenomas is more reliable due to fewer chances 
of errors and artefacts occurring compared to PCR amplification of targets and 
mutation analysis. The copy number profiled revealed that adenomas within the 
bowel share both small and large chromosomal aberrations. The smaller 
aberrations in particular which are unique to that patient e.g. the pattern of loss of 
seen in chromosome 11 in patient 3 provide evidence that these adenomas have a 
clonal origin and then have developed further, independent aberrations. 
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5.2 Final conclusions 
 Mechanical dissociation of colonic crypts in the presence of a chelating 
agent is an effective method of isolating colon epithelial cells from fresh 
tissue. 
 The sensitivity of pyrosequencing varies depending on the type of base 
change being detected and lies between 5% and 25% mutant allele 
frequency. 
 The sensitivity of NGS is 0.5% for fresh tissue and 1% for FFPE. 
 PCR-based enrichment techniques such as RFLP are not reliable with NGS 
as they enrich a high proportion of error. 
 Formalin induces G>A and C>T base changes in DNA once amplified and 
these can be removed bioinformatically by testing samples in duplicate. 
 KRAS mutations are present at low level in carcinoma associated normal 
mucosa. 
 Mutations were also found in APC, CTNNB1, PIK3CA and SMAD4 in 
carcinoma associated normal mucosa using the Fluidigm Access Array. 
 Further validation is required of the Fluidigm Access Array to be certain of 
FAP adenoma mutation status by testing samples in duplicate. 
 The most commonly seen chromosomal aberrations in FAP adenomas were 
gains of chromosomes 7,8 and 13 which is similar to reported aberrations in 
sporadic adenoma. 
 FAP adenomas share marker aberrations indicating that some have a clonal 
origin. 
 Wide variation in chromosomal aberrations was seen on top of clonal 
variations suggesting further independent evolution of adenomas. 
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6.1 Solution recipes 
6.1.1 Hanks Buffered Salt Solution (HBSS) 
HBSS Stock Solutions: 
Solution 1 
Dissolve the following in 90ml of distilled H2O: 
 8.0g NaCl 
 0.4g KCl 
Make up final volume to 100ml with distilled H2O 
Solution 2  
Dissolve the following in 90ml of distilled H2O: 
 0.358g anhydrous Na2HPO4 
 0.60g KH2PO4 
Make up final volume to 100ml with distilled H2O 
Solution 3 
Dissolve 0.72g of CaCl2 in 50ml of distilled H2O 
Solution 4 
Dissolve 1.23g MgSO4.7H2O in 50ml of distilled H2O 
Solution 5 
Dissolve 0.35 g NaHCO3 in 10ml of distilled H2O  
HBSS Premix 
 10.0 ml Solution 1 
 1ml Solution 2 
 1ml Solution 3 
 86.0 ml distilled H2O 
 1ml Solution 4 
HBSS 
 9.9 ml Hank's Premix 
 0.1ml Solution 5 
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6.1.2 Hanks Buffered Salt Solution Calcium and Magnesium Free 
(HBSS CMF) 
Dissolve the following in 900ml of distilled H2O: 
 8g NaCl 
 0.4g KCl 
 0.06g KH2PO4 
 0.35g NaHCO3 
 0.012g Na2HPO4.12H2O 
Adjust the pH to 7.4 with 2M NaOH 
Make up final volume to 1000ml with distilled H2O 
 
6.1.3 HBSS CMF + EDTA 
Dissolve 2.23g EDTA in 150ml HBSS CMF 
Make up final volume to 200ml with HBSS CMF 
  
240 
 
 
6.2 Spot counting analysis 
 
Section  
number 
Number of 
spots 
counted 
Number of 
spots on 
epithelium 
Percentage 
epithelium 
(%) 
Case 1 1 292 158 54.1 
2 294 139 47.3 
3 283 127 44.9 
4 275 137 49.8 
5 293 151 51.5 
 
Case 2 1 276 137 49.6 
2 280 156 55.7 
3 285 150 52.6 
4 260 153 58.8 
5 276 149 54.0 
 
Case 3 1 272 112 38.9 
2 285 126 40.5 
3 253 142 56.1 
4 276 143 51.8 
Table 51. Spotcounting analysis for epithelial cell content for 14 frozen sections of normal 
colorectal mucosa. 
 
 
 
Section 
number 
Spots on 
lamina 
propria 
(%) 
Spots on 
crypt 
Lumen 
(%) 
Spots on 
muscle 
(%) 
Spots on 
mucin 
(%) 
Case 1 1 34.9 8.9 2.1 0.7 
2 37.7 11.6 3.7 - 
3 35.0 18.0 1.8 - 
4 33.5 14.9 1.8 - 
5 34.5 11.9 1.4 - 
  
Case 2 1 37.7 12.0 0.7 - 
2 32.1 12.1 - - 
3 33.7 11.6 1.1 - 
4 31.5 9.2 0.4 - 
5 33.3 11.6 1.1 - 
  
Case 3 1 45.6 10.3 2.9 - 
2 34.7 18.2 2.5 0.4 
3 32.4 9.9 1.2 0.4 
4 36.6 10.1 1.1 0.4 
Table 52.  Spotcounting analysis for other cellular components, 14 frozen sections of normal 
colorectal mucosa. 
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6.3 Pyrosequencing of serial dilutions of mutant KRAS 
A 
 
B 
 
 
 
242 
 
 
C 
 
D 
 
 
 
243 
 
 
E 
 
F
 
Figure 91.  A-F Pyrosequencing of serial dilutions of 6 KRAS 12+13mutations, run2. 
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Figure 92. A-B Pyrosequencing of serial dilutions of 6 KRAS 12+13mutations, run3. 
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6.4 Scripts 
6.4.1 Reference fasta file 
This is the reference fasta file that was used for analysing targeted amplicons. 
Firstly reads were aligned to this reference using BWA alignment software. This file 
then acted as the reference input for the AllFreChecker.pl script. Pseudogene 
sequences were added to allow for these reads to be removed from the analysis. 
 
>KRAS1213 
GGCCTGCTGAAAATGACTGAATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTGCCTTGACGA
TACAGCT 
>KRAS1213_PSEUDO 
GGCCTGCTGAAAATGACTGAATATAAACTTGCGGTAGTTGGAGCTGGTGGCGTAAGCAAAAGTGTCTTGACGA
TACAGCT 
>KRAS61 
AATTGATGGAGAAACCTGTCTCTTGGATATTCTCGACACAGCAGGTCAAGAGGAGTACAGTGCAATGAGGGAC
CAGTACA 
>KRAS61_PSEUDO 
AATTGATGGAGAAACCTGTCTCTTGGATATTCTTGACACAACAGGTCAAGAAGAGTACAATGCAATGAGGACCA
GTACA 
>NRAS1213 
CTTGCTGGTGTGAAATGACTGAGTACAAACTGGTGGTGGTTGGAGCAGGTGGTGTTGGGAAAAGCGCACTGA
CAATCCA 
>NRAS61 
GAAACCTGTTTGTTGGACATACTGGATACAGCTGGACAAGAAGAGTACAGTGCCATGAGAGACCAATACATGA
GGACAGG 
>BRAF 
TGAAGACCTCACAGTAAAAATAGGTGATTTTGGTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGT
TTGAAC 
>BRAF_PSEUDO 
TGAAGACCTCACAGTGGAAATAGGTGATTTTGGTCTAGCCACAGTGAAATCTTGATGGAGTGGGTCCCATCAG
TTTGAAC 
 
 
6.4.2 AllFreqChecker.pl 
This script reports the number of A, G, T, C and N bases at each position within the 
reads of a SAM FILE for specified targets. Targets are inputted using the above 
reference fasta file containing the target sequences. The command line for the script 
is: 
perl allele_freq.pl <reference file.fa> <input.sam> 
The output is an excel file that shows the number of A, G, T, C and N bases at each 
position in the amplicon as well as the total coverage and finally  the percentage of 
bases that do not align that that position. This output file can be easily manipulated 
in excel to produce a final report. 
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#!usr/bin/perl 
use strict; 
use warnings; 
 
## Kate's super-duper script to give the allele frequencies from a fasta file 
## usage = perl allele_freq.pl <ref file.fa> <input.sam> 
 
print "usage = perl allele_freq.pl <ref file.fa> <input.sam>\n"; 
 
my $ref = $ARGV[0]; 
my $in = $ARGV[1]; 
my $out = "$in"."pfreqs.xls"; 
#my ($ref, $in) = shift(@ARGV); 
 
open (REF, '<', $ref); 
open (OUT, '>', $out); 
 
 
my $line; 
my $header; 
my $amplicon; 
my %seqs= (); 
 
### READ FASTA FILE INTO HASH 
while ($line = <REF>) { 
 chomp $line; 
 if ($line =~ /^>/) { 
  $header = substr($line, 1); 
        $header =~ s/\r$//; 
 } else { 
  $amplicon = $line; 
 $seqs{$header} = $amplicon; 
 }; 
}; 
 
### up to here all is ok! 
 
foreach my $gene (keys %seqs) { 
 next if ($gene =~m/PSEUDO/g); 
    open (IN, '<', $in); 
    my @countT = ("0") x (length $seqs{$gene}); 
    my @countG = ("0") x (length $seqs{$gene}); 
    my @countC = ("0") x (length $seqs{$gene}); 
    my @countA = ("0") x (length $seqs{$gene}); 
    my @countN = ("0") x (length $seqs{$gene}); 
    my @countTO = ("0") x (length $seqs{$gene}); 
 my $average; 
 my $std; 
 my @nonmatch; 
 my $entry; 
 my $result; 
 print OUT "$gene\n"; 
  print  OUT "\tA\tG\tT\tC\tN\tTotal\t%Error\n"; 
 my $read; 
 while ($read = <IN>) { 
        chomp $read; 
        next if ($read =~ m/^\@/); 
        my @field = split(/\t/, $read); 
  if (($field[5] eq "80M") and ($field[4] > 1) ) { 
   my $align = $field[2]; 
   my $read = $field[9]; 
   my $loc = $field[3]; 
   my $n = $loc-1; 
   if ($align eq $gene) {  
    my $amp = $seqs{$gene}; 
    my ($countT_ar, $countG_ar, $countC_ar, $countA_ar, $countN_ar, 
$countTO_ar) = freq ($n, $amp, $read); 
    my @localCountT = @{$countT_ar}; 
    my @localCountG = @{$countG_ar}; 
    my @localCountC = @{$countC_ar}; 
    my @localCountA = @{$countA_ar}; 
    my @localCountN = @{$countN_ar}; 
    my @localCountTO = @{$countTO_ar}; 
    @countT = addCount(\@countT, \@localCountT); 
    @countG = addCount(\@countG, \@localCountG); 
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    @countC = addCount(\@countC, \@localCountC); 
    @countA = addCount(\@countA, \@localCountA); 
    @countN = addCount(\@countN, \@localCountN); 
    @countTO = addCount(\@countTO, \@localCountTO); 
   }; 
  }; 
 }; 
    close IN; 
 for (my $a=0; $a<@countTO-1; $a++) { 
  my $d = $a+1; 
  if ($countTO[$a]>0) { 
   $nonmatch[$a] = 
($countA[$a]+$countG[$a]+$countT[$a]+$countC[$a]+$countN[$a])/ $countTO[$a] * 100; 
   print OUT 
"$d"."\t"."$countA[$a]"."\t"."$countG[$a]"."\t"."$countT[$a]"."\t"."$countC[$a]"."\t"."$countN[$a]"."\t"."$countTO[$a]"."\t
"."$nonmatch[$a]"."\n"; 
  }; 
 }; 
 
 print OUT "\n"; 
}; 
    
    
sub freq { 
 my ($n, $amp, $read) = @_; 
 my @bases = split (//, $read); 
 my @countT = ("0") x (length $amp); 
 my @countG = ("0") x (length $amp); 
 my @countC = ("0") x (length $amp); 
 my @countA = ("0") x (length $amp); 
 my @countN = ("0") x (length $amp); 
 my @countTO = ("0") x (length $amp); 
 for (my $x=0; $x<@bases; $x++) { 
  $countTO[$n+$x]++; 
  my @seq = split (//, $amp); 
  if (defined($seq[$n+$x])) { 
   if ($bases[$x] ne $seq[$n+$x]) { 
    if ($bases[$x] eq "G") { 
     $countG[$n+$x]++; 
                }; 
                if ($bases[$x] eq "T") { 
     $countT[$n+$x]++; 
    }; 
                if ($bases[$x] eq "C") { 
     $countC[$n+$x]++; 
    }; 
    if ($bases[$x] eq "A") { 
     $countA[$n+$x]++; 
    }; 
    if ($bases[$x] eq "N") { 
     $countN[$n+$x]++; 
    }; 
   }; 
  }; 
 }; 
 return (\@countT,\@countG,\@countC,\@countA,\@countN,\@countTO); 
}; 
 
sub addCount { 
 my ($count_ar, $localcount_ar) = @_; 
 my @count = @{$count_ar}; 
 my @localcount = @{$localcount_ar}; 
 for (my $n=0; $n<@count; $n++) { 
  $count[$n] = $localcount[$n] + $count[$n]; 
 }; 
 return @count; 
}; 
 
 
sub average { 
 my @nonmatch = @_; 
 my $total = 0; 
 ($total +=$_) for @nonmatch; 
 my $average = ($total / @nonmatch); 
 return $average; 
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}; 
 
 
sub stdev{ 
        my($average, @data,) = @_; 
        my $sqtotal = 0; 
        foreach(@data) { 
                $sqtotal += ($average-$_) ** 2; 
        } 
        my $std = ($sqtotal / (@data-1)) ** 0.5; 
        return $std; 
}; 
   
6.4.3 Var_an.pl 
This perl script allows for the output of VarScan 2 to be read more easily, opened in 
excel and acts as input for the matrix script mut_matrix.pl. It outputs an excel file 
that shows the Aligned Chromosome, position in that chromosome, the reference 
base at that position, the variant base at that position and finally the allele frequency 
of that variant. 
 
#!usr/bin/perl 
use strict; 
use warnings; 
 
my $in = shift(@ARGV); 
my @name = split (/\./, $in); 
my $out = "$name[0]".".xls"; 
open (IN, '<', $in); 
open (OUT, '>', $out); 
 
print OUT "Chromosome\tPosition\tRef\tVar\tAllFreq\n"; 
my $line; 
 
while ($line = <IN>) { 
        chomp $line; 
        next if ($line =~ m/^C/); 
        my @field = split (/\t/, $line); 
        my @freq = split (/:/, $field[4]); 
        print OUT "$field[0]\t$field[1]\t$field[2]\t$field[3]\t$freq[4]\n"; 
 
6.4.4 Mut_matrix_maker.pl 
This perl script contains a mutational matrix that can be read in excel with shared 
mutational sites as the header and samples as the columns. Each cell within the 
matrix shows what base is present for each sample at that position. The samples 
are inputted as the output files from the var_an.pl script. The input also requires a 
reference file of shared mutations. Each line of the reference file has the mutational 
position followed by a tab followed by the WT base at that position. The command 
line for this script is as follows: 
Perl mut_matrix_maker.pl <mutational reference file.txt> <sample file.xls> 
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#! usr/bin/perl 
 
use strict; 
use warnings; 
 
my $in = $ARGV[1]; 
my $ref = $ARGV[0]; 
open (REF, '<', $ref); 
open (IN, '<', $in); 
my $out = "mutmatrix.txt"; 
open (OUT, '>>', $out); 
 
my %muts; 
my $entry; 
 
while ($entry = <REF>) { 
 chomp $entry; 
 my @split = split (/\t/, $entry); 
 $muts{$split[0]} = $split[1]; 
}; 
 
my $line; 
my @list; 
my %var; 
 
while ($line = <IN>) { 
 chomp $line; 
 my @field = split (/\t/, $line); 
 my $match = $field[6]; 
 push (@list, $match); 
 $var{$match} = $field[4]; 
}; 
 
my %counter; 
foreach my $rec (keys %muts) { 
 $counter{$rec} = 0; 
 for (my $n=0; $n<@list; $n++) { 
  if($list[$n] =~ m/$entry/) { 
   $counter{$entry}++; 
  }; 
 }; 
}; 
 
print OUT "$in\t"; 
foreach my $record (keys %counter) { 
 print OUT "$record\t"; 
}; 
 
print OUT "\n"; 
 
foreach my $record (keys %counter) {  
 if ($counter{$record} == 0) { 
  print OUT "\t$muts{$record}"; 
 } else { 
  print OUT "\t$var{$record}"; 
 }; 
}; 
 
print OUT "\n"; 
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6.4.5 CNVmatrix1.pl 
This script is the first script to create a matrix for copy number variant. It checks the 
CNV ratio for each window in the sample file and records those that are above 1.2 
or below 0.8. It also detects the centromeric and telomeric regions and removes 
these from the analysis. The input is a txt file with the window positions and the 
copy number ratio which is produced from the CNAnorm programme. The input also 
requires a reference text file that specifies the length of each chromosome and the 
position of the centromere. This can be created in excel from the sample output 
files. The output file from this script is a text file that can be inputted into the 
CNVmatrix2.pl script plus a target file that is used for the CNV2matrix2.pl scriptThe 
command line for this script is: 
CNVmatrix1.pl <reference file.txt> <sample file.txt> 
 
#! usr/bin/perl 
 
use strict; 
use warnings; 
 
my $in = $ARGV[1]; 
my $ref = $ARGV[0]; 
my @name = split (/\./, $in); 
open (REF, '<', $ref); 
my %end1; 
my %end2; 
my %cen1; 
my %cen2; 
open (IN, '<', $in); 
my $out = "$in.mi"; 
open (OUT, '>', $out); 
my $newref = "targetfile.txt"; 
open (OOUT, '>>', $newref); 
 
my $entry; 
while ($entry = <REF>) { 
        chomp $entry; 
        my @col = split (/\t/, $entry); 
        $end1{$col[0]} = $col[1]; 
        $end2{$col[0]} = $col[2]; 
        $cen1{$col[0]} = $col[3]; 
        $cen2{$col[0]} = $col[4]; 
}; 
 
my @oref; 
 
#print OUT "Chr\tStart\tEnd\tScore\t\n"; 
 
my $line; 
while ($line = <IN>) { 
        chomp $line; 
        next if 1..1; 
        my @field = split (/\t/, $line); 
        next if ($field[6] eq "NA"); 
        next if ($field[0] =~ m/Y/); 
        next if ($field[0] =~ m/X/); 
        if ( 0.9 > $field[6] or $field[6] > 1.1) { 
                foreach my $rec (keys %end1) { 
                        if ($field[0] =~m/$rec/ and $field[1] > $end1{$rec}) { 
                                foreach my $rec1 (keys %cen1) { 
                                        if ($field[0] =~m/$rec1/ and $field[1] < $cen1{$rec1}) { 
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                                                print OUT "$name[0]\t$field[0]\t$field[1]\t$field[6]\n"; 
                                                my $join = "$field[0]".":"."$field[1]"; 
                                                push (@oref, $join); 
                                        }; 
                                }; 
                        }; 
                }; 
                foreach my $rec3 (keys %cen2) { 
                        if ($field[0] =~m/$rec3/ and $field[1] > $cen2{$rec3}) { 
                                foreach my $rec4 (keys %end2) { 
                                        if ($field[0] =~m/$rec4/ and $field[1] < $end2{$rec4}) { 
                                                print OUT "$name[0]\t$field[0]\t$field[1]\t$field[6]\n"; 
                                                my $ojoin = "$field[0]".":"."$field[1]"; 
push (@oref, $ojoin); 
                                        }; 
                                }; 
                        }; 
                }; 
        }; 
}; 
 
my @final = uniq2(@oref); 
for (my $n=0; $n<@final; $n++) { 
        print OOUT "$final[$n]\n"; 
}; 
 
 
sub uniq2 { 
    my %seen = (); 
    my @r = (); 
    foreach my $a (@_) { 
        unless ($seen{$a}) { 
            push @r, $a; 
            $seen{$a} = 1; 
        } 
    } 
    return @r; 
} 
 
6.4.6 CNVmatrix2.pl 
This script uses the text file from the CNVmatrix1.pl script generated for each 
sample, plus the target file created from this first script. The output of CNVmatrix2.pl 
is an excel matrix with chromosomal location as the header (split according to 
windows from CNAnorm programme) and samples as the rows. Each cell indicates 
whether the copy number at that positon for that sample is normal (0), greater than 
1.2 (1) or less than 0.8 (2). The command line for this script is as follows: 
CNVmatrix2.pl <target file from CNVmatrix1> <sample file from CNV matrix1> 
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 #! usr/bin/perl 
 
use strict; 
use warnings; 
 
my $in = $ARGV[1]; 
my $ref = $ARGV[0]; 
open (REF, '<', $ref); 
open (IN, '<', $in); 
my $out = "matrix.txt"; 
open (OUT, '>>', $out); 
 
my @ref = <REF>; 
chomp @ref; 
 
my $line; 
my @list; 
my %scores; 
 
while ($line = <IN>) { 
        chomp $line; 
        my @field = split (/\t/, $line); 
        my $match = "$field[1]".":"."$field[2]"; 
        push (@list, $match); 
        $scores{$match} = $field[3]; 
}; 
 
my %counter; 
 
for my $entry (@ref) { 
        $counter{$entry} =0; 
        for (my $n=0; $n<@list; $n++) { 
                if ($list[$n] =~ m/$entry/) { 
                        $counter{$entry}++; 
                }; 
        }; 
}; 
 
print OUT "$in\t"; 
foreach my $record (keys %counter) { 
        print OUT "$record\t"; 
}; 
 
print OUT "\n"; 
 
foreach my $record (keys %counter) { 
        if ($counter{$record} == 0) { 
                print OUT "\t0"; 
        } elsif ($scores{$record} > 1) { 
                print OUT "\t1"; 
        } elsif ($scores{$record} < 1) { 
                print OUT "\t2"; 
        }; 
}; 
 
print OUT "\n"; 
 
 
 
